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Sustained research efforts have advanced our knowledge of the complexities that make 
cancer a highly diverse and clinically challenging disease. Of the many factors, the 
tissue microenvironment is increasingly appreciated for its crucial role in tumor initiation, 
progression, recurrence, and treatment response. The microvasculature is a critical 
determinant of tissue perfusion, with important consequences for cellular metabolism, drug 
delivery, and metastasis.  To better understand how tissue perfusion contributes to 
tumor malignancy, I fabricated microphysiological in vitro models of the tumor-vascular 
microenvironment and assessed the differential regulation of tumor hypoxia response in 2D 
versus 3D culture. Results from these studies point to the value of tissue engineering 
approaches for deciphering the interdependence between cancer cells and their vascular 
microenvironment. 
Laboratory-based research provides important insights on the biological mechanisms of 
disease, and these basic sciences approaches are strengthened by a broad understanding of the 
human and social dimensions of cancer. To this end, I helped initiate and sustain a community-
based partnership that fosters dialogue between cancer patients and scientists. The partnership 
enables the mutual exchange of knowledge and experience across the community-
campus boundary. This project led to several major outcomes, including a monthly seminar 
for non-academic audiences, a certificate program for public engagement, an undergraduate 
writing class about cancer, and several avenues for informal science education. The 
patient-researcher partnership has a sustained impact in graduate and postdoctoral training at 
Cornell and provides a valuable forum to our local cancer community. 
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CHAPTER 1 
INTRODUCTION 
Cancer is an intricate disease on all scales: at the microscopic level, malignant cells evolve 
within a complex biological landscape. At the human level, the diagnosis accompanies a cascade 
of physical, emotional, and financial stresses. On population and institutional levels, cancer 
constitutes a global epidemic (8.8M deaths worldwide, accounting for nearly 1 in 6 deaths in 2015), 
and enormous resources are exchanged in the relentless quest for effective treatments (total costs 
estimated at $1.16T globally in 2015). Due to its broad scope, cancer demands the mutual exchange 
of knowledge, skills, and ideas across many different groups, including physicians, researchers, 
patients, industries, and government officials.  
The NCI Physical Sciences-Oncology Centers (PSOC) initiative is one strategy to foster 
dialogue between stakeholders that do not ordinarily interact with each other. The program disrupts 
traditional approaches to cancer research by encouraging radical ideas and transformative 
paradigms. In particular, the PSOC emphasizes the value of seeing cancer from many different 
perspectives. As a young investigator in the Cornell Center for the Microenvironment and 
Metastasis (now the Center for the Physics of Cancer Metabolism), I was enculturated into an 
academic community that values innovation and transdisciplinary collaboration, and this became 
the foundation for my graduate research experiences. 
The following dissertation contains eight publications that I produced during my doctoral 
studies. These articles represent major academic milestones; in addition to these chapters, there 
are many aspects of my scholarship that I cannot directly translate into static documents, such as 
events, relationships, and personal development. Non-traditional scholarly products have 
contested value in academia; nevertheless, these elements make a substantial and original 
contribution toward knowledge of biomedical sciences and engineering. 
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Part 1: Tissue Engineering Models of Cancer 
Within the PSOC, the Fischbach lab investigates a fundamental problem in cancer biology 
regarding the relationship between cancer cells and their surrounding tissue, including the links 
between cell metabolism and angiogenesis. As cancer cells proliferate, they eventually outgrow 
their blood supply. Without adequate vasculature, tumor growth is typically limited to 2 mm 
diameter. In order to continue growing, cancer cells secrete pro-angiogenic factors to promote new 
vessel growth and enable tumor progression. 
In 1971, Judah Folkman proposed that interfering with angiogenic signaling might provide 
a way to cut off the blood supply and effectively starve the tumor. Several arguments support his 
idea, including that endothelial cells may be more susceptible than malignant epithelial cells. In 
2004, the US FDA granted approval for Avastin (bevacizumab) for advanced colon cancer, the 
first pharmacological inhibitor of vascular endothelial growth factor (VEGF). The drug was later 
approved for lung, kidney, brain, and breast cancers. In the past 40 years, the principle of anti-
angiogenic therapy was successfully translated into dozens of treatments for regulating vessel 
growth in cancer and other diseases. However, results were not all positive. In 2011, the FDA 
announced that the metastatic breast cancer indication for Avastin was withdrawn after finding no 
significant improvement in overall survival and an increased incidence of adverse effects.  
The inconsistent benefits of anti-angiogenic therapy caused researchers to carefully 
reevaluate this treatment paradigm and the underlying mechanisms that regulate vessel growth. 
For example, Rakesh Jain proposed a conceptual shift from tumor starvation to vascular 
normalization. Rather than inhibit vessel growth, the same angiogenic compounds might instead 
be used to restore vessel maturation and tissue perfusion. According to Jain, a more stable 
endothelium might enhance drug delivery and radiation therapy. This idea was supported by 
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emerging evidence that angiogenic drugs work better in combination with chemotherapy and 
radiation, but are not effective by themselves. As the paradigm of anti-angiogenic therapy evolved, 
scientists and clinicians required a better understanding of microvascular regulation within the 
tumor microenvironment. 
To address this problem, a subgroup from the Fischbach lab was working with Dr. 
Abraham Stroock to develop in vitro models of tumor vasculature. An expert in microfluidics, Dr. 
Stroock and his team were in the process of patterning microfluidic channels within cell-laden 
hydrogels. These channels provided a template for a biomimetic microvascular network, fully 
embedded within a biomaterial scaffold. In 2011, I joined this collaboration; the outcomes of my 
involvement are reported in Part I of this dissertation. 
Chapter 2 provides the relevant background information for Part I. The article introduces 
the use of in vitro models to simulate the physical and fluid dynamic properties of a tumor, with 
special emphasis on the context of drug delivery. It reviews the biological characteristics, 
engineering principles, and in vitro model systems associated with microvascular and interstitial 
transport functions. The article also presents the limitations and future opportunities for 
microfluidic devices, patient-derived culture platforms, and integrating in vitro platforms with 
computer simulations.  
Chapter 3 presents data from a comprehensive microarray gene expression analysis of 
tumor cells cultured in 2D and 3D environments. Oral squamous cell carcinoma (OSCC3) cells 
were embedded within microfabricated alginate discs or cultured on polystyrene and subjected to 
1% or 17% O2. Gene expression and protein secretion of molecules of interest were validated by 
qPCR and ELISA with three additional tumor cell lines. 3D microwell invasion assays were used 
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to evaluate endothelial cell response to tumor-secreted soluble factors or corresponding inhibitors, 
including IL-8 and VEGF. Our results revealed strong coupling between culture dimensionality 
and hypoxic response, which was mediated in part by pro-inflammatory signaling pathways. In 
particular, IL-8 emerged as a major player in the microenvironmental regulation of the hypoxic 
program. Notably, this interaction between dimensionality and oxygen status via IL-8 exhibited 
pro-angiogenic consequences in a 3D endothelial invasion assay. Taken together, our data suggest 
that pro-inflammatory pathways may underlie the differential regulation of hypoxic response and 
facilitate tumor angiogenesis in 3D environments. These results highlight the importance of 
pathologically relevant tissue culture models to study the complex physical and chemical processes 
by which the cancer microenvironment mediates new vessel formation. 
Chapter 4 is a protocol paper describing a method to fabricate microvascular networks in 
vitro. Despite its considerable therapeutic significance, the study of vascular biology lacks well-
controlled experimental platforms to investigate microvascular growth, structure, and function in 
a physiologically appropriate context. We used soft lithography to fabricate explicit microvascular 
structures, fully embedded within remodelable hydrogel scaffolds. These platforms allowed the 
precise distribution of biomolecular signals, localized heterotypic cell seeding, and tunable matrix 
properties and fluid forces. The system supported multiday co-cultures and enabled in situ confocal 
microscopy of living or fixed tissues. Altogether, this model appropriately simulated the structure 
and function of microvascular networks in diseased tissue, and can be used to explore the 
interactions between tissue metabolism, angiogenesis, and microcirculation. 
In chapter 5, I discuss the physical determinants of aberrant tumor metabolism and 
highlights how engineered culture models that recapitulate these properties may advance 
personalized drug screening. There is a demand for model systems to screen anti-cancer agents, 
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including drugs that target metabolic pathways, for precision medicine. In order to predict drug 
response, model systems must be attentive to tissue properties that regulate tumor metabolism. 
While much focus has been placed on the biochemical and cellular composition of the tumor 
microenvironment, physical aspects are similarly important. In particular, transport phenomena 
and matrix mechanics are major determinants of disease progression and treatment outcomes in 
general, and play an especially important role in regulating cell metabolism. In our article, we 
explain how engineered culture platforms allow modeling physical aspects of the tumor 
microenvironment in a relevant biological context and how these systems may help guide drug 
selection and dosing for precision oncology. 
Part II: Public Engagement in Cancer Research 
My involvement in the PSOC was not limited to the laboratory. I was also a founding leader 
of the Cancer Brainstorming Club (CBC), a student organization dedicated to coordinating 
education, outreach, and training programs for PS-OC young investigators. As a CBC officer, I 
planned various events to facilitate peer networking and information sharing, including exchange 
visits, journal clubs, and work-in-progress seminars. I also helped arrange workshops at two of the 
PSOC annual meetings and regularly contributed to NCI site visits, quarterly reports, and grant 
preparation. 
In 2012, the CBC officers learned that colleagues at Moffitt were hosting a "Patient Night 
Out," where cancer patients and survivors would tour their labs and learn about research. 
Enchanted by this idea, Alex McGregor contacted our center's patient advocate to discuss the 
possibility of replicating this event at Cornell. After several unsuccessful inquiries, Alex decided 
to contact the executive director (Bob Riter) of a local cancer support center (the Cancer Resource 
Center of the Finger Lakes). Bob immediately responded to the idea. Coincidentally, he had 
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already started to build a relationship with cancer researchers at Cornell, led by Robert Weiss in 
the College of Veterinary Medicine. In March 2013, we all met together to discuss plans for the 
patient-researcher partnership. 
The Patient-Researcher Partnership was a simple idea with powerful outcomes. Initially, 
we started hosting monthly seminars that were open to the public. These events encouraged 
interaction between scientists and community members, and we soon developed a deep 
appreciation for patients’ perspectives. Our sustained relationship with the cancer community 
produced a continuous stream of new opportunities to strengthen and extend the partnership. 
The partnership started as an outreach activity, but it gradually became an important part 
of my scholarship. I noticed that our program was part of a larger trend in higher education, which 
recognizes the value of collaborating with non-academic communities. Public engagement is 
particularly relevant in biomedical research. Because patients are at the center of the healthcare 
industry, it makes sense that aspiring researchers should interact with people who are affected by 
the diseases they study. This began my inquiry into public engagement in cancer research, which 
constitutes Part II of this dissertation. 
In Chapter 6, Alex McGregor and I explain how a partnership transformed our graduate 
research experience. This article presents outcomes from our collaboration with Bob Riter, Robert 
Weiss, and the Cancer Resource Center. We argue that patient involvement contributes to all 
aspects of biomedical research, beginning with the training of new scientists. We hope that people 
who read our article will be encouraged to initiate or support similar programs at their own 
institutions. 
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Chapter 7 is a reflective essay that grapples with the concept of public engagement in 
biomedical engineering. The purpose of this article is to convey the meaning that I attached to my 
experiences as a "engaged scholar." As I began to deviate from a typical laboratory research career, 
I struggled to reconcile a new set of attitudes, priorities, and aspirations.  Chapter 7 presents the 
messages that might have helped me as I learned to navigate this unfamiliar landscape. My goal 
was to provide affirmation and solidarity to students who found themselves in a similar situation. 
Appendix 
Appendix I is a commentary about an article that appeared in Nature Materials. The 
original paper presented a biocomposite scaffold for spatial analysis of cell metabolism within a 
molecular gradient. The "tumor roll" comprised a hydrogel-coated coffee filter wrapped around an 
aluminum spindle; as the material was unraveled, biochemical assays could be performed on each 
layer within the scaffold. This platform provides an extremely simple and reproducible method for 
investigating the relationship between cancer cells and their physical and soluble 
microenvironment. My article highlights the value of developing robust technologies that can be 
immediately adopted in non-engineering labs. 
Appendix II is a review article about the using microfluidic biomaterials to recapitulate the 
tumor microenvironment. The article discusses materials and methods that can be used to generate 
physiologically-relevant in vitro culture models, and new opportunities that are afforded by these 
technologies.  
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CHAPTER 2 
IN VITRO MODELS OF TUMOR VESSELS AND MATRIX: 
ENGINEERING APPROACHES TO INVESTIGATE TRANSPORT LIMITATIONS 
AND DRUG DELIVERY IN CANCER 
Bo Ri Seo*, Peter DelNero*, and Claudia Fischbach. (2014) In vitro models of tumor 
vessels and matrix: engineering approaches to investigate transport limitations and drug 
delivery in cancer. Advanced Drug Delivery Reviews 69–70:205–16. 
*Authors contributed equally.
Abstract 
Tumor-stroma interactions have emerged as critical determinants of drug efficacy. 
However, the underlying biological and physicochemical mechanisms by which the 
microenvironment regulates therapeutic response remain unclear, due in part to a lack of 
physiologically relevant in vitro platforms to accurately interrogate tissue-level phenomena. 
Tissue-engineered tumor models are beginning to address this shortcoming. By allowing selective 
incorporation of microenvironmental complexity, these platforms afford unique access to tumor-
associated signaling and transport dynamics. This review will focus on engineering approaches to 
study drug delivery as a function of tumor-associated changes of the vasculature and extracellular 
matrix (ECM). First, we review current biological understanding of these components and discuss 
their impact on transport processes. Then, we evaluate existing microfluidic, tissue engineering, 
and materials science strategies to recapitulate vascular and ECM characteristics of tumors, and 
finish by outlining challenges and future directions of the field that may ultimately improve anti-
cancer therapies.  
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Introduction 
Given its extensive socioeconomic impact, cancer continues to be a major focus of drug 
development and delivery research. Nevertheless, clinical success of anti-cancer therapies remains 
limited, and most treatment strategies exhibit marginal efficacy, serious side effects, and the 
development of resistance. Moreover, complete tumor eradication is mostly impossible, and time 
until patient relapse or metastasis remains a tragic measure of clinical success. Targeted therapies 
interfering with specific genetic and molecular mechanisms of tumorigenesis have offered 
improvement relative to conventional cytotoxic therapy; however, cancer cells frequently evade 
therapy by assuming resistance mechanisms including secondary mutations and epigenetic 
modifications (1-3). 
While many therapies directly target tumor cells, the microenvironment in which tumor 
cells reside is an equally important participant in disease progression. During health, normal 
“contextual cues” of the host microenvironment prevent the cancerous outgrowth of epithelial cells 
(4, 5). However, perturbation of this homeostasis, e.g., due to chronic inflammation, metabolic 
changes, or hormonal imbalance, enables the initiation and progression of malignancy (6-9) as 
well as the emergence of resistance (10, 11). 
In addition to directly affecting tumor cell behavior, microenvironmental conditions may 
promote recurrence by simply preventing effective transport of therapeutics. When anti-cancer 
drugs are systemically administered, steps of drug delivery include transport (1) within the 
circulation, (2) across blood vessel walls, and (3) through the interstitial space to the tumor (12, 
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13). Alterations of microenvironmental conditions interfering with any of these processes may 
affect drug bioavailability with consequences on efficacy.  
The physicochemical properties of the vasculature and the interstitial extracellular matrix 
(ECM) are key regulators of anti-cancer drug distribution and efficacy (14). As the primary 
conduits of perfusion, blood vessels determine the availability of drugs throughout the body and 
within individual tissues. However, heterogeneous microvascular function as present within 
tumors can compromise delivery and undermine the effects of therapeutic agents (14). Enhanced 
permeability and retention (EPR) in leaky vessels has facilitated the targeting of macromolecular 
therapies (15-19). Yet, the asymmetric distributions of oxygen or drugs within a tumor provide a 
conducive landscape for the evolution of resistance within heterogeneous populations of cancer 
cells (20). Although vascular structure and function largely regulate the spatiotemporal distribution 
of drug, interstitial space can also affect transport rates (21). In particular, excessive ECM 
deposition due to fibrotic remodeling (also termed desmoplasia) physically hinders diffusion of 
large anti-tumor molecules through the interstitium (21). 
Despite the well-established physical principles governing biological transport 
phenomena, the opportunity to leverage these principles to improve therapeutic outcomes is 
limited. Conventionally, new anti-cancer compounds are first tested in 2D tissue culture, which 
provide homogeneous access to drug and neglect the 3D microenvironmental properties inherent 
to tumors. Additionally, even positive results from animal studies do not always translate to 
efficacy in humans due to species-dependent discrepancies in signaling and physiology (22, 23). 
The development of tissue-engineered model systems that accurately recapitulate human tumor 
with increasing physiological complexity may help to understand and test microenvironmental 
parameters affecting tumor response. Here, we review current understanding of the biological 
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characteristics underlying tumor-associated changes of the vasculature and ECM properties, 
examine the consequences of these parameters for mass transport and drug delivery, and present 
emerging in vitro strategies that may provide new insights for improved anti-cancer therapies (24-
26). 
Tumor vasculature: biophysical changes and their relevance to drug delivery 
Biological characteristics of tumor microvasculature 
Since Judah Folkman’s seminal observations in 1971 that tumorigenesis is associated with 
the ingrowth of abnormal blood vessels (27, 28), vascular dysfunction has become an enduring 
theme in cancer biology and anti-cancer therapy. When compared to healthy vasculature, tumor 
vessels are leaky, fenestrated, tortuous, and dilated, with chaotic branching patterns including 
shunts and loops, as well as irregular hierarchy of vessels (29-34) (Figure 1). The tumor 
vasculature comprises at least six types of vascular structures with distinct properties, including 
mother vessels (MVs) and several varieties of daughter vessels (capillaries, glomeruloid 
microvascular proliferations, vascular malformations) (35, 36). MVs are enlarged sinusoids 
resulting from pericyte detachment, basal membrane (BM) degradation, and endothelial thinning 
(36). Despite this distension, MVs do not increase blood flow, possibly due to their hyper-
permeable membrane function (35). Meanwhile, immature daughter vessels are fenestrated and 
lack functional perfusion. Vascular leakage, coupled to dysfunctional lymphatic drainage, results 
in an accumulation of interstitial fluid, which compromises the hydrostatic and osmotic pressure 
gradients that drive transvascular convection (37). Collectively, this heterogeneous network of 
aberrant blood vessels yields erratic perfusion of diseased tissue, with important consequences for 
pathogenesis and therapy. 
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Fig. 1. Biophysical changes of tumor vasculature. A) Schematic illustration of the structural and functional
changes in tumor vasculature, in duding tortuous vessels, chaotic branching, disrupted barrier function, and
compromised hydrostatic and osmotic gradients. B) Aberrant vasculature undermines transport processes within
diseased tissue, resulting in asymmetric distributions of oxygen and drugs to the tumor. This micrograph
illustrates the penetration depth of doxorubicin and highlights the large, hypoxic regions of the tumor unaffected
by therapy (154). Reproduced with permission from Nature Publishing Group.
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Hypoxia and acidosis are the most prominent consequences of deregulated vascular 
function. Compromised vessel characteristics lead to poor supply of oxygen and clearance of 
metabolic wastes, mediating sustained hypoxia (<1% O2) and acidosis (as low as pH ~6.6-6.8 in 
some areas) (38-40). These microenvironmental conditions directly promote tumor progression 
and new vessel formation by activating a variety of transcriptional programs (41-44). In particular, 
stabilization of the alpha subunit of the hypoxia inducible factor 1 (HIF-1) transcription factor in 
low-oxygen conditions leads to an orchestrated program of hypoxic response (42, 45-47) that 
includes the up-regulation of pro-angiogenic morphogens (including vascular endothelial growth 
factor [VEGF] and basic fibroblast growth factor [bFGF]). However, rather than promoting the 
formation of healthy blood vessels that could normalize tissue O2 levels and pH, excess pro-
angiogenic signaling activates a vicious cycle that undermines vascular stability by impairing 
vessel organization and permeability thus exacerbating these pathological conditions (48-50). 
In addition to metabolic transport, impaired vascular function also compromises the 
homogeneous delivery of therapeutic agents, resulting in poor distribution of drugs throughout the 
tumor (51). Low vascular function at the tumor interior prevents therapeutic access to large regions 
of tissue (31). Homogeneous delivery is further undermined by the absence of hydrostatic and 
osmotic pressure gradients, which are necessary for interstitial convection to distribute large 
therapeutic agents (52, 53). In some cases, enhanced vascular permeability and retention (EPR) 
has been coopted as a mechanism for tumor targeting of large particles such as antibodies and 
micelles (15). However, although high molecular weight drugs and drug carriers easily traverse 
the endothelial membrane of the tumor, they have poor penetration depth and achieve little benefit 
in regions distal to blood vessels (51, 54, 55). Therefore, vascular normalization is an emerging 
theme for improving therapeutic delivery (56-58).  
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Whereas most vascular therapies emphasize the destruction of blood vessels to stunt tumor 
growth, some researchers hope to re-appropriate angiogenic drugs as adjuvant therapy in order to 
improve drug distribution (59). By increasing perfusion in the tumor, this method may overcome 
major disadvantages of chemotherapy such as short half-life and small therapeutic index (range of 
concentration between efficacy and toxicity) (60). In the past decade, numerous clinical trials have 
revealed the benefits of anti-angiogenic therapy as an adjuvant to chemotherapy or radiation 
therapy (60-62). However, the dearth of pre-clinical models to recapitulate vascular transport 
remains a challenge for the development of new strategies for vascular normalization.  
Effects of microvascular dysfunction on transport physics 
 Whereas conventional pharmacokinetic metrics (e.g. distribution volume, half-life, 
clearance rate) characterize the average availability of drug in tissues, these measurements only 
poorly approximate the effective distribution of agents within tumors. In fact, large regions of 
tumors lack adequate vascular perfusion and thus, can remain unaffected by treatment, even at 
high doses. This is particularly true of large molecules (>10 kDa), which are not able to freely 
diffuse across the endothelium and through the tissue. Instead, convective forces govern the 
exchange of large compounds from the circulation (Box 1). In healthy tissues, these forces balance 
the influx and outflux at the arterioles and post-capillary venules to provide adequate perfusion. In 
the case of a tumor, however, vascular leakiness reduces hydrostatic pressure in the vessel while 
increasing osmotic pressure in the interstitium (approximately 29 +/- 3 mmHg in breast tumor, 
compared to -0.3 +/- 0.1 mmHg in healthy breast tissue) (63, 64). Together, these changes 
significantly diminish the bioavailability of drugs by reducing transcapillary hydrostatic gradients 
necessary for fluid exchange (65).  
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Box 1. Forces governing transvascular transport.
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In addition to simple mass transport equations, a variety of tools have been developed to 
quantitatively evaluate the effectiveness of mass transport in tissues. Dimensionless numbers are 
particularly useful to identify transport limitations (66).  For example, the Biot number compares 
the relative resistance attributed to the endothelial membrane versus the interstitial matrix. 
Likewise, the effectiveness factor describes the rate of transport compared to the rate of reaction. 
Both of these parameters can help identify limitations to drug penetration and efficacy. For 
example, in cases where transvascular transport limits therapeutic efficiency, combinations with 
permeabilizing agents may improve delivery, while other therapies limited by interstitial diffusion 
may benefit from stroma-targeted treatments. A modified effectiveness factor can incorporate the 
Biot number to identify the relative resistance due to vascular versus interstitial transport (67, 68).  
Similarly, the “observable modulus” evaluates penetration distance based on transport and 
reaction considerations (67).  This parameter defines a “dimensionless reaction rate” (the 
effectiveness factor * thiele modulus), and is defined as a function of the distance from the nearest 
vessel. This parameter allows the calculation of a penetration depth, or the distance at which the 
concentration drops below an effective dose. A low modulus indicates deeper penetration, and 
high modulus indicates poor distribution away from the capillary. The observable modulus has 
been used to determine the Krogh distance, or the range for diffusion-limited oxygen transport 
before reaching anoxia and necrosis (67). In the case of therapy, the same parameter can describe 
the effective therapeutic range of a drug and thus characterize and inform angiogenic therapy or 
EPR designs.  
By evaluating the specific physical contributions to therapeutic resistance by transport or 
reaction kinetics, these quantitative methods may help identify major barriers of delivery and 
enable the rational design of dosing strategies, including in combination with drugs that target the 
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vasculature or the stroma to optimize therapeutic efficacy. Nevertheless, many of these 
quantitative approaches are frequently neglected. This may be due in part to the inaccessibility of 
the various coefficients needed to determine the dimensionless parameters. Conventional methods 
to test vascular permeability, such as Evan’s blue staining, provide little chance for rigorous 
quantification. Meanwhile, in vitro methods to measure endothelial permeability or tissue 
diffusivity, such as multilayer or spheroid cultures, may not accurately reflect in vivo parameters 
(55). Therefore, new methods to accurately determine the parameters affecting vascular and 
interstitial mass transport will provide a valuable resource for the design of therapeutic strategies 
that target the tumor microenvironment (66). 
Recapitulating tumor-associated vascular transport through in vitro models 
 Organotypic 3D culture models present an emerging opportunity to create controlled 
experimental conditions that faithfully reproduce aspects of the physiological environment. 
However, as sufficient mass transport within cell-laden biomaterials remains a significant 
limitation of 3D cultures, these approaches are typically performed in a microscale format and lack 
the recapitulation of tumor-inherent transport physics. New in vitro platforms that integrate 
functional vascular structures can help to overcome this limitation (69). Biomimetic microvascular 
networks provide controlled experimental platforms to evaluate specific interactions between 
endothelial cells and tumor environment, improve the design of therapies targeting the vasculature, 
and assess the efficacy of new drugs or drug delivery strategies (70, 71). 
Two categories of microfluidic vascular models have been introduced. The first design, 
pioneered by the groups of Roger Kamm and Lance Munn, employs microfabricated silicone 
molds to confine biological hydrogels between parallel microfluidic channels (Figure 2A). 
Endothelial cells cultured on the surface of these confined gels are able to sprout into the matrix 
17
Fig. 2. Examples of microengineered vascular structures. A) Vascular structures created by culturing
endothelial cells in confined gels within a microfluidic platform are useful for evaluating endothelial cell
response to angiogenic gradients, shear stresses, or paracrine interactions (73). B) Anastomosis between parallel
vessels enables the autonomous formation of capillary-scale networks fully embedded within 3D biological
matrices. The original vessel structures were fabricated by the pull-through method (75). C) Live/dead staining
illustrates dependence of cell viability on spatial differences in oxygen and nutrient supply caused by diffusion-
limited transport from perfused vascular channels. Vessels were produced by molding a hydrogel against
a bioprinted sacrificial scaffold (77). D) Vascular networks enabling control over endothelial cell (CD31)
interactions with pericytes (α-SMA) and membrane permeability (fluorescein leakage) permit complex studies
of vascular biology in healthy and disease conditions. Networks were generated in hydrogels by soft lithography
(81). Images were reproduced with permission from the Royal Society of Chemistry (A) and the National
Academy of Sciences, USA (B-D).
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and recapitulate aspects of angiogenic invasion, including sensitivity to shear stress, interstitial 
flow, and various angiogenic gradients (72-74). These assays have been used to facilitate co-
culture with stromal or tumor cells and evaluate paracrine effects in angiogenesis (74). However, 
these models are confined by thin geometries (~100 μm) and are therefore sensitive to boundary 
effects due to cell and molecular interactions with the device surface. In addition, the endothelial 
cells initially form a monolayer against the gel region, rather than a fully-mimetic lumen structure. 
Therefore, more advanced models of microvascular structure and function have recently been 
developed. 
This second type of platform comprises bona fide vascular structures fully embedded 
within 3D ECM. Such structures can be developed by molding biomaterials against a thin needle 
to define a vessel lumen and subsequently seeded with endothelial cells (75, 76) (Figure 2B). These 
vessels allow high throughput and facile fabrication, but they are restricted to simple linear 
geometries and are limited by the resolution of the needle. More complex channel configurations 
can be fabricated by patterning of a sacrificial resist that dissolves after gel crosslinking (77, 78) 
(Figure 2C), or by replica molding and soft lithography methods, originally developed by George 
Whitesides group in silicone plastics (79, 80). Recently, advances in this technique allowed 
patterning of cell-laden biological materials (81, 82) and the perfusion of scaffolds with 
endothelialized microvascular channels (77, 78, 82, 83) (Figure 2D). Although lithographic 
techniques are limited to planar configurations, the bioprinted sacrificial molds were capable of 
generating a lattice of interconnected vessels (78). Finally, modular assembly of cell-laden beads 
permits the formation of contiguous endothelial architectures, although the geometries of these 
networks are less defined than the other approaches (84, 85).  Together, these platforms enable 
unprecedented access to questions in vascular biology and vascularized tissue function (86). 
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In vitro microvascular platforms are particularly suited to quantify physiological 
parameters governing mass transport and drug delivery (76, 82). For example, microfabricated 
vascular structures permit measuring endothelial permeability in authentic lumenized channels as 
a function of pericyte coverage, and in response to biochemical factors known to interfere with 
endothelial cell signaling (82). Furthermore, microvascular platforms offer exquisite opportunity 
to measure cell viability as a function of Krogh distance and metabolic consumption at specific 
cell densities (78, 81) and to monitor transvascular and interstitial transport of therapeutic agents. 
Finally, they provide increasingly accurate models of the tumor environment, allowing tumor-
stromal cell cross talk in the assessment of efficacy (74, 87-90). Taken together, engineering 
models of vascular transport facilitate pre-clinical studies of drug delivery with human cells within 
a biomimetic tissue environment.  
Tumor desmoplasia and ECM remodeling: biophysical changes and their relevance to drug 
delivery 
Biology of tumor desmoplasia and ECM remodeling 
As tumors progress from a benign to malignant stage, they recruit cancer-associated 
fibroblasts (CAFs) that can modulate drug response through altering ECM physicochemical 
properties (Figure 3). CAFs, which include myofibroblasts, deposit abundant amounts of fibrillar 
ECM molecules including collagen I and fibronectin (91). These ECM compositional changes 
entail structural and mechanical alterations of the ECM (92-94). For example, CAFs mediate the 
partial unfolding of fibronectin, which increases both the stiffness of individual fibronectin fibers 
(95, 96) and their ability to bind other ECM molecules such as glycosaminoglycans (GAGs) and 
collagen (97). Along with elevated collagen crosslinking (e.g., by lysyl oxidase, non-enzymatic 
glycation, or transglutamination (98, 99)) and GAG concentration (93), these pronounced changes 
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Fig. 3. Biophysical changes of mammary tumor stroma. A) Schematic illustration of the structural and
functional changes in tumor-associated mammary stroma. Tumor-derived cytokines not only promote
recruitment of inflammatory cells, but also cancer-activated fibroblasts, which stiffen tumors by thickening,
linearizing and aligning fibrillar ECM components. These changes alter the transport of growth factors and
cytokines, but also of therapeutic compounds with consequences on cancer cell drug resistance. B) Visualization
of collagen structure in mammary tissue of normal and tumor-bearing mice via second harmonic generation
imaging. Coiled and disorganized collagen fibers are present in normal mammary tissue. Upon tumorigenesis,
thicker and linearized collagen fibers develop, which are tangentially and radially oriented along the boundary of
premalignant and invasive mammary tumors, respectively (148). Reproduced with permission from Biomed
Central.
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in ECM density and intermolecular interactions globally enhance tumor stiffness with direct 
consequences for tumor progression.  
Despite this overall increase in matrix deposition and cross-linking, tumor cells 
simultaneously mediate the degradation of the ECM, in part by secreting enzymes such as matrix 
metalloproteinases (MMPs). In addition to generating tumorigenic ECM fragments (100), elevated 
MMP activity affects the local (microscale) physical properties of the tumor ECM. For example, 
MMPs can govern degradation and reorganization of fibrillar collagen, while enhancing 
interactions with other ECM components through exposure of cryptic binding sites (101-103). 
Nevertheless, it has to be kept in mind that non-proteolytic functions of MMPs may be similarly 
important. For example, MMP-9 has been associated with smooth muscle cell adhesion, migration, 
and cell-mediated collagen contraction, independent of it’s proteolytic function (103, 104). The 
diverse roles of MMPs in tumorigenesis have previously been reviewed by Egeblad (105) and 
Page-McCaw (106). 
Alterations of ECM composition, structure, and mechanics stimulate malignancy and drug 
resistance by inducing manifold changes in cell signaling (107-110). In general, cell-ECM 
interactions facilitate the clustering of integrin adhesion receptors leading to cytoskeletal 
reorganization and cell contractility (108, 111). These changes activate signaling cascades that 
play critical roles in cell fate decisions, tumor progression, and drug resistance (e.g., Rho/Rock, 
ERK/MAPK, and PI3K) (112-115). For example, integrin signaling alters the co-activation of 
certain growth factor receptors (e.g., epidermal growth factor receptor [EGFR]) (116) which can 
impact targeted therapies designed to interfere with the related signaling cascades (e.g., cetuximab 
and panitumumab targeting EGFR, PLX4720 and PLX403 interfering with BRAF kinase 
activity) (117, 118). Changes in ECM composition and exposure of cryptic binding domains 
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partially modulate these signaling cascades by affecting integrin selectivity (119, 120). Likewise, 
increased stiffness-mediated integrin signaling plays a major role in promoting cell contractility, 
which directly stimulates malignancy by fueling tumor cell proliferation and migration (121). 
Moreover, matrix stiffness alters the behavior of tumor-associated stromal cells to drive disease 
progression. For example, increased stiffness promotes the pro-tumorigenic capability of 
mesenchymal stem cells (114, 122), compromises endothelial barrier functions (123, 124), and 
alters macrophage functions (125). Finally, stiffness-dependent changes in cell contractility are 
critical to the myofibroblastic differentiation of stromal fibroblasts (97), thus, providing a positive 
feedback mechanism that further stimulates desmoplastic remodeling. For these reasons, stromal 
markers have the potential to serve as important indices that can help to assess and predict patient 
diagnostics and outcomes (126-133). 
In addition to the direct mechano-biological effects, physicochemical changes in the ECM 
can impact soluble factor signaling (134). Specifically, the increase of ECM components with 
growth factor-binding domains affects the bioavailability of these molecules. However, this 
process is complicated by the reciprocal interplay between multiple ECM molecules. For example, 
interactions with GAG (e.g. heparin) modulate fibronectin conformation and expose cryptic 
binding sites involved in growth factor sequestration (135). Likewise, changes in cell contractility 
can expose these latent binding sites and thereby cause the release of morphogens from their ECM 
depots (e.g. post-translational activation of latent transforming growth factor β [TGF-β]) (136). 
Effects of tumor-associated ECM on transport physics 
Transport of therapeutic molecules through interstitial tissue is dependent on convection 
and diffusion (21). However, the combination of leaky vasculature and dense ECM increases 
interstitial fluid pressure (IFP) (137, 138) and inhibits convection-mediated transport. 
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Consequently, drug-delivery within tumor stroma primarily depends on diffusion (21). However, 
dense cellular and matrix components represent diffusion barriers that hinder transport through the 
interstitium (139, 140). Specific parameters that regulate diffusion efficiency through the stroma 
include 1) diffusion distance, 2) available volume fraction of pores (accessible space where 
molecules can pass through), 3) tortuosity of pathway, 4) hydrodynamic resistance, and 5) ECM 
affinity of the molecule of interest (67) (BOX2). All of these parameters are affected by tumor 
stroma remodeling. For example, desmoplasia-mediated enhancement of ECM density and 
structural changes decrease the available volume fraction of pores and increase the tortuosity of 
the void space, both of which reduce the rate of diffusion through the stroma (141, 142). Therefore, 
properties of both the drug (e.g. size, charge, configuration, etc.) (143) and the ECM (e.g., 
composition, viscoelasticity, geometrical arrangement, and/or electrostatic properties) should be 
considered when approximating an agent’s bioavailability (139, 141, 144-146).  
The specific structure of ECM components also modulates diffusion fluxes of therapeutic 
molecules. Analysis of collagen fiber orientation via second harmonic generation imaging (SHG) 
revealed that increased malignancy is associated with collagen fiber re-orientation. While collagen 
in initiating tumors is characterized by isotropic orientation, progression leads to tangential and 
ultimately radial alignment in expanded and invading tumors, respectively (147, 148) (Figure 3B). 
These changes in ECM fiber network orientation can promote diffusion anisotropy without 
affecting the overall diffusion coefficient of the drug (149). For example, fibers tangentially 
aligned to the tumor boundary could redirect drug diffusion away from the tumor and, therefore, 
impair therapy efficacy during initial stage of tumorigenesis. Theoretically, radially aligned fibers 
should mediate the opposite effect; however, at this stage tumor cells may have developed 
resistance phenomena rendering them unresponsive to therapy.  
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Box 2. Forces governing interstitial transport.
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Finally, changes in ECM composition can affect delivery by altering hydrodynamic and 
electrostatic interactions of the drug with the ECM. Generally, tumor-mediated elevation of ECM 
viscosity increases the hydrodynamic resistance of molecules and hence slows down their 
movement through the interstitial space (67, 139, 142, 144, 150). These differences are aggravated 
by changes in ECM charge distribution (e.g. due to increased association with negatively charged 
sulfated GAGs including heparan sulfate (134, 144). More specifically, electrostatic repulsion or 
attraction of charged particles can reduce the available volume fraction of pores and/or cause local 
sequestration of the drug. Furthermore, electrostatic interaction may not only be relevant to ECM-
drug interactions per se, but can also alter the conformation of ECM molecules (e.g. as outlined 
above for fibronectin-heparin interactions (151)). These variations, in turn, can impact their ability 
to bind morphogens ultimately exaggerating asymmetric drug distribution within tumors. 
The potential opportunity for enhancing drug transport by modifying tumor matrix was 
demonstrated in a mouse model of pancreatic cancer, where gemcitabine delivery was improved 
through depletion of desmoplastic stroma by inhibition of hedgehog signaling (152).  However, 
Infinity Pharmaceuticals’ phase II clinical trials for saridegib (IPI-926) in combination with 
gemcitabine were halted last year due to increased mortality, suggesting that this strategy may 
require improved understanding of tumor-stromal interactions in human patients. Consequently, 
tumor-associated ECM remodeling critically impacts diffusive transport, yet, most drug testing 
approaches neglect the contribution of the above-described parameters. Physiologically relevant 
3D tumor models recapitulating the physicochemical properties of the ECM that interfere with 
diffusion fluxes offer promise to selectively define coefficients modulating drug transport 
dynamics in tumors. 
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In vitro models recapitulating ECM-mediated changes in tumor transport 
Natural biomaterials can be employed to assess tumorigenesis as a function of altered ECM 
characteristics. Matrigel®, a basement membrane mixture isolated from murine Engelbreth-Holm-
Swarm sarcoma, is currently most widely used. However, inherent batch-to-batch variability, 
incomplete controllability of physicochemical parameters (e.g. narrow range of stiffness), and lack 
of covalent crosslinks critical to the basement membrane barrier function (95, 153-155) represent 
limitations of this material. Collagen type I is a defined biological scaffold that can be synthetically 
modified to provide a wider range of physicochemical properties. For example, collagen stiffness 
can be adjusted through covalent crosslinking by non-enzymatic glycation (156). However, this 
procedure can impact cell behavior by preventing enzymatic degradation of the matrix and by 
accumulating advanced glycation end products, both of which affect biochemical signaling. (157).  
Synthetic biomaterials have emerged as attractive alternatives to modulate stiffness in a 
more controlled manner. ECM-coated polyacrylamide (PA) gels allow adjustment of stiffness 
independent of ligand concentration. This platform has been critical to the identification of 
mechanoregulatory signaling mechanisms of tumorigenesis (121). However, PA gels cannot be 
remodeled by cells, and the fabrication method further limits their use to 2D studies which may 
affect critical cell functions (110, 158). Moreover, altering crosslinking density can affect the 
surface porosity of PA gels, which may cause conformational changes of the ECM coating that 
modulate cell behavior (159).  
Poly(ethylene glycol) (PEG)-based materials can address some of these challenges. For 
example, remodelable PEG-based hydrogels have been developed to study the independent effects 
of stiffness and peptide ligand density on lung cancer cells in a 3D context (Figure 4A) (160). 
Moreover, photodegradable or photoreversible crosslinks may be introduced to enable temporal 
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Fig. 4. Examples of engineering approaches to recapitulate tumor-associated ECM characteristics. A)
Covalently cross-linked PEG-based hydrogels with controlled stiffness and ligand concentration have been used
to investigate the impact of these parameters on lung cancer cells (159). B) Tunable hyaluronic acid-based 3D
hydrogels containing proteolytically cleavable crosslinks revealed a role of ECM degradation-mediated cellular
traction in cell fate decisions (162). C) Studies with stretchable PDMS molds containing fibrillar collagen gels
revealed that axially oriented collagen fibers promote epithelial co-orientation, which is prevented by randomly
oriented collagen fibers (167). D) Tumor-mediated changes in fibronectin conformation can be simulated with
conducting polymers. Applying an appropriate potential to the cytocompatible conducting polymer poly (3,4-
ethylenedioxythiophene) doped with p-toluenesulfonate (PEDOT:TOS) yields conformation gradients of
adsorbed fibronectin that can be confirmed by FRET analysis and that influence cellular adhesion
(green calcein staining) (150,175). Images were reproduced with permission from American Association for
Cancer Research (A), Nature Publishing Group (B), Cell Press (C), Wiley Online Library and Royal Society of
Chemistry (D).
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control of substrate stiffness in situ (161, 162). By allowing dynamic physicochemical changes in 
the ECM, such platforms can provide important new insights to tumor development. For example, 
studying proteolysis-mediated variations of cellular traction could reveal the temporal effects of 
substrate stiffness on cell fate decisions (as recently shown with hyaluronic acid-based degradable 
materials (Figure 4B) (163). Furthermore, integration of growth factor binding sites could mimic 
the effects of matrix-binding on morphogen or drug distribution (164). 
While the above approaches rely on changing the material chemistry, ECM structural 
changes can also be introduced by varying the scaffold fabrication conditions. One relatively 
simple approach to modify collagen fibril characteristics is by adjusting the gelation temperature, 
pH, and/or material concentration (165). Additionally, the collagen isolation technique is a critical 
consideration, as fibers from acid-solubilized collagen may mimic in vivo microarchitecture, but 
these gels also contain telopeptides that may compromise biocompatibility relative to pepsin-
digested collagen (166, 167). Furthermore, the random orientation of spontaneously formed 
collagen fibrils does not recapitulate fiber alignment in tumors. One method to orient collagen 
fibers is by casting collagen gels into PDMS molds and exposing them to tensile stress axially 
(168) (Figure 4C). However, this loading method may also modulate the behavior of the embedded 
cells, and interpretation of results is complicated by non-linear cellular response to combinations 
of mechanical forces and ECM properties (169). Electrospinning of artificial ECM scaffolds may 
help to overcome some of these challenges and allow the selective manipulation of ECM structural 
features at relevant length scales (170-173). 
Fibronectin represents an important tumor-associated ECM component whose 
conformation can be quantified and recapitulated using biomaterials-based approaches. FRET-
based analysis as established by the Vogel lab has provided quantitative insights into tumor-
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mediated fibronectin unfolding (96, 174). This unfolding impacts integrin selectivity by altering 
the spatial separation between the RGD adhesion and PHSRN synergy sequence. One elegant 
approach to study the consequences of protein conformation is to modify synthetic, otherwise 
nonadhesive, hydrogels with RGD and PHSRN peptides either alone or in combination (175). 
Alternatively, conducting polymer substrates have been employed to unfold native fibronectin. 
Applying differential voltages to poly (3,4-ethylenedioxythiophene) doped with p-
toluenesulfonate (PEDOT:TOS) permits selective manipulation of the conformation of adsorbed 
fibronectin (Figure 4D) (151). Such systems have been used to elucidate that fibronectin 
conformational changes influence cell adhesion and secretory patterns for both stromal and tumor 
cells (176, 177). Yet, fibronectin does not occur in isolation, but is part of complex ECM scaffolds, 
which can be partially mimicked with fibroblast-derived 3D ECMs. These matrices are generated 
by detergent-based decellularization and recapitulate various physicochemical aspects of native 
ECMs including fiber alignment, composition, and density (115, 178). Furthermore, they allow 
the delineation of effects mediated by healthy and tumor-associated ECMs and have revealed 
differential cell morphology, orientation, and migration, as well as drug response in healthy versus 
disease conditions (179).  
In order to be useful in drug discovery and screening, the in vitro platforms described above 
must support high-throughput testing of complex libraries of bio-chemical-physical cues. 
Recently, sophisticated high throughput methods were introduced to screen for combinational 
effects of ECM physicochemical parameters on cells incorporated in 3D hydrogels (180). These 
high throughput microarrays, combined with topographically-controllable biomaterial-based 
scaffolds, afford a more comprehensive understanding of the integrated effects of the tumor 
microenvironment on drug delivery and efficacy. 
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Future directions 
Artificial cell culture platforms have traditionally benefited from the ability to isolate 
individual biological parameters in a controlled experimental environment, but many challenges 
exist when moving toward increasingly realistic models for replicating tumor pathology and 
therapy. Specifically, such biomimetic cultures are confined by boundaries of space, time, and 
complexity. Addressing these limitations will help to accurately study cancer biology and translate 
the findings to clinical practice.  
Spatial resolution is a critical parameter of engineered tissues. Although microfabrication 
technologies afford unprecedented access to cell-scale precision, integrating this resolution into 
meaningful tissue or organ-level organization is nontrivial. For example, artificial tumors grown 
in confined structures may undergo differential morphogenesis relative to human disease. In 
addition, most microfluidic geometries present boundary artifacts, including mechanical and 
chemical interactions along the walls of the device that may contribute to this end (181-183). 
Moreover, engineered tumors are often isolated systems that lack an organism-level context. 
Recent integration of multiple organ compartments into body-on-a-chip devices has started to 
simulate aspects of organism physiology, including drug metabolism and toxicity of anti-cancer 
drugs (184, 185). These in vitro models provide a first glimpse at holistic consequences of tumor 
growth or therapy; however, they still neglect critical physiological characteristics, including 
cellular transport through the blood contributing to tumor progression or metastatic homing. For 
example, the molecular communication between breast cancer cells and bone marrow-derived 
progenitor cells may contribute to pre-metastatic niche formation in the target organ (186). 
Systemic in vitro models that connect diverse organ compartments through engineered vascular 
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systems may facilitate a more comprehensive understanding of the mechanisms underlying 
metastasis and define future treatment strategies (187, 188). 
The temporal scale of in vitro models introduces a second experimental obstacle. Culture 
conditions of days to weeks must simulate emergent phenomena of months and years. This 
challenge is especially relevant in the evolution of drug resistance, where population drift relies 
on many generations of cell division (189, 190). In vitro platforms may approximate these effects 
of tumor heterogeneity by cell sourcing from primary tumors or by seeding mixed cell populations 
representing different stages of tumor development (191). In addition to drug resistance, 
morphological changes in tissue stroma, including vascular and ECM remodeling, often require 
longer durations than conventional experimental techniques. This motivates the use of artificial 
factors such as phorbol 12-myristate 13-acetate (PMA) to rapidly stimulate cellular response (192, 
193), or the use of low density matrices to accelerate remodeling and migration (194, 195). 
Although useful experimental tools, these artifices may compromise the integrity of the in vitro 
system. Computational models of tumorigenesis offer an alternative strategy for recapitulating the 
time-scale of pathogenesis (196). For example, multiscale computational models of the tumor 
microenvironment can be used to predict changes in tumor malignancy as a function of stroma-
dependent selective pressure (20). However, in order to mimic physiological growth rates, these 
models rely on the accurate measurement of cell kinetics. By providing controlled platforms to 
measure these critical coefficients, in vitro tumor models may inform the development of accurate 
in silico models of progression and response. 
Physiological complexity, including matrix composition, cellular components, or 
spatiotemporal presentation of soluble factors, introduces additional compromises for in vitro 
tissue culture. Notably, increasing complexity often undermines the controllability of the system. 
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For example, although in vitro tumor models enable human-specific drug screening, tumor cells 
have a broad spectrum of characteristics depending on originating organ, stage or malignancy, and 
patients’ genetic background, additional health complications, and life style. Therefore, short-term 
culture of cell lines may not cover organ-, patient-, and stage-specific features of tumors. 
Furthermore, genomic and epigenomic instability leads to diverse clonal populations within a 
single tumor that cross-communicate (197, 198), and this signaling is lost given the uniformity of 
conventional cell culture lines. Advances in personalized medicine have begun to appreciate the 
unique molecular signature of individual patients. Integration of patient-derived biopsies within 
engineered models may allow personalized drug screening prior to treatment. The advantages of 
closely approximating physiological complexity is an asset of engineered tumor models, but 
remembering these limitations will help guide the interpretation and translation of data collected 
with these systems.  
Conclusions  
By integrating cancer biology and engineering approaches, realistic tumor models may be 
developed that have the potential to advance current anti-cancer therapies. More specifically, this 
approach will help to better define qualitative and quantitative parameters currently complicating 
drug transport in tumor-associated blood vessels and stroma. In the future, however, further 
improvements are needed to enhance the relevance of these models. For example, integration with 
organ-on-a-chip devices may not only help to recapitulate systemic aspects of the disease, but also 
to better define the spatiotemporal relationships and patient-inherent complexity complicating 
drug transport in the clinic. Together with current advances in cancer (epi)-genomics and 
computational modeling engineered tumor models offer promise to bridge the gap between bench 
to bedside research and help translate new therapeutic approaches to the clinic. 
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CHAPTER 3 
3D CULTURE REGULATES TUMOR HYPOXIA RESPONSE AND ANGIOGENESIS 
VIA PRO-INFLAMMATORY PATHWAYS 
Peter DelNero, Maureen Lane, Scott Verbridge, Brian Kwee, Pouneh Kermani, Barbara 
Hempstead, Abraham Stroock, and Claudia Fischbach. (2015). 3D culture broadly 
regulates tumor cell hypoxia response and angiogenesis via pro-inflammatory pathways. 
Biomaterials 55(1):110–118. 
Abstract 
Oxygen status and tissue dimensionality are critical determinants of tumor angiogenesis, a 
hallmark of cancer and an enduring target for therapeutic intervention. However, it is unclear how 
these microenvironmental conditions interact to promote neovascularization, due in part to a lack 
of tumor models that allow independent control of oxygen levels within three-dimensional (3D) 
culture. Here, we integrated biomaterials and microfabrication technologies to generate oxygen-
controlled 3D tumor models, which permit evaluating the interdependence of culture context and 
the hypoxia response. A comprehensive microarray gene expression analysis of cells cultured in 
2D versus 3D under ambient or hypoxic conditions revealed strong coupling between culture 
dimensionality and hypoxia response, which was mediated in part by inflammatory signaling 
pathways. In particular, interleukin-8 (IL-8) emerged as a major player in the microenvironmental 
regulation of the hypoxia program. Notably, this interaction between dimensionality and oxygen 
status via IL-8 increased angiogenic sprouting in a 3D endothelial invasion assay. Taken together, 
our data suggest that inflammatory pathways are critical regulators of tumor hypoxia response 
within 3D environments that ultimately impact tumor angiogenesis, potentially providing 
important therapeutic targets. Furthermore, these results highlight the importance of pathologically 
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relevant tissue culture models to study the complex physical and chemical processes by which the 
cancer microenvironment mediates new vessel formation. 
Introduction 
Hypoxia, and subsequent angiogenic signaling, is conventionally attributed to increased 
oxygen consumption in a proliferating, 3D tumor mass (1). Spatiotemporal depletion of oxygen 
due to absent or dysfunctional vasculature activates a hypoxia response program largely controlled 
by the stabilization of transcription factor hypoxia inducible factor-1 (HIF-1) (2). As a 
consequence of HIF signaling, the up-regulation of pro-angiogenic morphogens including vascular 
endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and interleukin-8 (IL-8) 
activates the ‘angiogenic switch’ necessary for new vessel growth (3, 4). However, 
microenvironmental conditions other than hypoxia may also modulate the pro-angiogenic 
capability of tumors (5-7). For example, changes in tissue dimensionality and integrin engagement 
can activate nuclear factor-κB (NF-κB) and activator protein-1 (AP-1) transcription factors, which 
regulate the expression of IL-8 and VEGF (8, 9). Nevertheless, how the interactions between 
hypoxia and tissue dimensionality may contribute to tumor vascularization is poorly understood, 
due in part to the lack of culture systems that allow independent control of oxygen levels in 3D 
scaffolds.  
Due to diffusion-limited oxygen transport, hypoxic gradients inevitably accompany 3D 
tumor growth (10, 11). However, in addition to transport limitations, the 3D context also 
introduces myriad changes in matrix architecture, adhesion receptor signaling, cell morphology 
and polarity, and substrate mechanics (12). These changes have profound consequences for cell 
behavior (13-15). When tumor cell hypoxia response and angiogenic capability is typically studied 
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in 2D monolayer culture, 3D microenvironmental conditions are absent and accordingly, these 
alternate phenotypic characteristics are also lost. For example, hypoxia and the resulting oxidative 
stress is necessary to stimulate IL-8/NF-κB signaling in 2D culture, whereas this signaling axis is 
constitutively active in 3D (16). Accordingly, we have previously shown that hypoxia upregulates 
secretion of IL-8 in 2D, while causing an opposite effect in 3D culture (16). Hence, pathologically 
relevant culture conditions may provide new insights regarding the role of tissue dimensionality 
in guiding hypoxia-related tumor cell responses. Insights gained from such studies will be critical 
to advance our understanding of tumor angiogenesis and to identify routes toward more effective 
therapy. 
Biomaterials-based in vitro models are increasingly employed to study the role of tissue 
dimensionality in tumorigenesis and angiogenesis (17-27). We recently developed an oxygen-
controlled, 3D culture system with which we circumvented the challenges of diffusion-limited 
mass transport to control oxygen concentrations (28). Fabrication of thin (200 µm) hydrogel-based 
scaffolds relieved interior oxygen depletion, allowing us to create homogeneous O2 levels within 
the 3D matrix (28, 29). Here, we used this model to distinguish the independent and co-dependent 
effects of dimensionality and oxygen tension in regulating the tumor hypoxia response and 
angiogenesis. More specifically, we determined gene expression profiles of tumor cells cultured 
in 2D and 3D under uniform hypoxic or normoxic conditions using a comprehensive microarray 
analysis. We validated the results for molecules of interest by RT-PCR and ELISA, and we 
confirmed their relevance across multiple tumor cell lines. Finally, using a 3D model of endothelial 
cell invasion, we evaluated the functional consequences of 3D culture and oxygen conditions on 
sprouting angiogenesis.  
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Materials and Methods 
Cell Culture 
Cell lines used in this study included human oral squamous cell carcinoma (OSCC)-3 (gift 
from Peter Polverini, University of Michigan), A549 lung carcinoma, KATO-III gastric signet ring 
carcinoma, and MDA-MB231 breast cancer cells (all from ATCC). Tumor cells were cultured in 
Dulbecco’s modified eagle medium (DMEM, Gibco), supplemented with 10% fetal bovine serum 
(20% for KATO-III), and 1% penicillin-streptomycin (P/S). In addition, human umbilical vein 
endothelial cells (HUVEC, Lonza) at low passage (p < 6) were cultured in Bio-Whittaker medium 
199 (M199, Lonza), supplemented with endothelial cell growth supplement (ECGS, Millipore, 
Billerica, MA), 20% FBS, 1% P/S, 2 mM Glutamax, and 5 U/mL  heparin.  
Preparation of Alginate Discs 
Microfabricated alginate hydrogels (4% wt/vol) were used for 3D tumor cell culture, as 
previously described (16). Briefly, cells were suspended in alginate (Protanal LF, FMC 
Biopolymer, Philadelphia, PA) at 20 x 106 cells/mL. The cell-laden gel was cast in a Plexiglass 
mold (4 mm diameter, 200 µm deep to ensure uniform O2 concentration) and cross-linked with 60 
mM calcium chloride (CaCl2) solution for 15 minutes. Alginate disks were cultured in 24-well 
plates (one disk per well) on an orbital shaker for 6 days in the appropriate media at 37o C and 5% 
CO2. Oxygen levels were set to either hypoxic (1%) or ambient (17 %) O2 in a controlled 
atmosphere incubator (ThermoFisher Scientific, Inc., Waltham, MA). Media was changed every 
48 hours. 
Endothelial Invasion Assays 
Collagen-based microwell invasion assays were fabricated as previously described (30). 
Briefly, PDMS microwells (200 µm deep, 4 mm diameter; Dow Corning, Midland, MI) were 
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fabricated by soft-lithography against an SU-8 mold. The PDMS surface was pre-treated with 1% 
poly(ethyleneimine) (PEI; Aldrich Chemical, St. Leouis, MO) and 0.1% glutaraldehyde (GA; 
Fischer Scientific, Fair Lawn, NJ) for 10 minutes and 20 minutes, respectively, and washed 
thoroughly with sterile water. Stock solutions of 1.5% (wt/vol) type I rat tail collagen in 0.1% 
acetic acid were osmotically balanced (9:1) with 10x M199 media, neutralized with 1N sodium 
hydroxide (NaOH), and diluted to 0.8% (wt/vol) for mono-culture assays. For co-culture invasion 
assays, tumor cells were suspended in 0.068% collagen gel at a density of 10 million cells/mL. 
The collagen gel was then cast onto the PDMS microwell mold and cross-linked at 4o C for 15 
minutes, followed by 37o C for 15 minutes. HUVECs were seeded at 300 cells/mm2 on the collagen 
surface and cultured in HUVEC invasion media at ambient O2, 5% CO2, and 37
o
 C. Invasion media 
was HUVEC growth media spiked with 1% [v/v] L-ascorbic acid (50 µg/mL; Acros Organics, 
Morris Plains, NJ), and 0.16% [v/v] tetradecanoyl phorbol acetate (TPA; 50 ng/mL; Cell Signaling 
Technology Inc., Danvers, MA) to sensitize endothelial cells. In mono-culture experiments, 
recombinant human IL-8 (GenScript, Piscataway, NJ) and VEGF (R&D Systems, Minneapolis, 
MN) was added at 40 ng/mL, and their respective inhibitors were added at 200 ng/mL in co-culture 
experiments (both from R&D Systems). Co-culture invasion assay media also contained 40 ng/mL 
bFGF (Invitrogen, Carlsbad, CA). After three days, gels were fixed in 10% formalin and stained 
with 4’,6-diamidino-2-phenylindole (DAPI), phalloidin (Alexa Fluor 568; Introgen), and a 
combination of mouse anti-human CD31 (BD Biosciences, San Jose, CA) with goat anti-mouse 
IgG (Alexafluor 488, Invitrogen). Imaging was performed by confocal microscopy (Zeiss 710, 
Carl Zeiss, Inc., Thornwood, NY) at 250x magnification for a 0.46 mm2 area and z-slices up to 40 
μm depth. Images were analyzed using ImageJ software by counting the number of CD31+ cell 
invasions extending beyond 12 μm (~3 slices) from the surface. 
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Microarray Processing  
Total RNA from cells was isolated by using Trizol (Invitrogen) according to 
manufacturer’s instructions. A one-round in vitro transcription (IVT) RNA Amplification Kit (Life 
Technologies, Grand Island, NY) was used to amplify 1.5 micrograms of total RNA. The cDNA 
was synthesized with a primer containing oligo (dT) and T7 RNA polymerase promoter sequences. 
Double-stranded cDNA was then purified and used as a template to generate biotinylated cRNA. 
The quantity and quality of the amplified cRNA was assessed using NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific, Wilmington, DE) and Agilent Bioanalyzer (Santa Clara, 
CA). The biotin labeled cRNA was fragmented and hybridized to the Affymetrix ChIP kit 
(Genechip Human Genome U133 plus 2.0) (Santa Clara, CA) for analysis of over 39,000 
transcripts on a single array. After Hybridization, GeneChip arrays were washed, stained, and 
scanned by GeneChip Scanner 3000 7G according to the Affymetrix Expression Analysis 
Technical Manual. 
Affymetrix GeneChip Operating Software was used for image acquisition. The target 
signal intensity from each chip was scaled to 500. The data normalization, statistical analysis, and 
pattern study were performed with GeneSpring GX 12.6.1 software.  Pathway and functional 
analyses were generated through the use of IPA (Ingenuity® Systems, www.ingenuity.com). 
Confirmation of Microarray Results by ELISA and qRT-PCR 
Secreted protein levels were measured by ELISA (R&D Systems) following 24 hours of 
culture in serum-free media, according to the manufacturer instructions. Cells were released by 
dissolving alginate disks with ethylenediaminetetraacetic acid (EDTA) and lysed in Caron’s 
buffer. DNA content of cell lysates was fluormetrically measured with Quant-iT PicoGreen 
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dsDNA reagent (Invitrogen) and used to normalize secretion levels. To determine changes at the 
transcriptional level, total RNA was harvested from isolated cells using TRIzol (Invitrogen). 
Reverse-transcription of 1 μg to cDNA (qScript cDNA supermix, Quanta BioSciences, 
Gaithersburg, MD) was performed with random hexamer and IL-8 specific oligo(dt) primers, 
followed by qRT-PCR using SYBR green detection (Quanta Biosciences) and an Applied 
Biosystems 7500 system. Quantification was normalized relative to β-actin using the ΔΔCt 
method.  
Statistical Analysis 
Chip data raw intensity files (.cel) that were processed using the RMA algorithm were 
imported into the GeneSpring GX 12.6.1 program (Agilent Technologies, Foster City, CA). Signal 
values <0.01 were set to 0.01, arrays were normalized to the 20th percentile, and individual genes 
normalized to the median. A one-way analysis of variance (ANOVA) with a corrected asymptotic 
p-value of <0.05 for significant differential gene expression and a p-value of < 0.0001 for pathway 
analysis was performed comparing OSCC3 cells grown under the following conditions:  3D matrix 
in 1% oxygen, 2D matrix in1% oxygen, 3D matrix in 17% oxygen, and 2D matrix in 17% oxygen. 
Multiple Testing Correction (Benamini-Hochberg) was performed and a filter for greater or less 
than 2.0-fold differences was applied to determine potential differential expression. A post-hoc 
test using the Student-Newman Keuls (SNK) method was also applied.  Data were imported into 
Ingenuity Pathway Analysis software (Ingenuity Systems, Redwood City, CA) for molecular 
pathway analysis using a 2.5 fold change filter. ELISA, RT-PCR, and invasion assays were 
compared using Fisher’s T-test. All experiments were performed in triplicate (N=3). Results are 
presented as mean +/- the standard deviation. 
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Results 
Dimensionality and oxygen status interdependently regulate tumor cell gene expression 
In order to determine the interdependent effect of hypoxia and dimensionality on gene 
expression, microarray analysis of 46803 gene transcripts was performed on OSCC3 cells cultured 
in a 2D monolayer on conventional tissue culture polystyrene or encapsulated within 
microfabricated alginate discs after 6 days.  OSCC-3 cells were chosen as representative of an 
aggressive tumor whose highly vascular nature may result from a latent relationship between 
oxygen depletion and dimensionality. The 3D discs were microfabricated at 200 μm thickness 
(Fig. 1A), allowing uniform control of intrascaffold oxygen concentration by incubation at either 
hypoxic (1% O2) or ambient (normoxic, 17% O2) conditions. Homogeneous oxygen transport was 
previously predicted by finite element models incorporating oxygen diffusion and cellular 
consumption and confirmed by histological analysis (16). Principle component analysis of gene 
expression assays performed on 2D and 3D samples from normoxic or hypoxic cultures (Fig. 1B) 
showed a consistent clustering of samples within each treatment, as well as maximum disparity 
between groups along each axis (Fig 2A). This data distribution affirms that cells in each condition 
exhibited a unique and reproducible expression profile.   
In total, 29866 genes satisfied the corrected p-value criteria (p < 0.05), and 8637 genes 
were identified based on a response to hypoxia and/or dimensionality by a relative fold-change 
greater than 2. The populations of genes associated with each comparison are provided in the Venn 
diagram in Fig 2B. We begin by noting that interaction between oxygen status and dimension 
played a role in the transcription of 77% of genes (6653 genes, denoted “a”). One fifth of oxygen-
sensitive genes were independent of dimensionality: the expression of 19% of the genes (1592), 
denoted “b”, occupy the intersection of the blue (1% vs. 17% in 3D) and green (1% vs. 17% in 
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Fig. 1. Experimental design to compare 2D versus 3D hypoxic response. A) Schematic illustrating the
fabrication of microscale alginate scaffolds. Cells were suspended within algmate and cast onto an array of 200
µm-deep x 4 mm-diameter wells. CaCl2 solution was applied through a filtration membrane to crosslink the gels.
Scaffolds were removed from the mold and cultured in suspension. B) Experimental design comprised culturing
OSCC-3 cells on conventional tissue culture polystyrene (2D) or embedded within microfabricated alginate
discs (3D) inside ambient (17% 02) or hypoxic (1% 02) incubators for 6 days. Subsequently, total RNA was
isolated and transcriptional changes analyzed by Affymetrix GeneChip microarray.
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2D) ovals, but were unaffected by changes in dimensionality at either hypoxic (brown oval) or 
normoxic (orange oval) conditions.  Furthermore, merely 5.6% (392 genes, denoted “c”, 
intersection of brown and orange ovals) of dimension-associated genes were not also affected by 
oxygen concentration. Surprisingly, the majority (66%, 4558 genes, denoted “x”) of hypoxia-
associated genes were unique to either 2D or 3D culture; only 34% (2316 genes, denoted “y”) were 
similarly regulated by hypoxia in both substrate conditions. Likewise, only 19% (838 genes, 
denoted “z”) of genes regulated by substrate dimension were shared in both low- and high-oxygen 
conditions. Notably, dimensionality affected a larger number of genes in hypoxia (3093 genes, 
sum of red oval) than in normoxia (2230 genes, sum of orange oval), suggesting that the hypoxia 
response depended strongly on whether cells were cultured under 2D or 3D conditions. 
Specifically, hypoxia may have sensitized cells to respond to changes in dimensionality, or 
conversely, changes in dimensionality may have sensitized cells to hypoxia. Altogether, this data 
suggests a strong interdependence between oxygen status and dimensionality at the gene 
expression level.  
Although the Venn diagram identified populations of genes that respond to 3D context and 
oxygen concentration, the direction and magnitude of regulation are also important. In order to 
more clearly define these parameters, we generated a scatter plot of the relative fold-change 
expression levels in response to hypoxia in 2D and 3D culture (Fig 2C). Changes in gene 
expression were ranked by the magnitude of the residual (3D FC/2D FC), and a total of 2563 genes 
were identified that exhibited a differential response to hypoxia greater than 2-fold in 2D versus 
3D culture (blue data points). Of the genes that responded differently in 2D versus 3D hypoxia, 
12% (317 genes, purple quadrants) exhibited an inversion of expression, 28% (714 genes, yellow 
quadrants) produced an exaggerated up or down regulation, and the remaining 60% (1536 genes, 
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Fig. 2. Global changes in gene expression induced by hypoxia or dimensionality. A) Principal component
analysis of the microarray data was performed using GeneSpring GX 12.6.1 software. Clustering of each
substrate and oxygen level indicated the reliability of each treatment to generate independent and self-consistent
gene expression profiles. B) The Venn diagram displays genes that were associated with changes in
dimensionality and/or oxygen status. Intersections between various groups indicate populations of genes that are
significantly altered (fold-change > 2, corrected p-value < 0.05) in multiple comparisons of oxygen treatment or
substrate dimension. Most of the changes in expression were linked with both dimensionality and oxygen status
(sum of regions denoted "a"), indicating an intimate interdependence in gene regulation associated with these
conditions. C) The scatterplot of the 3D hypoxia vs normoxia (y-axis) and 2D hypoxia vs normoxia (x-axis)
shows the magnitude (FC: fold change) and direction (↑ and ↓ : up- and down-regulation, respectively) of gene
expression changes. This plot depicts a large cluster of genes (2563 genes, blue) for which the hypoxic response
is differentially regulated (greater than 2-fold change) depending on substrate dimension.
58
grey background) were regulated by hypoxia in one context but not the other. The subset of genes 
displaying a differential regulation of hypoxia response based on 2D or 3D substrate became the 
subject of subsequent analysis in the link between hypoxia and dimensionality. 
Interactions between hypoxia and dimensionality regulate inflammatory response pathways 
Ingenuity Pathways Analysis (Ingenuity Systems) software was used to identify signaling 
networks and biofunctions that were associated with the differential changes in gene expression 
for the 3D versus 2D hypoxia response. Data for this analysis used a gene list of 11,828 entities 
satisfying a p-value of < 0.0001 and a FC cut- off of 2.0; data was further filter in IPA to a fold 
change cut-off of 2.5. Top ranked networks from the individual comparisons are listed in 
Supplementary Table 1. Not surprisingly, top categories included cancer-associated cell and tissue 
functions, including cell cycle, cellular development and growth, metabolic processes, and tissue-
specific disorders. In most cases, these networks were significant in all four comparisons (2D 1% 
vs 17%; 3D 1% vs 17%; 1% 2D vs 3D; 17% 2D vs 3D; data not shown). In order to identify 
divergence between the 2D and 3D hypoxia response, we performed an analysis of the changes in 
gene expression in response to both oxygen status and substrate dimension. Again, top networks 
were associated with traditional cancer motifs which are known to depend on hypoxia and 3D, 
including cell cycle, DNA replication, cell death and survival, cell signaling, cell growth and 
proliferation, and cancer (Fig 3A). Interestingly, the inflammatory response was highly ranked in 
this meta-comparison, and also emerged among the top biofunctions in the 3D 17% vs 2D 17% 
and the 3D 1% vs 3D 17% comparisons (Supplementary Table 1). This result suggests that 
inflammatory signaling is one of the top functions linked to both substrate dimension and oxygen 
status. 
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Next, we identified the top signaling pathways associated with each treatment by 
comparing the expression profiles to canonical responses; several metabolic and cell cycle 
signaling cascades emerged as prominent features of this analysis (Supplementary Table 2). 
Looking at the divergence between the 2D and 3D hypoxia response, we observed that leukocyte 
trafficking signaling, as well as interferon signaling and pattern recognition receptor (PRR) 
activity, were strongly co-regulated by dimension and hypoxia (Fig 3B). The differential 
regulation of these inflammatory pathways is consistent with the biofunctions analysis described 
above.  
 Finally, we investigated the integrated effects of culture dimensionality and hypoxia on 
the transcription of individual genes (Fig 3C, Supplementary Tables 3-4). In accord with the 
network and pathways analyses, we observed that several of the top regulated genes (PLAT, IL-8, 
CXCL1, and TFAIP6) were associated with inflammatory signaling (Fig 3C, red boxes). Taken 
together, this analysis suggests that the differential regulation of hypoxic signaling in 2D versus 
3D culture has significant consequences for inflammatory signaling at the network, pathway, and 
molecular level. 
Validation of IL-8 expression and secretion confirms regulation of inflammatory signaling in 3D  
Because IL-8 was prominently regulated by the integrated effects of hypoxia and 
dimensionality at both the individual gene (Fig. 3C) and canonical pathway level (Fig. 3B), and 
because IL-8 has pleiotropic effects on inflammation and angiogenesis (31-33), we chose to pursue 
this molecule as a representative candidate for further investigation. Interestingly, IL-8 was one of 
214 genes affected by all four combinations of oxygen status and dimensionality, and also one of 
351 genes that exhibited an inverted hypoxia response depending on culture dimension. 
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Fig. 3. Inflammatory signaling may underlie the differential hypoxic response in 3D. A) Ingenuity’s Global
Functional Analysis was used to evaluate functional networks from the gene expression data. Top ranked
networks were identified based on the connectivity of focus genes in the Global Molecular Network in the
Ingenuity Pathways Knowledge Base, and the score, calculated as the -log10(p-value) of the network emerging
by chance, indicates the statistical improbability of a false positive result. B) Ingenuity’s Global Canonical
Pathways tool was used to associate changes in gene expression with known signaling processes. The p-value
was calculated based on the number of focus genes compared to a reference set for each pathway, and the ratio
represents the fraction of focus genes identified in each pathway. Top ranked canonical pathways were largely
linked to inflammatory processes, suggesting these pathways are differentially regulated by the culture
environment. C) When ranked by fold change in expression, five of the top ten genes were associated with
inflammatory signaling (outlined in red). The fold-change value represents the difference in the hypoxia-induced
expression in 3D versus 2D.
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Specifically, IL-8 expression was increased in 2D hypoxia but reduced in 3D hypoxia, compared 
to the respective expression under ambient conditions. Moreover, IL-8 was the most strongly up-
regulated molecule in 3D culture compared to 2D culture at 17% O2 (Supplementary Table 3). 
Indeed, the changes in IL-8 transcription detected via microarray analysis were relevant as 
quantitative RT-PCR and ELISA analysis similarly confirmed the direction and magnitude of 
regulation of IL-8 in response to hypoxia in 2D and 3D culture (Fig 4A-B). Most importantly, IL-
8 was expressed and secreted at significantly higher levels in 3D vs. 2D culture independent of 
oxygen concentration. These changes were not specific to the OSCC-3 cell line used for the initial 
investigations, but also applied to three additional human epithelial tumor cell lines: A549 alveolar 
basal adenocarcinoma, KATO-III gastric carcinoma, and MDA-MB231 breast carcinoma. Each of 
these cell lines similarly demonstrated a robust up-regulation of IL-8 in normoxic 3D versus 2D 
culture (Fig 5A-B). These results support the broad applicability of the microarray results, and 
specifically reaffirm that 3D microenvironmental conditions can regulate IL-8.  
Pro-inflammatory signals in the 3D environment may promote angiogenesis via IL-8 and VEGF 
interaction 
Next, we examined the relevance of microenvironmentally-induced IL-8 on tumor 
angiogenesis. To this end, we used a microwell invasion assay to evaluate the direct interactions 
between tumor and endothelial cells within a 3D culture environment. The microwell assay 
comprised remodelable type I collagen molded to the same dimensions as the alginate discs, but 
confined within a PDMS template to prevent gel contraction (Fig 6A). We had previously 
confirmed that culturing OSCC-3 in 3D collagen disks similarly upregulated IL-8 (16), but the 
assay used here additionally allowed the seeding of HUVECs on the surface of the scaffold, and 
the quantification of endothelial cell invasions into the collagen under mono- or co-culture 
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Fig. 4. Microenvironmental control of lL-8 signaling confirmed by qPCR and ELISA. A-B) Fold-change in
mRNA transcription and protein secretion of lL-8 by qPCR (A) and ELISA (B) between normoxia (17% 02) and
hypoxia (1% 02) for 2D and 3D cultures. Interaction between hypoxia- and dimensionality-associated changes in
IL-8 gene expression were validated at the mRNA transcription and protein secretion levels by qPCR (A) and
ELISA (B), respectively. IL-8 expression was constitutively increased in 3D environments compared to 2D
monolayers, but hypoxia produced an inverted effect on IL-8 activity depending on substrate dimension.
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Fig. 5. Relevance of 3D up-regulation of IL-8 across additional epithelial tumor cell lines. A-B) Fold-
change in mRNA transcription and protein secretion levels of IL-8 was measured by qPCR (A) and ELISA (B),
respectively, for 2D and 3D cultures of three cell lines (A549 lung carcinoma, KATO-Ill gastric carcinoma, and
MDA-MB231 mammary gland/breast adenocarcinoma). 3D up-regulation of IL-8 was consistent across 3
additional tumor cell lines under normoxic conditions.
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conditions (Fig 6B). In the mono-culture assay, IL-8 and VEGF were added exogenously to the 
media, either alone or in combination. While IL-8 has previously been reported to exert direct pro-
angiogenic effects (34, 35), our results suggest that exogenous IL-8 alone exhibits no effect on 
endothelial cell invasion. However, in the presence of VEGF, IL-8 synergistically enhances 
sprouting, suggesting that interactions with VEGF are necessary for IL-8 to modulate endothelial 
cell behavior (Fig 6C). Likewise, inhibition of either IL-8 or VEGF in the co-culture assay showed 
significant reduction in sprouting; combined inhibition of both molecules showed no additional 
benefits (Fig 6D). These results indicate a direct functional consequence of the 3D culture 
environment in regulating tumor hypoxia response and neovascularization as a function of 
increased IL-8 levels. 
Discussion 
Microenvironmental conditions are critical determinants of tumor angiogenic capability; 
however, due to a lack of culture systems capable of delineating the effects of tissue dimensionality 
and oxygen status, it is unclear how these conditions interact to regulate neovascularization (36, 
37). In order to evaluate the interdependence between tissue culture environment and the hypoxia 
response, we used custom biomaterials-based assays to control oxygen concentrations within 3D 
cell-laden scaffolds. A comprehensive microarray analysis revealed profound coupling between 
culture dimensionality and hypoxia response, which was mediated in part by inflammatory 
signaling pathways. In particular, IL-8 emerged as a major component of the microenvironmental 
regulation of the hypoxic program with important functional consequences on endothelial 
sprouting in a 3D invasion assay. Taken together, our results highlight the importance of 
pathologically relevant tissue culture models to study complex biological processes such as 
hypoxia-related cell responses and tumor angiogenesis. 
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Fig. 6. Synergistic IL-8 and VEGF interactions promoted endothelial cell sprouting. A) A custom,
3D microwell invasion assay used to evaluate endothelial cell invasion into collagen gels in mono- or co-culture
with tumor cells. Schematic illustrates the microwell design, in which HUVECs were seeded on the gel surface
and tumor cells were embedded within the matrix. A PDMS mold confined the gel to prevent
contraction. B) Representative micrographs of a co-culture invasion assay showing a series of z-slices and
the xz cross-section. Cells were labeled with DAPI (nuclear, blue), phalloidin (actin, red), and CD31
(endothelial-specific marker, green). Scale bar = 50 µm. C-D) Endothelial cell sprouting was evaluated by
counting the number of CD31+ invasions extending beyond 12 µm from the gel surface. Results from the mono-
culture invasion assay show no induction of sprouting with the addition of exogenous IL-8 or VEGF alone, but
the combination of both factors exhibited synergistically enhanced number of invasions (C). Likewise, co-
culture invasion assays containing OSCC-3 cells within the collagen bulk demonstrated sprout inhibition through
function-blocking antibodies for either IL-8 (anti-lL-8) or VEGF (anti-VEGF), possibly by preventing this
interaction (D).
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We maintained homogeneous oxygen-concentration by fabricating 200 μm alginate discs, 
which alleviated the depletion of oxygen typically found beyond 150 μm from the surface. 
Although we cannot exclude that subcellular level oxygen variations may exist in this model, it 
has demonstrated stable, uniform conditions throughout the culture period at the cellular scale (16). 
We used this platform to conduct a comprehensive microarray analysis of gene expression for cells 
cultured in 2D, or in 3D alginate discs, subjected to hypoxic (1% O2) or normoxic (17% O2) 
conditions.  
Results from the microarray analysis revealed a striking interdependence between oxygen 
status and culture dimensionality. Of the 8637 genes that responded to dimension or oxygen 
conditions by greater than 2-fold change, 77% were co-regulated rather than independent. 
Similarly, we found that changes in gene expression induced by hypoxia varied greatly based on 
its 2D or 3D substrate, and genes regulated by dimensionality also depended on oxygen status. In 
total, 2563 genes were found to be differentially expressed by greater than 2-fold change. These 
results support the conclusion that the change in dimensionality had a strong effect on cells’ 
biological response to low oxygen conditions, and vice versa. Therefore, the intimate coupling of 
mass transport and 3D culture is both a physically and biologically relevant problem.  
Our results are consistent with previous efforts to characterize the effects of oxygen 
deprivation in 3D using spheroid models and biomaterials-based approaches. For example, the rate 
of osteogenic differentiation of adipose stem cells in response to low oxygen conditions has been 
reported to change in 3D poly(lactide-co-glycolide) (PLG) scaffolds compared to 2D polystyrene 
(38). Likewise, we previously reported that secretion of VEGF and IL-8 depends on both 3D 
environment and oxygen status (16). On the other hand, our results contrast with a recent proteomic 
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study comparing 11 different tumor cell lines cultured in 2D monolayers and 3D spheroids under 
ambient or hypoxic conditions (39), in which the authors concluded that changes due to 
oxygenation in 2D are predominantly similar in 3D. This disparity may be due to the method of 
acquiring and analyzing data. Whereas the previous study was designed to identify the top 
similarities between various treatments and across multiple cell lines at the protein level, our study 
specifically examined top differences in each condition at the gene expression level. In both cases, 
careful validation for individual molecules of interest should be performed when interpreting high-
throughput data. 
Our next task was to identify which genes were most affected by dimensionality and 
hypoxia. Not surprisingly, Ingenuity pathway analysis revealed significant regulation of cell cycle, 
cancer, cell growth and proliferation, and cell death and survival in all four comparisons. These 
are known consequences of both hypoxic and 3D culture conditions (40). Divergence in the 3D 
versus 2D hypoxia response was associated with an inflammatory phenotype at the network, 
pathway, and molecular levels, suggesting that this process is equally sensitive to the culture 
environment. Together, this supports the conclusion that inflammatory signals are closely linked 
to the differential regulation of hypoxic signaling in 2D and 3D culture. These results are consistent 
with a recent study focusing on IL-6/pSTAT signaling, which similarly suggested that the 3D 
tissue context can regulate inflammatory potential (41). Collectively, these data imply an important 
role of the environment in regulating inflammatory processes.  
The interdependence between hypoxia and dimensionality was particularly striking in the 
regulation of IL-8. In the microarray analysis, IL-8 was one of 214 genes affected by all four 
combinations of oxygen status and dimensionality, and also one of 351 genes that exhibited an 
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inverted hypoxia response depending on culture dimension. IL-8 was strongly up-regulated in 3D 
culture compared to 2D culture in both 1% and 17% O2. On the other hand, IL-8 levels were 
increased in 2D hypoxia but reduced in 3D hypoxia, compared to the respective ambient 
expression. This observation supports previous reports of microenvironmental regulation of IL-8 
(16). Furthermore, we confirmed the 3D-mediated up-regulation of this cytokine in a panel of three 
additional tumor cell lines derived from lung, breast, and gastric epithelial tissue, demonstrating 
relevance of microenvironmentally-regulated IL-8 signaling in multiple disease types. These 
results suggest that IL-8 may play a critical role in coordinating the interactions between hypoxia 
and dimensionality in the tumor microenvironment. 
Tumor angiogenesis is one of the clinically important consequences of hypoxic signaling 
(4). Because the tumor hypoxia response was clearly regulated by culture dimensionality, we 
explored the functional consequences of these changes on tumor vascularization using an 
endothelial invasion assay. Results from both the mono-culture and co-culture inhibition studies 
suggest a synergistic relationship between IL-8 and VEGF signaling pathways contributing to 
sprouting angiogenesis. Because conventional 2D angiogenesis assays typically supplement the 
culture media with VEGF, this interaction has not been previously reported. This result suggests 
that the 3D culture environment does indeed impact the efficacy of angiogenic signaling pathways. 
Compensatory IL-8 signaling has been implicated in the underwhelming clinical performance of 
targeted anti-angiogenic therapies (33, 42). In addition, our results motivate further study of 
specific interactions between inflammatory and hypoxia response pathways that may provide 
novel avenues for intervention. 
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The study and treatment of cancer requires the development of controlled experimental 
platforms that faithfully explore tissue phenomena in vitro. These systems, such as the alginate-
based disc assay described here, provide a unique opportunity to recreate critical features of the 
physiological environment. Furthermore, such platforms help delineate the individual and 
combined effects of various tissue-level conditions, including dimensionality, hypoxia, or 
inflammation. However, despite the advantages of simple and realistic tumor models, these 
systems remain only approximations of the true disease. As with any in vitro assay, these models 
neglect numerous features of in vivo tissue and provide a simplified representation of cancer 
pathology. However, by selective integration of salient microenvironment characteristics, tissue 
engineering approaches provide the opportunity for “designed complexity,” thus allowing the 
definition of specific microenvironmental conditions to examine their independent and co-
dependent effects. In this case, exploring the interactions between hypoxia and dimensionality 
helped distinguish their relative contributions to tumor angiogenesis.  
Taken together, these results present several ramifications. First, the distinct behaviors in 
various regions of a tumor or spheroid, particularly regarding the proximity to functional 
vasculature, may be linked to the differential response to these physiological stimuli. Second, these 
results suggest that the conventional hypoxia response observed in 2D culture may not accurately 
represent the pathophysiological hypoxic program. Finally, investigation of therapeutic agents that 
target hypoxia, matrix, or inflammatory signaling should consider the potential confounding 
interactions between low-oxygen and 3D that may interfere with or potentially facilitate the desired 
intervention. The rational design of therapeutic strategies that address this interdependence may 
enhance the efficacy of existing pharmaceutical regimens. 
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Conclusion 
Using biomaterials-based models of tumor hypoxia response and tumor angiogenesis with 
isolated control of oxygen distribution and culture dimensionality, we have demonstrated a 
differential response to hypoxic stress in 2D versus 3D culture, with direct consequences for tumor 
angiogenesis. Specifically, we found that the inflammatory response pathway, notably through IL-
8 signaling, represents a critical link between oxygen status and dimensionality. This observation 
proved functionally relevant through the synergistic enhancement of VEGF-dependent endothelial 
sprouting in a 3D microwell invasion assay. Because tumor hypoxia response and angiogenic 
capability are products of complex microenvironmental interactions, therapeutic strategies that 
target matrix structure, hypoxia, angiogenesis, or inflammation may benefit from an improved 
understanding the interdependence between of these processes. 
Supplementary information 
Supplementary information is available in the online version of the paper.  
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Abstract 
This protocol describes how to form a 3D cell culture with explicit, endothelialized 
microvessels. The approach leads to fully enclosed, perfusable vessels in a bioremodelable 
hydrogel (type I collagen). The protocol uses microfabrication to enable user-defined geometries 
of the vascular network and microfluidic perfusion to control mass transfer and hemodynamic 
forces. These microvascular networks (mVNs) allow for multiweek cultures of endothelial cells 
or cocultures with parenchymal or tissue cells in the extra-lumen space. The platform enables real-
time fluorescence imaging of living engineered tissues, in situ confocal fluorescence of fixed 
cultures, and transmission electron microscopy (TEM) imaging of histological sections. This 
protocol enables studies of basic vascular and blood biology, provides a model for diseases such 
as tumor angiogenesis or thrombosis, and serves as a starting point for constructing 
prevascularized tissues for regenerative medicine. After one-time microfabrication steps, the 
system can be assembled in less than 1 d and experiments can run for weeks. 
Introduction 
The microvasculature is a pervasive organ system that mediates the transfer of solutes (for 
example, metabolites, waste products, and signals) and cells (for example, leukocytes) throughout 
the body. These living pipes have a central role in the regulation of metabolic activity, 
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development, healing, immune response, and the progression of many diseases. This diversity of 
function places stringent constraints on the physical (network architecture) and biological (cellular 
composition) properties of the microvasculature. These constraints limit the size, complexity, and 
physiological relevance of tissues grown in vitro for applications in regenerative medicine, 
pharmaco-toxicological studies, and basic research. The development of methods to incorporate 
appropriate microvascular infrastructure into scaffolds for tissue engineering is indispensable for 
the progression of the field. Microfluidic control of mass transfer within biological scaffolds 
provides one solution to this crucial challenge in tissue engineering. 
This protocol describes a platform (Fig. 1) that recapitulates the structure and function of 
microvascular vessels to serve in studies of basic vascular and blood biology, as models of diseases 
such as tumor angiogenesis or thrombosis, and as a starting point for engineering prevascularized 
tissues for regenerative medicine (1-5). In contrast to other uses of microfluidic endothelial cell 
cultures by confined gels or 2D models (6-9), our approach (1-5) leads to fully enclosed vessels in 
a bioremodelable hydrogel, suitable for biological questions that require a fully 3D extracellular 
environment with a contiguous parenchymal or stromal space. Our model represents a 
complementary extension of simpler, 3D assays of vasculogenesis and invasion angiogenesis (10); 
this extension is necessary where explicit vessel structure and perfusion of lumens have important 
roles in the study or application of interest. 
Development of the protocol 
Tissue engineers have long appreciated the need to incorporate vascular functionality in 
the design and fabrication of biological scaffolds (11-14). Diverse efforts have been made toward 
the incorporation of endothelial cells (15-17) and explicit vessel structures (18-21) within 3D 
biomaterials. The approach presented in this protocol builds on work over the past decade to bring 
76
Fig. 1. Examples of vessel configuration. (a-e) Diverse vessel configurations have been adapted for various
applications, including µVNs (a-c), steady-state morphogen gradients (d), and live imaging under controlled
flow regimes (e). (a,b) Illustration of an endothelial cell-coated microfluidic network in a cell-laden collagen
construct; inset highlights the endothelial confluence, pericyte-endothelial cell interactions, and angiogenic
sprouting from the vessel. (c) Appropriate endothelial cell health, integrity, and confluence are demonstrated by
uniform CD31 (also known as PECAM-1) (red) staining of cell-cell junctions in a quiescent vascular network;
such networks provide nutrient and waste transport to sustain cells within the contiguous biological matrix. Scale
bar, 100 µm. (d) The incorporation of parallel source (C1) and sink (C2) channels generates a stable biochemical
gradient to mimic the heterogeneous distribution of potent morphogens, such as VEGF, and to stimulate
endothelial cell sprouting in the study of invasion angiogenesis. (e) µVNs are used to study responsiveness of
vessels to hemodynamic forces with live imaging of GFP-expressing endothelial cells. Under physiological
shear stress and flow, the endothelial cells align in the direction of the flow. Diagrams in a,b are reproduced with
permission from Franco and Gerhardt (47). Micrograph in c is adapted with permission from Zheng et al. (2).
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microfluidic structure—sub-millimeter channels formed by microfabrication—into biomaterial 
scaffolds. The design and fabrication of micropatterned biomaterials was pioneered by Whitesides 
and colleagues (22, 23) with the development of replica molding of soft polymer microfluidic 
systems, also known as soft lithography. These techniques were later adapted to the molding of 
hydrogel scaffolds (24, 25). Alternatives to soft lithography such as bioprinting, sacrificial 
elements (21, 26) or modular assembly (27) have emerged; Gauvin et al. (28) have reviewed the 
distinct advantages and limitations of these methods. Soft lithography was first exploited to form 
vascular-like structure by Borenstein and colleagues (29-31) within poly(lactic-co-glycolic acid) 
films, poly(glycerol-sebacate), and silk fibroin; however, such materials prohibit cell 
encapsulation during the fabrication process. Building on this work, our group and others used 
micropatterning of natural hydrogels to provide convective transport to cells embedded within the 
bulk of physiologically relevant biological scaffolds (1, 19, 32). The Tien laboratory was the first 
to generate perfusable, endothelialized microvascular tubes and networks in such materials using 
lithographic methods and sacrificial elements (20, 33, 34). Our current protocol extends this 
progress with the incorporation of cells in the perivascular space, perfusion with whole blood, and 
functional angiogenic and thrombotic response to appropriate biochemical stimulation (2). Here 
we present the methods for the design, fabrication, and application of such μVNs. 
Application of the method 
In our first report, confocal fluorescence and TEM of the in vitro μVNs demonstrated the 
formation of a confluent, functional endothelium on the walls of the microfluidic channels and the 
viability of cells within the collagen bulk (Fig. 1c; ref. (2)) . In addition, we demonstrated 
appropriate morphology, barrier function, angiogenic remodeling, and appropriate cell-cell 
junctions. We further examined pericyte-endothelial cell interactions in defining barrier function 
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and angiogenesis, as well as blood-endothelium interactions, including thrombosis. We have also 
exploited the microfluidic control of flows to study angiogenesis in the presence of well-defined 
gradients of vascular endothelial growth factor (VEGF) and doses of anti-VEGF (Avastin) (3). 
Moving forward, this assay presents opportunities to address questions in vascular biology 
that are inaccessible in planar cultures, such as the effects of geometry, hydrodynamic stresses, 
and convective mass transfer on vessel stability, angiogenesis, and development (35). μVNs also 
provide a basis for in vitro models of clinical conditions that implicate the vasculature in tissue-
scale processes, such as wound healing, solid tumor cancers, and diabetes. Within such models, 
the explicit vasculature and perivascular space could, for example, allow for the study of 
mechanisms of intra- and extravasation (4, 5), the capture and incorporation of circulating 
endothelial progenitor cells (36), and the interplay of stroma, matrix, and endothelium in defining 
health and disease (37). In technological contexts, the ability to form vascularized scaffolds in 
vitro also opens new possibilities. For example, scaffolds with functional vasculature will have a 
central role in the engineering of any macroscopic and highly metabolically active tissue (38); 
tissue models with explicit vasculature could markedly improve the effectiveness of in vitro 
screens of drugs and of strategies of drug delivery (39). Further examples of the use of μVNs in 
models of solid tumors are reviewed in Stroock et al. (4). Wong et al. (40) present a comprehensive 
review of the opportunities for microfluidic models of vascular physiology. 
Experimental design 
This protocol describes a vascularization strategy to sustain 3D cell-laden biological 
scaffolds by convective mass transfer through endothelialized microfluidic networks. By 
combining a simple biomaterial and replica molding, artificial μVNs fully enclosed within cell-
remodelable hydrogel constructs can be constructed. Our protocol includes photolithography 
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(Steps 1–11), biomaterial-based soft lithography (Steps 12–47), 3D microfluidic culture (Steps 
48–54), live fluorescence imaging (Step 55A), in situ immunofluorescence staining and confocal 
imaging and analysis (Step 55B), and TEM imaging (Step 55C), as well as assays for the 
characterization of endothelium diffusivity and permeability (Box 1) and interactions with whole 
blood (Box 2). For a detailed overview of lithographic processes (Steps 1–6), see reference (23). 
Alternately, Steps 1–6 can be contracted to a custom third-party service, such as 
http://www.creatvmicrotech.com/intromicro.html, http://www.micralyne.com/novel-material-
processing, or http://www.nilt.com/default.asp?Action=Details&Item=500. Videos are provided 
that show detailed assembly of the microfluidic culture device (Supplementary Video 1); seeding 
of cells into the channels of the microfludic culture device, including both successful 
(Supplementary Video 2) and unsuccessful (Supplementary Videos 3 and 4) examples; and live 
fluorescence imaging (Supplementary Video 5). 
Limitations 
Because this assay emphasizes physiological accuracy over simplicity, it introduces 
challenges with regard to throughput and multiplexing. This μVN assay is most appropriate for 
applications that require explicit vessel structures and network architectures and the ability to 
control perfusion of lumens. In some cases, simpler angiogenesis assays (10) may be more 
appropriate, such as to perform screens of cell types, reagents, and biomaterials (41). These simpler 
platforms can be used to establish parameters for the μVN assay presented here. In our experience, 
the soft lithographic manipulation of native collagen used in our protocol fails to provide good 
fidelity of channel structures for lateral dimensions below 50 μm. In addition, microfabrication by 
SU-8 soft lithography described here necessarily generates unphysiological rectangular channel 
cross-sections, although remodeling of the matrix by endothelial cells yields a rounded vessel 
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morphology after about 2 d. Alternatively, fabrication of molds with isotropic etching could 
produce hemispherical cross-sections without altering the rest of the protocol. We have not 
attempted to create μVNs with multiple layers of channels; such extensions of the microfluidic 
approach have been shown in other materials (42). Chemical adhesion of the matrix to the 
boundaries of the jig and the use of higher densities of collagen mitigate contraction of 
microvessels as the density of cells embedded within the collagen bulk increases, as we have 
demonstrated in previous publications (5, 41). To date, human umbilical vein endothelial cells 
(HUVECs) are the only endothelial cells that have been cultured in this system; however, we 
believe that the assay will be broadly applicable to diverse endothelial cell types that have been 
successfully cultured on collagen substrates for angiogenesis and vasculogenesis assays, if used 
with the appropriate culture medium (20, 43). 
Materials 
Reagents 
• Photoresist SU-8 2000 series (Permanent epoxy resist for photolithography, Microchem) 
! CAUTION Wear protective goggles and gloves and suitable protective clothing. 
• Silicon wafers for master mold (100-mm SSP silicon wafers, 500 μm in thickness, 
undoped; University Wafer) 
• Photoresist developer (Microchem) 
• Silane for passivation of master mold: tridecafluoro-1,1,2,2-tetrahydrooctyl-1-
trichlorosilane (Gelest, cat. no. SIT8174.0) 
• Isopropyl alcohol (for photolithography; Sigma-Aldrich) 
• Sylgard 184 silicone elastomer base and curing agent (for soft lithography, Dow Corning) 
• (poly)-dimethylsiloxane (PDMS) (Sylgard 184, Dow Corning) 
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• Sterile 1× PBS, pH 7.4 (Invitrogen, cat. no. 10010-023) 
• Ethanol, 70% (vol/vol) in sterile deionized water (VWR, cat. no. BDH1162-4LP) 
• Poly(ethyleneimine) (PEI, see Reagent Setup; Fluka Analytical, cat. no. P3143-500ML) 
• Glutaraldehyde (GA, see Reagent Setup; Fluka Chemika, cat. no. 49629) 
! CAUTION Use GA in a chemical hood and wear protective goggles and gloves and 
suitable protective clothing. 
• Lyophilized type I collagen isolated from rat tails (Pel-Freez, cat. no. 5654-1) according to 
the procedures described by Bornstein (44) or Rajan et al. (45) 
• HEPES buffer (Cambrex, cat. no. CC-5024) 
• Sodium hydroxide (NaOH) solution, 2N (BDH, cat. no. 3223-1)  
! CAUTION Wear protective goggles and gloves and suitable protective clothing. 
• Cells of interest, e.g., human umbilical vein endothelial cells (HUVECs, Lonza, cat. no. 
CC-2519) or human brain perivascular cells (ScienCell, cat. no. 1200) 
• DMSO (Sigma Life Science, cat. no. D8418-100ML) 
• Medium appropriate for the cells being cultured, e.g., HUVEC culture medium EGM-2 
(Lonza Clonetics, cat. no. CC-4176) or Lonza M199 (Lonza, cat. no. 12-117F) 
• Endothelial cell growth factor (Millipore, cat. no. 02-102) 
• FBS (Tissue Culture Biologicals, cat. no. 101) 
• Penicillin-streptomycin (Lonza, cat. no. 17-602F) 
• Heparin sodium (Acros, cat. no. 41121-0010, 9041-08-1) 
• Trypsin-EDTA, 0.025% (wt/vol) (Invitrogen, cat. no. R-001-100) 
• l-Glutamine (Cambrex, cat. no. 17-605C) 
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• l(+)-Ascorbic acid, reagent ACS (Acros Organics, Code 401471000, cat. no. CAS:50-81-
7, EC:200-066-2) 
• Human vascular endothelial growth factor (VEGF; Millipore, cat. no. 01-185, GF315) 
• Human basic fibroblast growth factor (bFGF-2; Millipore, cat. no. 01-106) 
• Phorbol 12-myristate 13-acetate (PMA) also known as 12-O-tetradecanoylphorbol-13-
acetate (Sigma-Aldrich, product no. P 1585) 
! CAUTION Wear protective goggles and gloves and suitable protective clothing. 
• BSA (Calbiochem, cat. no. 126609) 
• Rabbit polyclonal antibody (Rb pAb) to CD31, also known as platelet endothelial cell 
adhesion molecule (PECAM-1) (Abcam, cat. no. ab28364) 
• Rabbit polyclonal antibody (Rb pAb) to vascular endothelial (VE)-cadherin (Abcam, cat. 
no. ab33168) 
• Mouse monoclonal antibody to α-smooth muscle actin (α-SMA; Abcam, cat. no. ab54723) 
• Anti-von Willebrand factor antibody conjugated with fluorescein isothiocyanate (FITC) 
(Abcam, cat. no. ab8822) 
• APC anti-human CD41a (BD Pharmingen) 
• PE anti-human CD45 (BD Pharmingen) 
• Goat anti-rabbit IgG conjugated with Alexa Fluor 568 or Alexa Fluor 647 (Invitrogen and 
Molecular Probes, cat. nos. A11011 and A21244, respectively) 
• Goat anti-mouse IgG conjugated with Alexa Fluor 488, Alexa Fluor 568 or Alexa Fluor 
647 (Invitrogen and Molecular Probes, cat. nos. A11001, A21124 and A21240, 
respectively) 
• DAPI, dilactate (Invitrogen, cat. no. D3571) 
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• Alexa Fluor phalloidin 488 (Invitrogen and Molecular Probes, cat. nos. A12379 and 
1023568 300U, respectively) 
• Formaldehyde, 16% (wt/vol) methanol-free, ultrapure electron microscopy grade 
(Polysciences, cat. no. 18814) 
• Triton X-100 solution (see Reagent Setup; MP Biomedicals, cat. no. 807426) 
• FITC protein label (Invitrogen, cat. no. F6434) 
• Fluorescein (Sigma-Aldrich) 
• TEM epoxy (Sigma-Aldrich) 
• Cacodylate buffer (Na(CH3)2AsO2·3H2O; 0.1M) 
• Ruthenium red (0.05%, wt/vol)  
! CAUTION Use this reagent in a chemical hood; wear protective goggles, gloves and other 
suitable protective clothing. 
• Osmium tetroxide (OsO4, 1.0% wt/vol)  
! CAUTION Use this reagent in a chemical hood; wear protective goggles, gloves and other 
suitable protective clothing. 
• Uranyl acetate (UO2(CH3COO)2·2H2O; 2%, wt/vol)  
! CAUTION Use this reagent in a chemical hood; wear protective goggles, gloves and other 
suitable protective clothing. 
• Acetone 
• Bleach 
Equipment 
• Plasma cleaner (for surface modification, Harrick, PDC-001, 115V) 
• Disposable biopsy punches (4 mm and 1 mm diameter, Miltex) 
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• Autoclave (Market Force Industries, Sterilmatic) 
• Incubator at 37 °C, 5% CO2, (Thermo Electron Forma Series II waterjacketed CO2 
incubator HEPA Class100, (also NAPCO series 8000WJ)) 
• Water bath at 37 °C (VWR International, Sheldon Manufacturing, model no. 1212) 
• Inverted microscope (for imaging cells, Nikon Eclipse TS100) 
• Confocal microscope (for imaging cells, Zeiss 710) 
• Transmission electron microscope (Technai F20) 
• ImageJ software (or similar) 
• Microtome (Leica Ultracut UCT ultramicrotome) 
• Sterile syringe filters (PALL, Acrodisc 13-mm syringe filter with 0.2-μm HT Tufryn 
membrane, cat. no. PN 4454) 
• Filter system, 500 ml, 0.22 μm (Fisher Scientific, cat. no. 09-761-102) 
• Flask, 25 cm2 with membrane cap (Fisher Scientific, cat. no. 10-126-28) 
• Flask, 75 cm2 with membrane cap (Fisher Scientific, cat. no. 10-126-37) 
• Petri dish, small, 100 × 15 mm, 500/CS (Fisher Scientific, cat. no. 08-757-11Z) 
• Petri dish, large, 150 × 15 mm, 100/CS (Fisher Scientific, cat. no. 08-757-14) 
• Aluminum foil 
• Syringe, 1 ml (VWR, BD Syringe, cat. no. BD329650) 
• Syringe, 3 ml (VWR, BD Syringe, cat. no. BD09656) 
• Pipette tips, 1,000 μl (VWR, cat. no. BD329650) 
• Stainless steel machine screws, Phillips head, 4–40 (thread size) for microfluidic culture 
device 
• Machine screws for aluminum casting jig 
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• Stainless steel dowel pins, 1 inch, 16-gauge diameter (Small Parts, cat. no. B001OBPJY6) 
• PDMS flat slabs (30 mm × 30 mm; 3–5 mm in thickness) 
• Self-standing, sterile conical tubes, 50 ml and 30 ml (VWR, cat. nos. 21008-777, 89012-
778) 
• Sterile conical vial, 15 ml (Fisher Scientific, cat. no. 14-959-49B) 
• Tweezers 
• Scalpel handle and blades 
• Spatula 
• Phillips head screwdriver 
• Glass crystallizing dish and cover (125 × 65 mm) (Corning, cat no. 3140-125) 
• Paper towels 
• Autoclavable, medical-grade tubing (CorSolutions) 
• Pump (CorSolutions) and pump connections (CorSolutions) 
Reagent setup 
! CAUTION Be sure to consult the relevant MSDS for safety information and use 
appropriate protective equipment when handling reagents. 
PEI solution Dilute PEI to 1.0% (wt/vol) with sterile deionized water. Filter-sterilize the solution 
with a 0.22-μm sterile syringe filter. It can be stored for up to 6 months if it is sealed and 
refrigerated. 
GA solution Dilute GA to 0.1% (wt/vol) with sterile deionized water. Filter-sterilize the solution 
with a 0.22-μm sterile syringe filter. It can be stored for up to 6 months if it is sealed and 
refrigerated at 4 °C. 
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Triton X-100 solution Dilute Triton X-100 to 1.0% (vol/vol) Triton X-100 in sterile deionized 
water and store it at room temperature (~20–25 °C). It can be stored for up to 6 months if it is 
sealed and refrigerated at 4 °C. 
Formaldehyde solution Dilute formaldehyde to 3.7% (wt/vol) formaldehyde in PBS and store it at 
room temperature in the dark. It can be stored for up to 1 year if it is sealed. 
Endothelial cell growth medium (GM) GM is a rich medium for expanding cells. To conduct 
rigorous biochemistry experiments, use a defined medium, such as EGM-2 (Lonza; see Reagents). 
To make GM, mix the components given in the following table: 
Components Supplier and cat. no. Volume 
Growth serum M199 Lonza, cat. no. 12-117F 500 ml 
L-Glutamine (for a 2-mM 
working concentration) 
Cambrex, 
cat. no. 17-605C 
6.5 ml 
 
 
Endothelial cell growth 
supplement (for a working 
concentration of 20 μg ml-1) 
Millipore, 
cat. no. 02-102 
 
15 mg 
(one vial) 
 
 
Heparin (10,000 U ml-1 
stock solution) 
 
Acros, cat. no. 
41121-0010, 9041-08-1 
250 μl 
 
 
FBS (for a working 
concentration of 18% (vol/vol)) 
Tissue Culture 
Biologicals, cat. no. 101 
100 ml 
 
 
Penicillin-streptomycin (for a 
working concentration of 150 U ml-1) 
 
BioWhittaker, 
10,000 U ml-1 
7.5 ml 
 
 
Cap and mix the contents gently without creating bubbles (the FBS enhances bubble 
formation). Connect a filter system (see Equipment) and attach it to a vacuum pump. Filter-sterilize 
the solution. It may be stored for up to 1 month if refrigerated at 4 °C. 
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Vasculogenesis medium (VM) VM is a rich medium used to activate endothelial cells to 
spontaneously form lumens and tubes in bulk collagen and undergo sprouting angiogenesis by 
invading from a monolayer. Determine the volume of VM needed (typically VM is only prepared 
as needed) on the basis of the volume of the channels, the flow rate, and the duration of the 
experiment. Calculate the volumes to be added into the base GM to form the VM, and mix these 
reagents (below) into GM that has been preheated to 37 °C. The following quantities should be 
added per the final volume of the VM: PMA at 50 ng ml-1; VEGF165 at 40 ng ml-1 (keep on ice 
while handling it); bFGF at 40 ng ml-1 (keep on ice while handling it), and ascorbic acid at 50 μg 
ml-1. 
The difference between the added volumes of these substances and the final VM volume 
desired is the volume of GM to add. For example, 1 ml of VM, 2 μl of VEGF (from a 20 μg ml-1 
stock), 1.6 μl of bFGF (from a 25 μg ml-1 stock), 1.6 μl of PMA (from a 50 μM stock), and 10 μl 
of ascorbic acid (from a 5,000 μg ml-1 stock) would be added to 985 μl of GM.  
! CRITICAL Owing to protein degradation, keep VEGF165 and bFGF on ice while 
handling them, and only prepare VM as needed, typically 5 ml per day for gravity-driven flow or 
10 ml for pump setup. The exact volume depends on device configuration and flow rates. 
Collagen stock Collagen stock takes ~2 d to prepare. Resuspend lyophilized type I rat tail collagen 
in 0.1% (vol/vol) acetic acid to 1.5 mg ml-1 in a conical tube, to create a working stock solution. 
Shake the conical tube vigorously once a day to mix the contents, and keep it refrigerated at 4 °C. 
The collagen will dissolve over an ~2-d period. When it has dissolved, centrifuge the mixture at 
1,950g for 5 min at 4 °C to remove air bubbles. The stock collagen can be maintained refrigerated 
at 4 °C for up to 3 months. 
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Procedure 
Fabrication of a master mold ● TIMING 3 h 
1| Design channel network geometry with appropriate computer-aided design (CAD) software, for 
example, AutoCAD, L-edit or Illustrator. Store it as a digital file (see Supplementary Data for an 
AutoCAD file of our system). 
! CRITICAL STEP When you design the device, ensure that the inlet and outlet ports of the 
microfluidic network will align with the reservoir ports in the top piece of the microfluidic culture 
device (v in Fig. 2a). 
2| Use the digital CAD file of the network channel geometry to create a photographic plate (the 
‘mask’) by using appropriate technology, e.g., a high-resolution laser printer on a transparency 
sheet (if no microfabrication laboratory is available) or a dedicated photo pattern generator (such 
as the Heidelberg Mask Writer DWL2000 or the GCA 3600F Pattern Generator) on a glass plate 
coated with chromium and photoresist. Develop and etch the chrome mask. 
! CRITICAL STEP The channel features should be transparent regions on the mask to allow for 
exposure of the SU-8 photoresist in the next step. 
3| Spin-coat SU-8 photoresist onto a clean silicon wafer to a thickness that corresponds to the 
desired channel height; follow the spin curves and prebake temperatures and times from the 
supplier (http://microchem.com/pdf/SU-82000DataSheet2025thru2075Ver4.pdf). 
4| Expose the wafer to UV light (365 nm), postbake it and develop it according to the supplier’s 
instructions (http://microchem.com/pdf/SU-82000DataSheet2025thru2075Ver4.pdf). 
5| Cut the wafer to fit into a molding jig (this is manufactured in Step 7; Fig. 2b). 
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Fig. 2. Summary of microfluidic device fabrication (Steps 1-54), assembly (Steps 24-48), seeding (Steps 49-
53), and culture (Steps 54A and 54B) processes. (a) Photograph of all the components for casting the PDMS
stamp and assembling the microfluidic culture device. (a-e) Individual components are cross-referenced between
the photograph in a and the diagrams in b-e using Roman numerals. (i) Machine screws for the aluminum
casting jig; (ii, iii) top and middle pieces, respectively of the aluminum casting jig; (iv, v) bottom and top pieces,
respectively, of the microfluidic culture device; (vi) bottom piece of the aluminum casting jig; (vii)
lithographically-patterned silicon wafer master mold; (viii) PDMS stamp; (ix) flat PDMS slab; (x) stainless steel
dowel pins; (xi) stainless steel machine screws (4-40 thread size) for microfluidic culture device; (xii) glass
microscope coverslip. Technical drawings for the aluminum casting jig and microfluidic culture device can be
found in Supplementary Figures 1 and 2, respectively. (b) Schematic of the aluminum jig assembly for casting
the PDMS stamp using the lithographically-patterned silicon wafer master mold. (c) (Top) 3D micropatterned
vessels are formed by injection molding of native collagen gel against the PDMS stamp through the injection
ports on the top piece of the microfluidic culture device. Stainless steel dowel pins are used to preserve the
connection between the cell culture medium reservoirs and the microfluidic channels. (Bottom) Collagen is
injected onto the glass coverslip in the bottom piece of the microfluidic culture device and molded into a thin
layer by sealing the gel cavity with a flat slab (~3 mm thick) of PDMS. (d) After the collagen gels, the top and
bottom pieces of the microfluidic culture device are assembled to form the micropatterned, 3D microfluidic
vessels, fully enclosed in collagen. The microvessels are then seeded with cells by pipetting a small (10 µl) cell
suspension into the inlet reservoir. (e) The microvascular network is perfused with gravity-driven or pump-
driven culture medium or whole blood. Photographs of detailed device assembly steps that are not depicted are
available in Supplementary Figure 3. A video showing the detailed preparation and assembly of the microfluidic
culture device (Steps 21-53) is available as Supplementary Video 2.
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6| Passivate the surface of the wafer to avoid adhesion to silicone (PDMS), as follows. Oxidize the 
master for 1 min at 100 W in a plasma cleaner. Place the wafer with the featured side facing up in 
a vacuum desiccator with a vial containing a few drops (~10 μl) of tridecafluoro-1,1,2,2-
tetrahydrooctyl-1-trichlorosilane. Evacuate the wafer, close the valve and leave the wafer under 
vacuum for at least 2 h. 
! CAUTION Avoid contact and inhalation of silane. Work and vent the vacuum pump in a fume 
hood. 
 PAUSE POINT The master can be stored indefinitely (in a protective cover) until further use. 
Fabrication of machined parts of the molding and culture jig ● TIMING 5 h 
7| Create aluminum jigs for molding the PDMS stamp with features on the silicon wafer (ii–iii, vi–
vii in Fig. 2a). This jig will generate a stamp of well-defined dimensions to facilitate alignment 
with the microfluidic culture device. Mechanical drawings of example parts are presented in 
Supplementary Figure 1. 
! CRITICAL STEP We used aluminum in our device for durability to prevent the jig from 
undesired deformation (when plastic was used) through multiple uses and because of its ease of 
machining. 
! CRITICAL STEP Molding biological hydrogels directly onto microfabricated structures in rigid 
materials such as silicon and SU-8 photoresist leads to difficulties in demolding (separating a 
structured gel from a micromold). For this reason, the structure should be transferred to a PDMS 
stamp (described in Steps 9–11). 
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8| Create a microfluidic device to contain culture (iv–v in Fig. 2a). Mechanical drawings of parts 
are presented in Supplementary Figure 2. 
! CRITICAL STEP We used polycarbonate in our device for its transparency, biocompatibility 
and absence of autofluorescence.  
Fabrication of the PDMS stamp ● TIMING 10 h 
9| Assemble the aluminum casting jig for casting the PDMS stamp from the silicon master as 
shown in Figure 2b. 
10| Mix the PDMS components in the weight ratio of 1/11 curing agent to 10/11 base. Remove the 
air bubbles by applying weak vacuum. Pour the liquid PDMS into the aluminum casting jig, 
carefully to prevent the formation of air bubbles. Partially cure it overnight at room temperature. 
Cure it for 1 h at 60 °C to finish hardening. 
! CRITICAL STEP Curing directly at an elevated temperature will lead to distortions of the 
features in the stamp caused by the thermal expansion of the aluminum jig. 
11| Disassemble the aluminum casting jig and remove the PDMS stamp slowly (viii in Fig. 2a); 
applying small volumes of ethanol facilitates easier demolding. 
Sterilization of materials for device assembly ● TIMING 30 min 
! CRITICAL All components must be sterilized with an autoclave or plasma cleaner, or by using 
another appropriate method such as gas sterilization with ethylene oxide. 
12| Sterilize the following components by autoclaving them: four stainless steel machine screws 
for the microfluidic culture device (xi in Fig. 2a; 4–40 (thread size)); two stainless steel dowel pins 
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(16-gauge diameter; x in Fig. 2a); tweezers, scalpel handle(s), a spatula, and a screwdriver; PDMS 
flat squares (30 mm × 30 mm; 3–5 mm in thickness; ix in Fig. 2a); glass culture dishes; paper 
towels; and autoclavable tubing and pump connections (for operation with pump only). 
13| Sterilize all polycarbonate components in 10% (vol/vol) bleach for 30 min. Rinse them with 
sterile water and dry them with compressed air. 
14| Sterlize all polycarbonate components (top piece of the microfluidic culture device for housing 
the 1 mm deep, 20 × 5 mm inset for bottom layer of collagen and bottom 50 mm × 50 mm piece 
of the microfluidic culture device with no. 1.5, 25 mm × 25 mm glass coverslip on top of it) in 
plasma cleaner for 5 min at 100 W. 
15| Transfer the components to a sterile biosafety cabinet using sterile techniques. 
16| Sterilize 1% (wt/vol) PEI and 0.1% (wt/vol) GA using a 0.22-μm sterile filter. 
! CRITICAL STEP All remaining steps must be performed in a sterile biosafety cabinet, while 
wearing sterile gloves, until fixation. 
Coating of devices with sterile PEI and GA ● TIMING 45 min 
17| Soak a glass coverslip (xii in Fig. 2a) in 1% (wt/vol) PEI for 10 min. Meanwhile, apply 1% 
(wt/vol) PEI via a 200-μl micropipette to the 1-mm-deep well (collagen reservoir) in the top piece 
of the microfluidic device (v in Fig. 2a) for 10 min (do not let it dry). 
18| Aspirate the PEI from the coverslip and device surface. Rinse the coverslip in sterile-filtered 
deionized water. Wash the device surface thoroughly with 10 ml of sterile water. Aspirate water 
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from the coverslip and device, and then dry it with dry air (sterilized through a sterile filter). If 
sterile air is not available, air-dry the device for 30 min. 
! CRITICAL STEP To avoid residue, do not allow PEI to dry on the device without aspirating it. 
Only apply PEI to the tissue culture region. 
19| Soak the glass coverslip in 0.1% (wt/vol) GA for 30 min. Apply 0.1% (wt/vol) GA via a 200-
μl micropipette into the 1-mm-deep well (collagen reservoir) in the top piece of the microfluidic 
culture device for 30 min (do not let it dry). 
20| Aspirate the GA from the coverslip and device surface to avoid deposition of residue. Rinse it 
thoroughly with sterile water and dry it in sterile air. If sterile air is not available, air-dry it for 30 
min. Place the top and bottom pieces of the device and the microscope coverslip in a refrigerator 
(4 °C) in a sterile, sealed container to chill, both while mixing the collagen (Step 21) and before 
injection-molding the collagen (Step 24). 
! CRITICAL STEP The device must be thoroughly rinsed after coating because free GA will be 
toxic to the cells. To avoid residue, do not let GA dry on the device without aspirating it. Only 
apply GA to the tissue culture region. 
! CRITICAL STEP The device should be chilled in a refrigerator (4 °C) before injection-molding 
the collagen (Step 24). This step will slow the rate of nucleation during collagen gelation and 
enable the proper formation of the collagen protein fibers. 
 PAUSE POINT The devices can be stored in a refrigerator (4 °C) for several days before 
injecting the collagen (Step 24), provided that they are kept in a sterile, sealed container. 
96
Preparation of 1% (wt/wt) collagen gel ● TIMING 10 min 
21| Use a 1-ml syringe with tapered Luer lock tip to transfer stock collagen with a desired volume 
to a sterile 30-ml conical tube. See Supplementary Video 1 for further guidance. For an acellular 
scaffold, calculate the volume of stock collagen by using the following formula: Vs_collagen = Vf × 
Cf_collagen/Cs_collagen, where Vs_collagen is the volume of stock collagen, Vf is the final volume of 
neutralized collagen, Cf_collagen is the final concentration of neutralized collagen, and Cs_collagen is 
the concentration of stock collagen. Each device requires a final volume of ~1 ml of neutralized 
collagen gel, depending on jig geometry. To avoid forming air bubbles during transfer, take up an 
initial small amount of collagen (~100 ml) into the syringe tip and move the plunger up and down 
to remove air bubbles. Next, push the collagen to the end of the syringe until it protrudes slightly 
from the tip and take up the remaining volume. Transfer the stock collagen to a sterile 30-ml 
conical tube. 
22| Prepare the neutralizing reagent, using micropipettes to collect it into a 15-ml conical tube. The 
neutralizing reagent consists of Lonza M199 EC medium (1× and 10×) and NaOH. For an acellular 
scaffold, calculate the volume of each reagent using these formulas: 
V10× = 0.1×Vf 
VNaOH = 0.022×Vs_collagen 
V1× = Vf −Vs_collagen −V10× −VNaOH 
where V10× is the volume of 10× Lonza M199 medium, Vf is the final volume of neutralized 
collagen (from Step 21), VNaOH is the volume of NaOH, Vs_collagen is the volume of stock collagen 
(from Step 21), and V1× is the volume of 1× Lonza M199 medium. 
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23| Mix the solution of neutralizing reagent prepared in the previous step and pipette it carefully 
on top of the collagen in the 30-ml conical tube in order to avoid air bubbles. Use a sterilized 
spatula to gently mix the gel until it is homogeneous. Avoid introducing any bubbles into the 
collagen. 
For cellular scaffolds, prepare the mixed, neutralized collagen gel at a concentration above 
that desired (see sample calculations in Steps 21 and 22), and then add cells suspended in an 
appropriate volume of medium (Vs_cell) to reduce the collagen to a 1% (vol/vol) solution, and then 
mix it again until it is homogeneous. Calculate the appropriate volume of medium for the cell 
suspension (Vs_cell) as follows: 
Vs_cell = Vf_cell – Vf 
Vf_cell = Vf ×Cf_collagen / Cf_cell 
where Vs_cell is the volume of cell suspension, Vf_cell is the final volume of neutralized collagen 
after adding the cell suspension, Vf is the volume of neutralized collagen before adding the cell 
suspension (from Step 21), Cf_collagen is the concentration of neutralized collagen before adding the 
cell suspension (from Step 21), and Cf_cell is the final concentration of collagen after adding the 
cell suspension (1% (vol/vol)). 
! CRITICAL STEP To make a different concentration of collagen, vary the reagent volumes 
according to the above formulas. 
! CRITICAL STEP Neutralized collagen gels rapidly at room temperature. Keep all reagents on 
ice. Confirm appropriate pH with litmus paper and add small volumes (1 μl dropwise) of NaOH 
until the pH reaches a physiological value of 7.4. 
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! CRITICAL STEP Dense collagen ( >5 mg ml-1 or 0.5 % (wt/wt)) is highly viscous. Use a 1-ml 
taper-tip syringe to transfer collagen solutions, moving the plunger up and down to remove air 
bubbles. Mix the collagen gently with a sterile stainless steel spatula to avoid generating bubbles. 
To ensure homogeneity, stir the mixture for about 2 min after the color becomes uniform. If 
bubbles form, centrifuge the mixture at 1,950g at 4 °C for 5 min. 
! CRITICAL STEP For cell-laden scaffolds, neutralize the stock collagen to pH 7.4 before 
introducing the cells. Ensure that the collagen is at pH 7.4 or the cells will die. Prepare this collagen 
at an initial concentration that is above that desired (see sample calculation in Step 23), and then 
add cells suspended in an appropriate volume of medium to reduce the collagen to a 1% (vol/vol) 
solution. 
Injection-molding microstructured collagen ● TIMING 15 min 
24| Immediately after preparing the collagen gel with or without suspended cells present (Steps 
21–23), sterilize and oxidize the surface of the PDMS stamp with the microstructure pattern by 
exposure to oxygen plasma for 5 min at 30 W (or 1 min at 100 W). The collagen will wet onto the 
oxidized surface of the PDMS such that the entrapment of bubbles is minimized. See 
Supplementary Video 1 for further details. 
25| Place the top piece of the microfluidic culture device (v in Fig. 2a) onto the PDMS stamp (viii 
in Fig. 2a) as shown in Figure 2c. Align the inlet and outlet ports of the micropatterned network 
on the PDMS stamp with the inlet and outlet ports on the top piece of the microfluidic culture 
device (Supplementary Fig. 3).  
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! CRITICAL STEP When you design the device, ensure that the inlet and outlet ports of the 
microfluidic network will align with reservoir ports in the top piece of the microfluidic culture 
device (Fig. 2c and Supplementary Fig. 3). 
26| Gently insert the 16-gauge stainless steel dowel pins (x in Fig. 2a) into the reservoir holes on 
the top piece of the microfluidic culture device. They should be loose within the reservoir holes 
and rest stably on top of the PDMS stamp without pushing down on it (Fig. 2c and Supplementary 
Fig. 3). These dowels are required to create the inlet and outlet ports within the bulk collagen (the 
ports for GM) by preventing the entry of collagen during the injection molding. 
27| Use a 1-ml taper-tip syringe to extract ~0.5–0.6 ml of collagen. Remove the bubbles in the 
syringe by gently moving the plunger up and down vertically. Slowly and steadily inject the 
collagen into the injection port on the top piece of the microfluidic culture device (Fig. 2c). 
28| Transfer the entire assembly to a fully enclosed, sterile glass dish, and then place it in an 
incubator at 37 °C for 30 min to allow for gelation. 
Molding collagen coating onto a glass coverslip ● TIMING 5 min 
29| Place the precoated glass microscope coverslip onto the bottom piece of the microfluidic 
device, and use a micropipette to dispense ~170 μl of collagen onto the glass microscope coverslip 
(xii in Fig. 2a) homogeneously (Fig. 2c and Supplementary Fig. 3). See Supplementary Video 1. 
30| Gently place the flat square of PDMS (ix in Fig. 2a) on top of the collagen and microscope 
coverslip to spread the collagen evenly across the coverslip (Fig. 2c and Supplementary Fig. 3).  
31| By using two pairs of tweezers, one to push down at the edge of the PDMS square to hold it in 
place and the other to spread the collagen, gently move the tweezers across the top of the PDMS 
100
square to spread the collagen evenly across the coverslip. Ensure that the collagen covers the gaps 
between the microscope coverslip and the microfluidic culture device on all four sides and that it 
does not accumulate in the center (Supplementary Fig. 3). 
Collagen gelation ● TIMING 30 min 
32| Transfer the entire assembly to a fully enclosed, sterile glass dish, and place it in an incubator 
at 37 °C for 30 min to allow for gelation. 
33| Remove the top and bottom pieces of the microfluidic culture device from the incubator after 
gelation and return them to the sterile biosafety cabinet. 
Assembling the device (top and bottom pieces) ● TIMING 15 min 
34| Pick up the top piece of the microfluidic culture device and hold it so that the PDMS stamp is 
on the top. See also Supplementary Video 1. 
35| Remove the PDMS stamp from the top piece of the microfluidic culture device by applying 
~250 μl of PBS around the interface of the stamp with the device. Gently lift the PDMS stamp 
from the surface of the top Plexiglas piece (Supplementary Fig. 3). If the collagen scaffold contains 
cells, use cell culture medium instead of PBS. 
! CRITICAL STEP The PDMS stamp is held against the top piece of the microfluidic culture 
device by surface tension. Be careful not to bump the stamp, because it may damage the collagen 
channels. The small volume of PBS (or cell culture medium for a cellularized collagen scaffold) 
applied around the interface serves as a lubricant for easier removal. 
36| Remove stainless steel dowel pins from the top piece of the microfluidic culture device with 
sterile tweezers. 
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37| Place the top piece of the device on a Petri dish cover, collagen side up, and dispense ~0.5–1 
ml of PBS on top of the micropattern in the collagen gel to prevent it from drying. If the collagen 
scaffold contains cells, use cell culture medium instead of PBS. 
38| Use a 3-ml syringe to add PBS around the perimeter of the PDMS flat square on the bottom 
piece of the microfluidic culture device (Supplementary Fig. 3). Gently remove the PDMS flat 
square from the bottom piece. Remove any excess collagen from the edges with a spatula. If the 
collagen scaffold contains cells, use cell culture medium instead of PBS. 
39| Pick up the bottom piece with a pair of tweezers or forceps and flip it upside down so that the 
collagen is facing the collagen on the top piece. 
40| Balance the bottom piece between two Petri dishes, with the collagen facing down, and place 
screws into three of its four corner holes, such that the pointed ends of the screws face down and 
the screw heads rest in the corner holes. 
41| Gently assemble the two pieces (joining the micropatterned collagen of the top piece with the 
flat collagen layer of the bottom piece) as follows. First, place the top piece into a large Petri dish 
with the collagen facing up. Then, dispense PBS onto the top piece so that it completely covers 
both the collagen and the surrounding polycarbonate of the device. If the collagen scaffold contains 
cells, use cell culture medium instead of PBS. Finally, carefully place the bottom piece (with 
collagen facing down) onto the top piece (that has the collagen facing up), by holding the bottom 
piece at an angle and inserting the tips of the two screws from one side of the bottom piece into 
the corresponding, matching holes of the top piece, and then gently roll (rotate the alignment) the 
bottom piece across the top piece to insert the third screw into position on the opposite side. This 
motion should displace the PBS liquid between the two pieces of the microfluidic culture device 
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and prevent the formation of air bubbles as the collagen from the top and bottom pieces join. See 
Supplementary Figure 3. If the collagen scaffold contains cells, use cell culture medium instead of 
PBS. 
42| Insert the fourth screw on the jig and use a screwdriver to gently tighten all four screws. 
! CRITICAL STEP To ensure that both collagen pieces are joined with a uniform, level seal, 
tighten the screws in the rotating manner of an automobile tire. Be careful not to tighten the screws 
too much or the channels will collapse (Supplementary Fig. 3). 
43| Aspirate excess PBS (or cell culture medium, for a cellularized scaffold) from the device. 
44| Use autoclaved paper towels or an aspirator to remove any remaining PBS (or cell culture 
medium, for a cellularized scaffold) surrounding the surfaces of the microfluidic culture device, 
and then put the device into an autoclaved glass dish. 
45| Turn the device over and remove the PBS (or cell culture medium, for a cellularized scaffold) 
from the reservoirs on the top of the device (Supplementary Fig. 3). 
46| Add cell culture medium to the inlet reservoir. 
47| Place the device in a fully enclosed, sterile Petri dish and inspect it under a light microscope to 
confirm the channel fidelity and the absence of air bubbles (Supplementary Fig. 3). 
! CRITICAL STEP Air bubbles must not be present in the channel. They will grow in the incubator 
and rupture the channel. If air bubbles are present in the channel, place the device (in a fully 
enclosed, sterile glass dish) in a refrigerator (4 °C) until the bubbles dissolve (~20 min). 
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Device incubation in preparation for seeding channels ● TIMING 1 h 
48| Place the device in the incubator for at least 1 h to allow the collagen to equilibrate with the 
cell culture medium and to attain the proper physiological pH. See Figure 2 for a summarized 
schematic diagram of the assembly process. 
 PAUSE POINT The device can be stored in the incubator overnight before the channels are 
seeded with cells. 
Seeding channels with endothelial cells ● TIMING 40 min 
49| Trypsinize HUVECs or other endothelial cell types and prepare a cell suspension, using 
appropriate cell culture medium (see Reagents), at a cell density of ~4–6 × 106 cells per ml. 
50| In a sterile biohood, remove the GM from the reservoirs in the device by using 200-μl pipette 
tips. If necessary, remove any residual GM remaining in the reservoir by using gel-loading tips 
(while in the biohood), being careful not to press the tips into the collagen. 
! CRITICAL STEP Do not attempt to remove medium from the channels, as this will introduce air 
bubbles. Air bubbles will grow upon incubation and rupture the channels. 
51| Inspect the channels with a bright-field microscope to ensure that no air bubbles are present in 
the channels.  
52| Add a 10-μl cell suspension into one reservoir at the entrance to the collagen channel (but 
without touching the bottom of the collagen channel) using a gel-loading pipette (Supplementary 
Fig. 3). The flow should start immediately, but it should be slow. It should balance between the 
inlet and outlet reservoirs within 10 min. (See Supplementary Fig. 4 and Supplementary Video 2 
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for examples of successful seeding. See Supplementary Videos 3 and 4 for examples of 
unsuccessful seeding.) 
! CRITICAL STEP To prevent introduction of air bubbles into the channel, before inserting the 
pipette tip into the reservoir entrance to the channel, push a droplet of medium to the tip of the 
pipette so that it protrudes. 
! CRITICAL STEP When you seed cells into the device, do not allow the tip of the gel-loading 
pipette to touch the collagen, as doing so will destroy the channel integrity. 
! CRITICAL STEP If the flow is too fast, add 2 μl of culture medium to the outlet reservoir before 
incubation. Reservoirs should equilibrate and the flow will stop during the first 10 min of 
incubation. 
53| Allow the cells to attach to the collagen for 30 min in the incubator (in a fully enclosed, sterile 
dish), and then transfer the device to the biohood and add cell culture medium to the inlet reservoir. 
Wash out any unattached cells from the channel or network by enabling flow, and then remove 
them from the outlet reservoir. Proceed with culturing the cells (Supplementary Fig. 3). A 
confluent monolayer of endothelial cells should form in the channel within 24 h. 
Perfusion culture 
54| If desired, set up perfusion via gravity (option A) or pump (option B). See also Figure 2e. 
Pump-driven perfusion provides more precise and stable flow rates than gravity-driven flow, and 
it can improve culture efficiency by recirculating the medium, thereby eliminating the need to 
replace it. In addition, a pump has the ability to impose different flow regimes (e.g., with respect 
to waveform, frequency and amplitude). Alternative experiments involving perfusion of the 
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endothelialized networks, such as measuring endothelial permeability (Box 1) or characterizing 
interactions with whole blood (Box 2), are presented herein. 
(A) Gravity-driven perfusion culture ● TIMING 5 min 
(i) Add cell culture medium, as appropriate, to the inlet reservoir and recycle or replace the medium 
as necessary during 14 d of culture. 
(ii) Select the desired shear stress for the culture and calculate the required volumetric flow 
accordingly. In the case of gravity-driven flow, the reservoir height will define the volumetric flow 
rate, Q (m3 s-1), and shear stress at the channel wall, τ (kg m-1 s-2). As an example, for a single 
channel of uniform dimensions, we have: 
𝑄 =  
𝜌𝑔
𝑅
∆ℎ(𝑡) 
𝜏 =  
𝑑
4𝐿
𝑅𝑄 
where ρ (kg m-3) is the fluid density, g (m s-2) is the gravitational acceleration, R is the hydraulic 
resistance of the channel, Δh(t) (m) is the difference in height of fluid between the reservoirs, d 
(m) is the diameter of the channel, and L (m) is the length of the channel. For this single-channel 
example,  
𝑅 =  
128 𝜇𝐿
𝜋𝑑4
 
where μ (kg m-1 s-1) is the viscosity of the medium. As the reservoirs equilibrate over time, the 
height difference decays according to the following equation: 
∆ℎ(𝑡) =  ∆ℎ0ℯ
−2𝜌𝑔
𝐴𝑅 𝑡 
where Δh0 (m) is the initial difference in height, A (m2) is horizontal cross-section of the reservoir, 
and t (s) is time. 
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! CRITICAL STEP To maintain approximately steady-state flow with the gravity-driven system, 
slow the rate of change of Δh(t) by using large reservoirs (A), by using an overflow system (46), 
or by periodically restoring the inlet and outlet fluid levels. 
(B) Pump-driven perfusion culture ● TIMING 15 min 
(i) Select an appropriate pump for the experiment. Syringe pumps present challenges for driving 
flow within μVNs; recycling of medium is difficult, and they are prone to fluctuations in pressure 
that can destroy the endothelium. Conventional peristaltic pumps are compatible with medium 
recirculation, but they generate unsteady flows and are susceptible to air bubbles. An effective 
solution is to use a high-precision, continuous-flow pump with an in-line flow sensor with 
submicroliter-per-minute flow accuracy based on feedback control and a bubble trap. Such a pump 
is available from CorSolutions (http://www.mycorsolutions.com/products/fluidic_pumps.html). 
(ii) For pump-driven flow, determine the desired shear stress for the endothelium and calculate the 
required flow rate as described in Step 54A(ii). Insert the appropriate pump connectors into the 
inlet and outlet reservoirs. 
! CRITICAL STEP Be very careful not to introduce air bubbles into either the connectors or the 
device. To prevent bubble formation, fill the connection ports with medium before inserting them 
into the inlet and outlet reservoirs. 
(iii) Attach sterile, nontoxic tubing (e.g., CorSolutions) to the pump and gently connect it to the 
device: first to the inlet reservoir and then to the outlet reservoir. 
! CRITICAL STEP To prevent air bubbles from being introduced to the microchannels, allow a 
drop of medium to collect at the opening of the tube before attaching it to the inlet connector port. 
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Similarly, allow a droplet of medium to collect at the surface of the outlet reservoir connector 
before connecting the tubing (Fig. 2e). 
Imaging of cells 
55| Cultures can be imaged and evaluated via live fluorescence microscopy (option A), for 
example, to characterize the permeability of the matrix and epithelium (Box 1). Alternatively, 
confocal fluorescence microscopy can be performed on fixed samples (option B), or greater 
resolution can be obtained via TEM (option C). Live imaging (option A and Boxes 1 and 2) allows 
the dynamics of the endothelial cells within the endothelium (e.g., proliferation, alignment and 
migratory behavior) to be tracked in the presence of well-defined luminal flow (Fig. 3, 
Supplementary Video 1). Confocal fluorescence microscopy (option B), which can also be 
performed following live fluorescence microscopy, enables the visualization of the molecular-
level features of the microvasculature, such as nuclei, individual proteins in the membrane or 
cytoplasm, and polysaccharide chains of the glycocalyx. TEM (option C) enables the identification 
of additional molecular level features, such as cell-cell junctions and the basal lamina, that are not 
readily distinguishable by other techniques. 
(A) Live imaging of fluorescent cells ● TIMING variable, 1 h or 2–3 d 
(i) To perform live imaging of fluorescent cells, use a microscope with an incubating stage (sterile 
with humidified and controlled temperature and carbon dioxide). Mount the device on the 
microscope stage and verify that it is level by checking the focus across the sample. 
! CRITICAL STEP Maintenance of a stable environment (humidity and CO2 level) is crucial to 
the health of the culture. The use of a secondary container of smaller volume with regulated 
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Fig. 3. Live fluorescence imaging of GFP-expressing HUVECs in µVNs, as described in Step 55A. (a-c) The
culture was run under physiological shear flow (-11 µl min-1, 17 dyne cm-2) with a feedback-controlled
peristaltic pump (Step 54B). The flow direction is from left to right. The snapshots reveal dynamic cell motility
throughout the vessel wall. Cell tracking (red dots) traces an individual cell's path (yellow lines) as it migrates
upstream and downstream within the endothelium. Yellow intensity corresponds to instantaneous velocity along
the path length, with dark zones representing faster motion. Scale bars, 50 µm. Time stamps show
hours:minutes:seconds after onset of flow. See Supplementary Video 1 for the full image sequence.
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humidity and CO2 may be required to maintain physiologic levels of CO2 and adequate humidity 
around the culture. 
(ii) To ensure that photographs captured during the culture are clear, focus the image with the 
microscope focus knob for coarse and fine adjustment while viewing it through the camera, not 
through the microscope ocular lens. 
(iii) For perfusion cultures, establish the flow using the procedures above (Steps 54A and 54B). 
(iv) Set the desired frequency of time-lapse images (e.g., once every 2.5–5 min). See Figure 3 and 
Supplementary Video 5 for examples of long-term, live images of GFP+ HUVECs in a 
microvessel. 
(B) Confocal fluorescence microscopy on fixed and stained samples ● TIMING 14 h 
! CRITICAL STEP Note that fluorescence imaging can be performed without disassembling the 
microfluidic culture device. Perform this step by flowing reagents through the channels and 
imaging through the microscope coverslip in the base of the device. 
(i) Fixing and staining. To fix the cells and the matrix at the end of the culture, replace the medium 
in the reservoir with 3.7% (wt/vol) formaldehyde in PBS and allow it to flow through the device 
at room temperature for 30 min. 
! CAUTION Wear suitable protective clothing and gloves when you work with 3.7% (wt/vol) 
formaldehyde. 
(ii) To remove the formaldehyde, perform three 5-min washes with PBS. 
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 PAUSE POINT The device can be stored with the reservoirs filled with PBS for up to 12 h if 
refrigerated and protected from light and evaporation (e.g., covered with aluminum foil). 
(iii) To block against nonspecific binding and to permeabilize the cell membranes to enable 
staining, incubate the cells in 3% (wt/vol) BSA and 1% (vol/vol) Triton X-100 in PBS for 1 h. 
(iv) Remove BSA/Triton X-100, but do not wash the cells with PBS. Incubate them with primary 
antibodies in PBS with supplemental 1% (wt/vol) BSA overnight at 4 °C in the following ratios: 
either Rb primary, polyclonal antibody (pAb) to CD31 (Abcam) at a ratio of 1:50 or Rb pAb to 
VE-cadherin (Abcam) at a ratio of 1:50; and mouse primary monoclonal antibody to α-SMA 
(Abcam) at a ratio of 1:100. They can be used for co-staining because they are from different 
species and are targeted by different secondary antibodies (Step 55B(vi)). 
(v) Remove excess, unbound primary antibodies by performing three 5-min washes with PBS. 
(vi) In a dark room, incubate the cells with secondary antibody in PBS with supplemental 1% 
(wt/vol) BSA for 1 h at room temperature in these ratios: Goat anti-rabbit Alexa Fluor 568 (CD31 
or VE-cadherin), 1:50; Goat anti-mouse Alexa Fluor 647 (α-SMA), 1:100; Alexa Fluor phalloidin 
488 (endothelial cell F-actin), 1:100; DAPI, dilactate (nucleus), 1:1,000.  
(vii) To remove unbound, excess secondary antibodies, perform three 5-min washes with PBS. 
! CRITICAL STEP Procedures with secondary antibodies, DAPI and phalloidin (i.e., any antibody 
conjugated to a light-sensitive, fluorescent dye) should be performed in the dark. Visible light will 
degrade the fluorophores that are conjugated to the antibodies and will prevent successful 
fluorescence imaging. Wrap the culture devices in aluminum foil during incubation and at all times 
afterward to prevent exposure to light. 
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Fig. 4. Characterization of vessel structure by confocal fluorescence microscopy (Step 55B) and
transmission electron microscopy (Step 55C). (a,b) Complex geometrical features such as corners, junctions,
and bifurcations are readily visualized by confocal fluorescence imaging, and cross-sections of microchannels
reveal rounded vessel morphology. Immunohistochemistry of CD31 (a, red) and VE-cadherin (b, red) are used
to demonstrate confluent and healthy endothelium throughout the network. Blue, nuclei; scale bars, 100 µm. (c)
Transmission electron micrographs enable imaging of cell-cell junctions, including focal contacts (arrow, top)
and overlapping junctions (arrow, bottom); scale bars, 1 µm. EC, endothelial cell. Adapted with permission from
Zheng et al. (2).
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Fig. 5. Heterotypic cell culture. (a) Endothelial cells (HUVECs) respond to stimulation in the presence of cells
(human brain vascular pericytes, H BVPCs) seeded in the matrix (Step 23) by sprouting new branches, as
visualized by confocal microscopy (Step 55B). (b) Smooth muscle cells seeded in the matrix (Step 23) associate
with the endothelium, as visualized by confocal microscopy (Step 55B). (c) Ultrastructure of the cellular
interfaces formed between HUVECs and HBVPCs, including a deposited layer of basal lamina, can be
visualized by transmission electron microscopy (Step 55C). In a,b: CD31, red; DAPI, blue; α-SMA, green; scale
bars, 100 µm. In c, scale bar, 1 µm. Adapted with permission from Zheng et al. (2).
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! CRITICAL STEP For best results, perform confocal imaging analysis (Step 55B(viii–xii)) as 
soon as possible after completing procedures with secondary antibodies (Step 55B(v–vii)) (Figs. 
4 and 5). 
(viii) Confocal imaging and analysis. Select an objective lens with appropriate working distance ( 
>0.4 mm) to allow for imaging of cells around channels through the coverslip and the bottom layer 
of the matrix. For example, we used an ×25 objective lens with a numerical aperture of 0.8 with a 
Zeiss confocal microscope LSM 710 to acquire the images presented in Figures 4a,b and 5a,b (use 
an ×0.6 zoom to increase the field of view if necessary). 
(ix) Acquire z-stacks of horizontal images through the scaffold. Use a spacing of 2–3 μm between 
images in order to provide sufficient vertical resolution for 3D analysis. Collect images with 
excitation and emission filters appropriate for the fluorescent dyes used in staining. 
(x) Evaluate cellular positions and densities in culture using the color channel of the nuclei (for 
example, blue for DAPI). Threshold images and use cell counting routines available in software 
such as ImageJ. 
(xi) Evaluate the health of the endothelium according to CD31 or VE-cadherin staining. A healthy 
endothelium will have contiguous staining surrounding each cell membrane. 
(xii) Evaluate the degree of alignment of the cells according to the staining of the actin fibers via 
the phalloidin conjugate. Endothelial cells will align in the direction of flow when subjected to 
physiologic levels of shear stress. Staining the actin fibers of the cytoskeleton will identify the 
extent to which cells in perfusion culture have aligned. 
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(xiii) Perform 3D analysis of the stack of images. For example, to evaluate morphology, reorient 
the volume to view vertical cross-sections as shown in Figure 4a. The 3D Viewer plugin embedded 
in ImageJ provides this functionality. 
(C) Transmission electron microscopy ● TIMING 3 d 
! CRITICAL STEP Perform cell fixation steps (Steps 55C(i–viii)) on the intact culture within the 
jig by flowing reagents through the channels. Remove the scaffold from the jig (Step 55C(ix)) for 
embedding, sectioning and staining for TEM imaging. 
(i) Fixing, embedding, sectioning, and staining for TEM. At the end of the culture, replace the 
medium in the reservoir with 0.1M cacodylate buffer, Na(CH3)2AsO2·3H2O containing 0.05% 
(wt/vol) ruthenium red to stain the glycocalyx for 5 min. 
! CAUTION Perform procedures with ruthenium red in a chemical hood; wear gloves, goggles 
and suitable protective clothing. 
! CRITICAL STEP To stain the glycocalyx, the cells must be incubated in ruthenium red before 
fixing the cells with GA in Step 55C(ii). 
(ii) Fix the cells and the matrix for 2 h using 2% (wt/vol) GA in 0.1M cacodylate buffer containing 
0.05% (wt/vol) ruthenium red. 
(iii) Perform three 5-min rinses of the cells with 0.1M cacodylate buffer containing 0.05% (wt/vol) 
ruthenium red. 
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(iv) Incubate the cells for 1 h in 0.1 M cacodylate buffer containing 1% (wt/vol) osmium tetroxide 
(OsO4) to cross-link lipids and embed a heavy metal in the cell membranes. The buffer should also 
be supplemented with 0.05% (wt/vol) ruthenium red to stain the glycocalyx. 
! CAUTION Osmium tetroxide is extremely toxic, even at low concentrations, and it can cause 
severe damage to the respiratory tract and corneas. Perform all procedures with osmium tetroxide 
in a chemical hood; wear gloves, goggles and suitable protective clothing. 
(v) Perform three 5-min rinses of the cells with pure 0.1 M cacodylate buffer. 
(vi) Dehydrate the cells by incubation in increasing concentrations of ethanol: first 25% (vol/vol) 
ethanol for 10 min and then 50% (vol/vol) ethanol for 10 min. 
(vii) Incubate the cells in 75% (vol/vol) ethanol, with 2% (wt/vol) uranyl acetate 
(UO2(CH3COO)2·2H2O), to stain proteins, for 24 h. 
! CAUTION Uranyl acetate is both radioactive and toxic. Perform all procedures with uranyl 
acetate in a chemical hood; wear gloves, goggles and suitable protective clothing. 
(viii) Perform three 5-min rinses of the cells with 75% (vol/vol) ethanol. At this point, the cells are 
stable and can be stored. 
 PAUSE POINT The cells can be stored, refrigerated (4 °C), in 75% (vol/vol) ethanol for several 
months. 
(ix) Carefully remove the collagen scaffold (containing the vessels) from the microfluidic device. 
Cut the sample into 1-mm2 squares. Place each square in a glass vial containing 95% (vol/vol) 
ethanol (~2 ml). 
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! CRITICAL STEP In disassembling the device, carefully separate collagen from the glass 
coverslip by using a scalpel. 
(x) Replace the 95% (vol/vol) ethanol with 100% ethanol (a stock of 100% ethanol should be 
stored over a molecular sieve to ensure dryness) and allow the sample to be submerged for 5 min. 
(xi) Replace the 100% ethanol with 100% acetone and allow the sample to be submerged for 5 
min. 
(xii) Repeat the 5-min incubation with fresh 100% acetone and allow the sample to be submerged 
for 5 min. 
(xiii) The samples must be gradually embedded in epoxy. This process can be performed in a 
simple-but-slow single procedure or done more quickly. For the slow procedure, add epoxy to the 
acetone/cell sample in a 1:1 ratio and mix it by gently pipetting up and down. Place the samples 
on a rotisserie and let them sit for 3 d (e.g., over a weekend). Alternately, to proceed more rapidly, 
incubate the samples in progressively higher ratios of epoxy:acetone as follows: 3 parts acetone:1 
part epoxy for 8 h; 1 part acetone:1 part epoxy for 8 h; and finally 1 part acetone:3 parts epoxy for 
8 h. 
(xiv) Embed the samples in coffin molds and fill them with 100% epoxy and incubate for 24 h. 
(xv) Trim the epoxy with a razor blade and then use a high-precision microtome to cut the samples 
into 60-nm slices. 
(xvi) Transfer the 60-nm slices to copper TEM disks with copper grids and store them in a grid 
box for imaging. 
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! CRITICAL STEP When you prepare the samples, ensure that all instruments are cleaned with a 
solvent such as methanol, that the grids have been cleaned with a solvent and the grid box is clean. 
(xvii) TEM imaging procedure. Follow your institution’s procedures for operating the TEM (see 
Figs. 4c and 5c for sample images). 
Troubleshooting 
Troubleshooting advice can be found in the following table: 
Step  Problem  Possible reason  Solution 
21–23 Air bubbles form in the 
collagen during mixing 
Lifting the spatula 
above the surface level 
of the collagen 
Centrifuge at 1,950g, 4 °C for 5 min 
26 Inlet and outlet reservoir 
ports are blocked with 
collagen, preventing flow 
through the device 
 
The dowel pins 
temporarily inserted 
into the inlet and outlet 
reservoir ports for 
collagen injection were 
not in contact with the 
PDMS stamp, or they 
became dislodged 
during injection 
The inlet and outlet reservoir port holes should 
be machined widely enough to allow the dowel 
pins to be loose within the reservoir holes and 
rest stably on top of the PDMS stamp. The pins 
should not be ‘press fit’ to the holes because it 
will potentially create a gap between the device 
and the stamp. If necessary, gently hold the 
pins in place during collagen injection 
41, 42 The channel is deformed 
after device assembly 
The top and bottom 
pieces of device are 
screwed together too 
tightly 
During assembly, stop tightening the screws 
when resistance is first encountered 
47 Air bubbles form in 
channels during assembly 
 
Mishandling of the 
joints between the top 
and bottom pieces 
 
To prevent the formation of air bubbles, ensure 
that the collagen is completely covered with 
buffer before assembling the top and bottom 
pieces together  
If bubbles are present after assembly, place the 
device in the refrigerator (4 °C) for ~20 min 
until bubbles dissolve 
53 Nonconfluent monolayer 
of cells after 24 h 
Insufficient seeding 
density 
Allow cells to grow for more 24 h. If the cells 
are still not confluent, increase seeding density 
 Unhealthy endothelium Evaporation of the 
medium, pH drift of the 
medium, or buildup of 
waste in the medium 
Keep the device in a covered, humidified 
chamber. Ensure the stability of humidity and 
CO2 in the incubator. Replace the medium 
regularly 
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● TIMING 
Steps 1–6, fabrication of a master mold of microfluidic channels by photolithography: 3 h 
Steps 7 and 8, fabrication of machined parts of the molding and culture jig: 5 h 
Steps 9–11, fabrication of the PDMS stamp: 10 h 
Steps 12–16, sterilization of materials for device assembly: 30 min 
Steps 17–20, coating of devices with sterile PEI and GA to enable adhesion to collagen: 45 min 
Steps 21–23, preparation of collagen gel: 10 min 
Steps 24–28, injection-molding microstructured collagen: 15 min 
Steps 29–31, molding collagen coating onto a glass coverslip: 5 min 
Steps 32 and 33, collagen gelation: 30 min 
Steps 34–47, device assembly: 15 min 
Step 48, device incubation in preparation for seeding channels: 1 h 
Steps 49–53, seeding channels with endothelial cells: 40 min 
Step 54A, gravity-driven perfusion culture: 5 min 
Step 54B, pump-driven perfusion culture: 15 min 
Step 55A, live fluorescence microscopy: variable, 1 h or 2–3 d 
Step 55B, confocal fluorescence microscopy on fixed and stained samples: 14 h 
Steps 55C, transmission electron microscopy: 3 d 
Box 1, characterization of permeability of matrix and endothelium: 30 min 
Box 2, characterization of blood-endothelial interactions: 1 h 
Anticipated results 
The fundamental platform comprises an endothelialized network of microchannels 
embedded within a bioremodelable hydrogel scaffold (Fig. 1a). This protocol allows for diverse 
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experimental design and analysis for the study of microvascular phenomena with precise control 
of geometry, coculture seeding, distributions of soluble signals, and mechanical stresses. The assay 
is amenable to in situ fluorescence confocal microscopy, histological analysis, or TEM for high-
resolution imaging. Furthermore, media or cell extracts can be used for proteomic or genomic 
biochemical analysis such as ELISA. 
Without stimulation, the culture yields a confluent monolayer of endothelial cells on the 
walls of the microchannels with appropriate morphology and cell-cell junctions. Via live imaging 
(Step 55A), the dynamics of the endothelial cells within the endothelium can be tracked in the 
presence of well-defined luminal flow (Fig. 3). Immunohistochemically stained cultures (Step 
55B) show that the endothelium remodels the walls to yield rounded vessels (Fig. 4a), expresses 
CD31 (Fig. 4a) and VE-cadherin (Fig. 4b) with appropriate localization, and presents low 
nonspecific permeability (Fig. 6). One advantage of this platform is the opportunity to increase 
biological complexity incrementally, including the incorporation of additional cell types, the 
control of hemodynamic fluid forces, or the generation of biochemical gradients (Fig. 1d). In 
cocultures with perivascular cells seeded in the bulk of the matrix (Step 23), one sees endothelial 
cell–perivascular cell interactions with the induction of sprouting (Fig. 5a), recruitment of 
perivascular cells to the abluminal side (Fig. 5b), and deposition of basement membrane (Fig. 5c). 
Upon exposure to tumor-like proangiogenic signals, robust sprouting angiogenesis occurs and the 
barrier properties of the endothelium are compromised (2). Notably, perfusion of an unstimulated 
microvessel with citrate-stabilized whole blood leads to minimal adhesion of platelets and 
leukocytes to the vessel wall (Fig. 7a). Upon proinflammatory stimulation, the endothelium shows 
a strong response in the form of secreted von Willebrand factor (vWF), self-assembling of fibers 
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Fig. 6. Characterization of the permeability of matrix and live endothelium (Box 1). (a,b) Fluorescence
micrographs show the distribution of 70-kDa FITC-dextran after injection into a network of channels in collagen
with no endothelium (a) and with a live endothelium (b). Time evolution of the fluorescence intensity profiles
(bottom) can be used to calculate the diffusivity of molecules in the matrix (acellular, a) and the permeability of
the vessel membrane (cellular, b). For the complete method, see Zheng et al. (2). Figure adapted with permission
from Zheng et al. (2). Scale bars, 100 µm.
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Fig. 7. Interaction with whole blood. (a) Time sequences of whole-blood perfusion through a µVN, either
quiescent (control vessels, top images) or stimulated (bottom images), at a flow rate of 10 µl min-1 at time points
of 5, 50, 100, 150 and 250 s after initiation of perfusion. The platelets are in green, labeled with CD41a to
platelet-specific glycoprotein IIb (integrin αIIb); flow direction is indicated with arrows (scale bars, 100 µm). (b)
vWF fibers were either coated on the walls of the activated vessel or traveled through the lumens. The locations
of vWF fibers in the vessel are color coded: bottom in blue, center in light green and top in red. Adapted with
permission from Zheng et al. (2). See Box 2.
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of vWF, and formation of platelet-vWF–derived thrombi in a manner that depends on the vessel 
architecture (Fig. 7b). 
One advantage of this platform is the assimilation of increasing biological complexity, 
including incorporation of additional cell types, control of hemodynamic fluid forces, or 
generation of biochemical gradients. Perivascular cells embedded within the collagen bulk 
migrated to and associated with the vascular network, and they stabilized vessel permeability under 
inflammatory assault. The device has been coupled to a sensitive pump apparatus for precise 
control of fluid dynamic forces, including various flow regimes, resulting in endothelial cell 
alignment. Finally, the inclusion of source and sink channels within the scaffold enables the 
steady-state generation of defined gradients to explore heterogeneous signals in the tissue 
microenvironment (3). Taken together, these efforts establish a novel assay for the study of 
physiological phenomena in a fully 3D context in vitro, which not only has considerable 
implications for the study of vasculature and vascular tissues in health, disease and therapy, but 
also has appealing potential for other emerging research areas such as brain (neuroglial) science 
and engineering. 
Supplementary information 
Supplementary information is available in the online version of the paper. 
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CHAPTER 5 
A PHYSICAL SCIENCES – ONCOLOGY PERSPECTIVE ON CANCER METABOLISM 
Peter DelNero, Benjamin Hopkins, Lewis Cantley, and Claudia Fischbach (In review). A 
physical sciences-oncology perspective on cancer metabolism. Sci Transl Med.  
Abstract 
Advances in the culturing of patient-derived cells has enabled analyzing drug sensitivity of 
individual patient samples. However, our ability to translate these findings to the clinic is constrained by 
the failure of culture models to accurately recapitulate the diversity of metabolic states within tumors.  Here 
we outline the myriad environmental factors that regulate cell metabolism in native tumors and describe 
how advances in engineered culture models could enhance the predictive power of precision medicine 
pipelines. 
Introduction 
Aberrant cell metabolism is a hallmark of cancer that influences cancer risk and prognosis and that 
is increasingly being pursued as a target for therapy (1–3). The biochemical repertoire present in cells, 
tissues, and body fluids arises from complex interactions between genetic alterations, tissue perturbations, 
energy balance, treatment history, and environmental exposures (Figure 1) (4). However, the 
interdependent mechanisms linking cell metabolism and cancer pathogenesis are not completely 
understood, and therapeutic agents that interfere with metabolic processes have yielded inconsistent and 
underwhelming clinical results. 
Interdisciplinary collaborations are critical for turning cancer metabolism into an actionable target 
for intervention. The mutual exchange of knowledge and expertise across disciplines affords a more 
complete and sophisticated understanding of cell metabolism for cancer prevention, detection, and 
management. In this spirit, the National Cancer Institute initiated the Physical Sciences Oncology Network 
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Fig. 1. Determinants of cancer metabolism. Metabolism is a multiscale process, comprising the full range of
biological factors. In order to understand the interdependent regulatory mechanisms, it is essential that model
systems simulate salient features that govern metabolic networks across multiple scales.
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(PS-ON) to promote dialogue between oncologists, engineers, and cancer biologists. As a new component 
of the PS-ON, the Cornell Center for the Physics of Cancer Metabolism aims to foster unconventional 
partnerships across disciplines to generate clinically-translatable insights on tumor metabolism and advance 
the understanding and treatment of cancer. This article presents a physical sciences-oncology perspective 
on the theme of cancer metabolism, with special emphasis on the physical tumor microenvironment and 
precision medicine. 
Metabolic Transport: Convection-Diffusion-Reaction Kinetics 
Metabolic processes govern the conversion of biomass, molecular energy, and redox equivalents 
required for virtually all biological functions (5, 6). Although one of the earliest recognized molecular 
signatures of cancer, tumor metabolism is not a unique, monolithic alteration. Instead, it is an adaptive 
biochemical network, which is responsive to both internal signaling and extracellular conditions and 
synchronizes the flux of metabolites through numerous interdependent pathways. Sustained efforts have 
yielded considerable progress in mapping the sequence of these biochemical events, but major gaps remain 
in our understanding of how these pathways are regulated.  
The Warburg effect (aerobic glycolysis) is the dominant metabolic phenotype for proliferating 
cells. Compared to normal counterparts, Warburg-like cells exhibit elevated nutrient uptake and glycolysis. 
Many intermediate products are diverted from the tricarboxylic acid (TCA) cycle toward biosynthetic 
pathways, presumably to generate building blocks for cell division (7). This reprogramming supports tumor 
growth, allows cells to survive adverse conditions (stresses), and promotes invasive behaviors. Warburg-
like changes are associated with driver mutations that activate oncogenic signaling pathways such as 
Ras/MAPK (mitogen-activated protein kinase) and PI3K (phosphoinositide 3-kinase)/Akt. However, these 
metabolic processes are also the cause and consequence of a perturbed microenvironment, which plays a 
significant role in producing the diversity of metabolic phenotypes that can be found in different regions of 
a tumor (8–10).  
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Metabolic processes are controlled in part by soluble factors in the tumor microenvironment, 
including transport-limited availability of oxygen, accumulation of lactic acid, and irregular concentrations 
of metabolic substrates. The distribution of these factors is primarily defined by the microcirculatory system 
(11). Dysfunctional tumor vasculature causes deregulated transport phenomena, in part by altering 
hydrostatic forces and therefore the spatial and temporal presentation of respiratory gases, metabolites, and 
soluble factors. Abnormal tissue perfusion and reaction kinetics result in heterogeneous biochemical 
gradients throughout the tumor. Hypoxia and lactic acidosis are principle consequences of aberrant 
microvascular transport (12). 
A small number of highly conserved regulatory systems control metabolic wiring to support tumor 
cell survival, growth, and proliferation in response to adverse microenvironmental conditions, including 
those mediated by hypoxia inducible factor (HIF) (13), mammalian target of rapamycin complex (mTORC) 
(14, 15), and AMP-activated protein kinase (AMPK) (16, 17). These metabolic sensors are interconnected 
with oncogene signaling (e.g. MYC, PI3K, MAPK, PTEN, p53, OCT1) and hormone balance (e.g. insulin) 
to monitor cellular energy and nutrient status (6).  
The combination of microenvironmental and signaling changes favors cancer cells that exhibit 
metabolic plasticity.  Metabolic flexibility allows tumor cells to regulate glycolytic and oxidative flux in 
order to overcome adverse tissue conditions, including hypoxia, acidosis, and limited nutrient availability 
at the interior of a tumor. For example, during lactic acidosis, cancer cells exhibit non-glycolytic 
metabolism, characterized by reduced glucose uptake and negligible lactate production (18). This non-
glycolytic phenotype provides a protective effect when cells are subsequently exposed to hypoglycemic 
conditions (18). Importantly, metabolic plasticity appears to be independent of genetic profile, as 
environmental changes can induce isogenic populations of cancer cells to switch from glycolytic to 
oxidative phenotypes (19). 
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Complementary modes of metabolism, which enable cells to adapt to fluctuating tissue conditions, 
also lead to the emergence of distinct subpopulations. Adjacent tumor niches interact through asymmetric 
“supply and demand” for intermediate metabolites, bioactive byproducts, and oxygen (20). For example, 
some oxygenated cancer cells express monocarboxylate transporter 1 (MCT1), which allows them to 
consume the energy-rich metabolites produced by Warburg-like cells (21, 22). This mechanism of nutrient 
exchange, known as “metabolic symbiosis,” uses lactate from hypoxic cells to fuel oxidative metabolism 
in aerobic tumor compartments (23). Cancer cells can even manipulate the metabolic properties of stromal 
fibroblasts to shift toward aerobic glycolysis, thus promoting metabolic efficiency and proliferative 
capacity.  
Spatial and temporal variations are a key feature of the metabolic landscape; tumor cells mutually 
shape and respond to their soluble environment. The full continuum of biochemical niches distributed 
throughout the tumor produces a mosaic of metabolic phenotypes that ultimately affect a patient’s response 
to treatment.  
Biophysical Forces: The Mechanics of Tumor Metabolism 
In addition to the soluble microenvironment, metabolic pathways are also sensitive to variations in 
tumor mechanical properties (24). Increased tumor stiffness can be attributed to a variety of parameters  
(25, 26). In particular, increased cell density and deposition and contraction of fibrillar extracellular matrix 
(ECM) proteins due to the formation of an activated tumor stroma play important roles. Furthermore, 
increased levels of glycosylated matrix components control tissue hydration and interstitial osmotic 
pressure (27). Water absorption, in turn, causes swelling, which further contributes to the palpable stiffness 
of solid tumors (28).  
The resulting changes in tissue architecture, as well as matrix structure and mechanics, can 
significantly impact cell behavior and regulate tumor metabolism (29). Through mechanotransduction, cells 
convert extracellular mechanical cues into biochemical outputs. Indeed, ECM structural elements that were 
132
once considered to be static architectural features are now known to regulate an intricate network of force-
sensitive signaling functions, which have a critical role in the development of disease (30).  
Mechanotransduction from the ECM is primarily mediated by integrin receptors, which are 
transmembrane heterodimers that physically link the ECM and the actin cytoskeleton (31). Integrin-
mediated mechanosignaling can be induced by external forces applied by the ECM or via cell-mediated 
contraction caused by phosphorylation of myosin light chain (MLC) by Rho kinase (ROCK) (32). Under 
mechanical tension, actin filaments bundle into stress fibers and integrins cluster to form focal adhesions, 
which both play active roles in regulating multiple aspects of cell metabolism (30).  
Integrin-mediated focal adhesions are important elements of mechanical signal transduction, and 
multiple signaling pathways converge at this interface that regulate metabolic processes. Focal adhesions 
are canonically associated with activation of focal adhesion kinase (FAK) and c-Src tyrosine kinase (CTK), 
which activate Ras and the MAPK pathway (33). In addition, the PI3K-AKT-mTOR pathway is a core 
element of focal adhesion signaling by operating as a transducer for growth factor receptors and Ras. 
Through receptor clustering, focal adhesions directly enhance growth factor-dependent PI3K signaling and 
a host of downstream functions (34–36). By exerting mechanical control over tyrosine kinase effector 
networks, focal adhesions directly contribute to malignant invasion, as demonstrated by the loss of tissue 
organization and concomitant changes in metabolic activity on stiffer substrates (37). Inhibiting the focal 
adhesion apparatus, or restoring appropriate matrix mechanics, results in cell quiescence and tissue 
homeostasis (38–40). Physical properties of the tumor microenvironment use focal adhesions to regulate 
diverse signaling networks responsible for malignant behavior and subsequent changes in metabolic status.  
While it is well-established that cytoskeletal remodeling is a key component of mechanosignaling, 
it was recently found that it also regulates a key step in glycolysis. Actin polymerization involves the rapid 
assembly and disassembly of fiber bundles that provide the structural framework of the cell. When actin 
fibers disassemble, they release the metabolic enzyme aldolase, which catalyzes the conversion of 6-carbon 
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fructose molecules to the 3-carbon molecules glyceraldehyde and dihydroxyacetone (41). The release of 
aldolase from the cytoskeleton accelerates glycolysis, as demonstrated by a sustained decrease in 
NADH:NAD+ ratio (41). This mechanism sensitizes glucose catabolism to external mechanical forces, thus 
establishing a direct link between matrix mechanical properties and cell metabolism. 
Vice versa, metabolic changes also affect the way cells interpret their mechanical environment. For 
example, glutamine metabolism appears to play a key role in mechanosignaling (42). A recent study 
reported that glutamine regulation partly controls the activity of RhoA, an oncogenic GTPase involved in 
focal adhesions and actin stress fiber assembly (43, 44). Hyperactive RhoA signaling typically causes 
oncogenic transformation, but this effect could be reversed using a small molecule inhibitor of glutaminase 
(GLS1), the amidohydrolase enzyme that converts glutamine to glutamate for entry into the TCA cycle 
(43).  A new study corroborated this observation by showing that stiffness-induced changes in glutamine 
flux were mediated in part by transcriptional regulation of GLS1 (45), suggesting reciprocal feedback 
between mechanosignaling and glutamine metabolism. 
Although metabolic activity is most often attributed to differences in cell and molecular biology, 
matrix mechanics also regulates metabolic functions. It is increasingly clear that denser, thicker, and 
mechanically rigid ECM promotes cancer growth and metastasis (46). Therefore, strategies to target cancer 
cell metabolism must carefully consider the physical context.  By exploring the role of biophysical factors 
in tumor metabolism and incorporating these factors into our models of patient disease, we expect to 
improve the predictiveness of our assays and thereby enhance our ability to identify effective therapeutic 
strategies. 
Experimental Platforms: Engineering Model Systems  
Culture-based model systems are central to the investigation of spatial, temporal, and physical 
elements of cancer metabolism. Although in vitro models can never capture a complete representation of 
the tumor microenvironment, they can be useful for examining the effect of its most salient features on 
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cellular metabolism, including physical properties of the matrix and the impact of fluid transport. One of 
the greatest challenges in studying metabolism is navigating between levels of space, time, and complexity, 
from molecular details to whole-body physiology. This is one area in which new tissue-engineered model 
systems are proving especially useful. 
Conventional in vitro assays are largely based on monotypic populations of cells cultured on plastic 
or glass substrates. Monolayer cultures of homogeneous cells, or mouse xenografts derived from 
commercial cell lines, diverge from the original tumor, most notably through the dramatic loss of 
heterogeneity and tissue structure (47). Even transient exposure to planar culture conditions causes 
irreversible changes in cell behavior (48, 49). A microarray analysis of cancer cells in 2D versus 3D culture 
revealed broad changes in hypoxia response and pro-inflammatory pathways (50). These observations 
reflect a growing consensus that the culture environment is a critical determinant of cell behavior, and that 
2D monolayer culture drives abnormal function whereas exposure to a 3D environment mimics a more 
physiologic state (51, 52). 
In the past twenty years, many labs have adopted 3D culture techniques to mimic 
microenvironmental aspects of native tissues. Merely embedding cells within 3D substrates can restore a 
mélange of important functions, including 3D morphogenesis, secretory functions, and tissue homeostasis 
(40, 53–55). However, “3D culture” has become an umbrella term that obscures a more nuanced reality. 
There are many differences between 2D, 3D, and physiological settings; dimensionality is complicated by 
the numerous parameters that define each model system. For example, “matrix mechanics” encompasses 
fiber architecture and conformation, matrix composition and porosity, covalent and ionic crosslinking, and 
cell density, polarity, and contractility (56–60). Similarly, “mass transport” is not merely a question of 
vascular proximity, but also involves osmotic and hydrostatic pressure gradients, fluid viscosity and shear 
stress, cell density and metabolic activity, concentrations of ions and dissolved gases, and matrix binding 
kinetics. Functional consequences emerge from the integrative effects of these manifold variables, rather 
than from a perfunctory switch from 2D to 3D (61, 62). 3D assays provide demonstrable evidence that 
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context is important, but we must carefully consider how various features of the experimental system 
provide instructive cues that alter cell behavior, especially with regard to metabolic programming. 
Emerging tissue-engineering technologies now provide attractive tools to control the physical 
microenvironment for studies of cancer cell metabolism. Hydrogel-based biomaterials are frequently the 
basis for 3D culture, and a catalog of natural and synthetic materials are available that support cell adhesion, 
viability, and remodeling; nutrient and waste exchange; and appropriate mechanical properties. Natural 
ECM components include type I collagen, fibrin, reconstituted basement membrane (EHS or Matrigel), and 
decellularized matrices deposited by fibroblasts (63, 64). Natural materials possess inherent biological 
functions, such as adhesive ligands and cleavage sites, but it can be difficult to precisely define and 
manipulate the composition and/or structural properties. On the other hand, synthetic gels afford greater 
control over materials properties, and can be readily manipulated with biological moieties such as matrix 
metalloproteinase (MMP)-cleavable domains, integrin binding sites, or specified fiber properties and 
crosslinking, but lack the biological complexity of native tumor-associated ECM (65–73). As modifications 
to the physical culture environment have a profound impact on tumor cell metabolism, accurate modeling 
of the ECM and spatiotemporal variations thereof is critical for proper characterization of metabolic 
behavior. 
Both natural and synthetic materials are readily integrated with microfluidic technologies to 
recapitulate matrix mechanics and fluid transport processes that affect tumor metabolism. For example, 
microfluidic biomaterials can be generated using a confined gel, whereby microchannels are patterned 
within a transparent silicone mold (74, 75). Alternatively, dense hydrogels allow imprinting of microfluidic 
conduits directly within the scaffold to control the spatial and temporal gradients of exogeneous factors or 
drugs, reminiscent of microvascular function (76–79). Both strategies have been used to construct 
biomimetic vascularized tissue constructs to recapitulate the individual and combinatorial effects of matrix 
structure, solute transport, and cellular composition that define the metabolic environment. 
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Microfluidic biomaterials can also be integrated with live cell imaging techniques to acquire spatial 
and temporal information about the complex interdependencies between the microenvironment and cell 
metabolism. These tools can be used to readily manipulate and measure real-time, single-cell dynamics by 
using endogenous or genetically-encoded fluorescent sensors. For example, a vascularized microtumor 
(VMT) model was used to map metabolic activity within different regions of hybrid microfluidic-organoid 
via fluorescence lifetime imaging of NAD+ and NADH (80). The VMT platform mimicked stromal 
composition, matrix structure, and vascular function, and it simulated metabolic response to pharmacologic 
agents (80). 
Advances in biomaterials and microfabrication technologies (like the VMT model described above) 
afford new methods to integrate vascular, stromal, and epithelial compartments with precise arrangements 
of parenchymal and interstitial elements (81–83). In addition, emerging tissue culture techniques have 
produced a new generation of microphysiological devices (“tissue chips”) that capture increasingly accurate 
representations of whole organs, including liver, kidney, heart, lungs, brain, GI system, blood vessels, skin, 
adipose, cervix, uterus, and ovaries (81, 84, 85). These culture analogs mimic the structure and function of 
human physiology, with particular attention toward the cellular microenvironment and tissue heterogeneity 
(86). Originally designed for pre-clinical drug screening, organ-on-a-chip models have been used to 
simulate first-pass metabolism, activation of anti-cancer prodrugs, synergistic actions of drug combinations, 
modulation of tissue bioavailability, membrane barrier function, off-target toxicity, and mechanisms of 
drug adsorptions, distribution, metabolism, excretion (ADME) (87). Tumor metabolism is a multiscale 
phenomenon, and these platforms make it possible to simulate higher-order metabolic regulation in vitro. 
The next milestone for microphysiological platforms involves the serial integration of multiple 
organs within a single device (87). A complete "body-on-a-chip" would simulate interactions between 
organs, such as drug adsorption through GI-tract, metabolism in the liver, clearance in the kidneys, and 
cytotoxic effects in the heart or other tissues (87). Already, pioneering systems have been strategically 
validated as physical analogs for pharmacokinetic/pharmacodynamic modeling (88). By carefully 
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controlling tissue volume and fluid residence time, integrated microphysiological systems can mimic drug 
distribution, uptake, and activity in surrogate organs (89). One such platform predicted nontarget drug 
retention in adipose tissue and nephrotoxicity. Similarly, a commercial model, called Hurel, was 
instrumental for identifying drug metabolites that were not present in traditional, monotypic cell culture 
(90).  
Collectively, microphysiological devices present a promising opportunity to navigate across cell, 
tissue, and organ systems when investigating cancer metabolism and drug response. Importantly, micro-
tissue devices are not delicate, "artisan" products, but increasingly robust platforms for broad application 
in the laboratory and the clinic. Several platforms are commercially available with high simplicity, 
reliability, and throughput. Multiwell plate and microscope slide formats make these technologies 
immediately suitable for implementation in non-engineering labs. 
Clinical Translation: Metabolism in Precision Oncology 
The manifold variables that influence metabolism and drug response make it challenging to infer 
susceptibility to targeted pharmaceutical agents. Factors related to metabolism and energetics (diet, physical 
activity, weight control, and vascular health) interact with genetic, physiological, and environmental 
variables to influence cancer risk, prognosis, and treatment outcomes in ways that are often impossible to 
predict. Every patient manifests a unique and ever-changing gene expression, metabolic profile, and tissue 
microenvironment.  
The precision medicine paradigm has been championed as a strategy to account for the dynamic, 
patient-specific variations in tumor behavior. Originally, precision oncology used molecular information to 
prioritize therapies for patients that expressed specific biomarkers.  Now, comprehensive approaches 
integrate pathology, -omics analyses, and functional diagnostics (e.g. rapid drug screening and animal 
modeling) to pre-determine the safety and efficacy of personalized treatments for individual patients (Figure 
2) (91–93). Information about the genetic aberrations, the gene expression profiles, and the patient-specific 
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drug responses helps guide new off-label use of FDA-approved therapies, which could not have been 
predicted from sequencing alone. By integrating data from multiple independent methodologies, these 
approaches can cross validate personalized therapies for cancer patients.  These approaches have special 
significance for patients with advanced disease or multi-drug resistant cancers, where standard therapies 
have failed. 
In order to formulate and test patient-specific combination therapies, clinicians require model 
systems that accurately recapitulate the salient characteristics of the native tumor. Microenvironmental and 
systemic metabolic feedback mechanism (such as increases in insulin secretion upon treatment with PI3K 
inhibitors) have the capacity to significantly alter tumor responses to therapy but are frequently not 
accounted for in culture platforms being utilized in the precision medicine setting (94). Such shortcomings 
may account for divergence between in vitro and in vivo responses observed in the precision medicine 
context (95). Therefore, model systems must be attentive toward the constellation of interdependent 
variables that influence drug sensitivity, including the genetic composition, proximal microenvironment, 
and systemic factors. This is especially true for drugs that target metabolic processes, in which the 
microenvironmental context plays an essential role in regulating aberrant behavior. As the tumor 
microenvironment is a major factor in determining drug efficacy, the use of models that recapitulate patient-
specific tissue properties may be critical for the success of precision medicine approaches. 
Patient-derived xenograft (PDX) models seem to be the most suitable platform to preserve the 
clonal architecture of the original patient sample, as well as its gene expression, histology, and epigenetic 
profile (96, 97). Indeed, PDXs, for which pieces of a patient's primary tumor are propagated in 
immunodeficient mice, enable highly representative, co-clinical testing of drug combinations (98). 
However, this approach is extremely time consuming and expensive, and lacks the capacity for high-
throughput screening or precise experimental manipulation. Furthermore, PDXs select for specific cell 
types over time, lack a functional immune system, and significant differences between humans and animals 
can lead to discrepancies with regard to drug metabolism and signaling mechanisms (99). These challenges 
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Fig. 2. A comprehensive precision medicine toolkit. A comprehensive approach to precision oncology
integrates pathology and sequencing analyses (left) with functional diagnostic platforms (right). More complete
information about individual patient susceptibility will help guide personalized treatment strategies (center).
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might be overcome by complementing PDX models with physiologically relevant in vitro assays that can 
be utilized to quickly and accurately perform high-throughput screening with potential therapeutic agents 
and provide mechanistic information to guide treatment (100, 101).  
Biomaterial-based, microfluidic tumor models that contain patient-derived cells should become an 
important component in a comprehensive approach to precision medicine. Patient-derived 
microphysiological systems combine the biological complexity of primary tissue samples with the 
simplicity of in vitro analysis (102). The fast timing, low cost, and small tissue volume permits testing large 
numbers of drug permutations and dose regimens, thereby ranking optimal combinations to be tested in 
vivo (98). These platforms avoid some of the limitations of traditional tissue culture systems, and they 
complement more intensive methods like PDXs.  
Engineered, clinically-derived culture models might help improve the use of anti-metabolic agents 
in precision oncology (92). Efforts to study cancer metabolism in vitro rarely consider the ubiquitous effects 
of vascular transport phenomena and matrix mechanical properties. This poses a challenge for determining 
the impact of pharmacological agents that target metabolic processes, as vascular transport not only affects 
local concentrations of biochemical factors, but also the bioavailability of drugs. Additionally, matrix 
mechanical properties not only affect metabolic signaling pathways as outlined above, but also directly 
contribute to therapy resistance by acting as a physical barrier to the delivery of therapeutic agents. Indeed, 
the tumor microenvironment and limited bioavailability of drugs is viewed as a major determinant of 
resistance to therapy, but is often overlooked in molecular analyses of clinical specimens and in chemo-
sensitivity testing. Functional screening platforms that incorporate a full range of biophysical cues might 
help predict whether a specific patient is likely to benefit from treatments with drugs that target the unique 
vulnerabilities afforded by tumor metabolism. 
Incorporating patient samples into sophisticated microphysiological systems may provide insight 
into underlying determinants of disease progression and drug response. For example, spatial information 
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about the activity of cells in different regions of a controlled microenvironment might simulate 
heterogeneous response to targeted therapies. When combined with quasi-physiological culture models, 
patient-derived samples can be used to determine how tissue-scale heterogeneity impacts tumor progression 
and response to pharmacological agents. As microphysiological culture platforms move toward clinical 
settings, they offer a promising strategy for guiding patient-specific drug selection and treatment modalities. 
Conclusions 
Physical scientists and engineers can contribute new tools and insights on the mechanisms by which 
cells, tissues, and organ systems regulate metabolic processes. Such outcomes require the expertise of 
biologists and clinical oncologists, who are most directly familiar with the physiology of patient tissues. 
The cross-disciplinary exchange of knowledge ensures the advancement of technologies and treatments to 
preserve or restore human health. This dialogue is especially critical for developing patient-derived model 
systems that faithfully recapitulate matrix mechanics and transport properties to evaluate anti-metabolic 
therapies in precision medicine settings.   
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CHAPTER 6 
FROM PATIENTS TO PARTNERS 
 
Peter DelNero and Alexandra McGregor. (2017) From patients to partners. Science 
358(6361):414.  
 
Manuscript 
When we started graduate school 5 years ago, we were determined to learn everything we 
could about cancer. We spent all our time in the lab developing an arsenal of experimental 
techniques. However, in our daily work with petri dishes and microscopes, we felt that something 
was missing. We learned all about tumor biology, but we knew very little about the human 
dimensions of cancer. Even though our research is far from the clinic, we believed that interacting 
with patients and survivors would improve our understanding of cancer and the quality of our 
science. 
 With permission from our advisers, we contacted the director of a local cancer center to 
find out whether he might be interested in working with us. He was enthusiastic about connecting 
scientists-in-training with the cancer community; in fact, he was already discussing this idea with 
another group at our university. Together, we started hosting monthly seminars where researchers 
and patients interact and learn from each other. Some months, a graduate student gives a lay-
language presentation about an important aspect of cancer research. Other months, community 
members describe their experiences of living with cancer. We also organize informal activities that 
promote patient-researcher dialogue, such as lab tours, book clubs, and participation in cancer 
support groups. One lung cancer survivor even spent a summer conducting experiments with us. 
Our relationship with the cancer center created a continuous stream of new opportunities.  
149
Fig. 1. Cancer patients contribute to all stages of the research process, beginning with the training of new
scientists. Illustration by Robert Neubecker.
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The partnership with the patient community has deeply influenced our formation as 
scientists. Our conversations have revealed gaps in our knowledge, exposed biases and 
assumptions, and even opened new paths for inquiry. We have learned about the hidden costs of 
cancer and the day-to-day obstacles patients face with their work, health insurance, family life, 
and plans for the future. By speaking with cancer patients, we have also learned to exercise 
openness, empathy, and reflective listening. Over time, we have fostered special relationships with 
patients and family members, and many have become our closest friends. Occasionally, we come 
face-to-face with the devastating reality that current treatments are not good enough.  
The patient-researcher partnership transformed our research from an intellectual exercise 
into a deeply personal endeavor. It reminds us that people with cancer are not merely cells or 
molecular pathways. They are neighbors, colleagues, friends, and relatives. They are valued 
partners in the fight against cancer. As one of our colleagues explained, “I used to care about 
accomplishments and great publications, but now I simply want to generate data that will be most 
reliable and important for improving cancer therapy.”  
Early in the process, we felt nervous about taking time and energy away from our lab work 
to develop this program. We felt we were “breaking the rules” for graduate student conduct. But 
we decided to ignore this nagging anxiety, and we gave ourselves permission to continue. With 
help from a team of faculty members, the partnership evolved into a formal curriculum for public 
engagement in cancer research. This aspect of our work became a highlight of our graduate 
experience.  
Through our partnership, we discovered that research is not the only way that scientists can 
make a positive difference in the fight against cancer. Outside the lab, we can nurture personal 
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relationships with individual patients, survivors, and families. Researchers are well placed to dis-
seminate information, dispel common misconceptions, and share the scientific process with the 
cancer community. Most importantly, we can be good, supportive listeners. As we pursue the next 
phase in our research careers, we know that our patient involvement will continue. For us, it has 
become an integral part of what it means to be a cancer scientist.  
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CHAPTER 7 
NAVIGATING A WAYWARD PATH TOWARD PUBLIC ENGAGMENT 
 
Peter DelNero. (In press) Navigating a wayward path toward public engagement. Michigan 
Journal of Community Service Learning.  
 
Abstract 
Graduate school is an intense period of identity formation, where scholars-in-training form 
the attitudes and values that shape their research. While pursuing their degree, graduate students 
navigate an evolving sense of personal and professional self-concept. This process is modulated 
by the presence or absence of public engagement paradigms. The extent to which students 
assimilate public engagement into their academic formation may depend on the system of beliefs 
that underpin their particular field of study. In some fields, public engagement disrupts the 
conventional forms of scholarship and elicits a peculiar tension. How can graduate students 
overcome a misalignment between their personal goals, values, and interests and those of their 
discipline? If graduate students are trained to think and act in certain ways, then what happens to 
people who choose to think and act differently in order to cultivate a community-engaged mindset? 
In this essay, I examine these questions through my experiences as a community-engaged doctoral 
student in biomedical engineering. 
Manuscript 
Graduate school represents a critical stage in the academic pipeline, where professional 
attitudes and priorities are internalized by future faculty and administrators. During graduate 
education, students construct the aspirations, commitments, and identities that ultimately define 
their careers. As such, there is growing appreciation for preparing graduate students for 
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professional roles that advance the practice of community-engaged scholarship (1, 2). But what if 
graduate students are trained in departments that do not value or reward these activities? Will 
emerging scholars perpetuate traditional attitudes toward teaching, research, and service? 
In this narrative, I reflect on my experience of disrupting a cycle of social reproduction in 
order to accommodate a community-engaged mindset. The article is autoethnographic in that I 
connect my personal experiences with an analysis of my academic culture (3, 4). I present this 
essay as a scholarly personal narrative (5); the italicized sections represent my personal 
experiences and interpretations.  
Graduate education is an intense period of cognitive and affective development. Through 
a process of socialization, students acquire specialized knowledge and skills, while coming to 
recognize the cultural norms, ideologies, and world views that characterize their profession (6, 7). 
At the same time, graduate students have entered a stage of self-authorship, where they exercise 
the capacity to define their own beliefs, identities, and social relations (8). Students play an active 
role in shaping their academic formation while learning to navigate professional norms and 
boundaries.  
I am a doctoral candidate in biomedical engineering, specializing in cancer biology. As a 
graduate student, I fall into an uncomfortable gap between advanced student and novice scholar. 
In addition to taking classes, I also teach, conduct research, and assume service roles at my 
institution. When I entered graduate school, I expected to receive instrumental training in 
biomedical research and become a credentialed professional in the field. During my first year, I 
quickly assimilated into the norms of my discipline.  
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Disciplinary norms are the values, behaviors, and responsibilities that characterize 
“business-as-usual” in an academic community. Academia is a diverse profession, but there is an 
implicit code-of-conduct that governs the epistemic culture within each field (9). This culture is 
often invisible to new students, concealed within the latent assumptions and biases of the discipline. 
As discussed by the Carnegie Initiative on the Doctorate, graduate education is largely a process 
of becoming acculturated to these norms (10). 
Jackson (1968) introduced the concept of a “hidden curriculum” to describe the cultural 
transmission that occurs within and beyond the classroom. The hidden curriculum is the way in 
which institutional systems “persist and reproduce themselves without being consciously 
recognized by the people involved” (12). In graduate education, disciplinary norms play a 
substantial role in the socialization of emerging scholars, but they “remain an embedded and 
largely ignored element of academic life” (13).  
As an engineering student, I inhabit a discipline where I perceive the culture to be relatively 
strict. Patterns of thought and behavior are enforced via institutional structures such as 
apprenticeship, peer-review, the curriculum, and the collective expectations of the community. The 
engineering identity, with its explicit maxim to “think like an engineer,” is an unequivocal way of 
being.  
Although socialization provides a stable mechanism for stewardship and knowledge 
transmission, the hidden curriculum can sometimes be problematic (14, 15). For example, the 
apprenticeship model of doctoral training has been criticized for perpetuating institutional 
discrimination (16). When experts evaluate prospective candidates, they “tend to look for someone 
like themselves, missing the valuable talents of people who are different” (17, 18).  
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Downey and Lucena connect the negative impact of socialization to the concept of 
“weeding out.” During interviews, “students regularly asserted that the goal of certain courses was 
to ‘weed out’ students {…} For students who stayed, these and other courses also appeared to 
weed out part of themselves as persons” (19). Similarly, Weidman and colleagues reported that 
the principal conflict for many graduate students was the feeling that they must sacrifice their own 
interests and goals to fit the expectations and interests of their advisors (20). Students who embody 
nonconforming social or intellectual identities confront systematic resistance, which subverts 
efforts toward equity, innovation, and risk-taking.  
Cech reported a “culture of disengagement” in engineering education, comprising a 
collection of ideologies that discourage civic awareness and activism (21). This culture is 
characterized by an exclusion of non-technical stakeholders in academic dialogue, the dismissal 
of public welfare concerns, and an inattention toward social justice, equity, and social 
responsibility (21, 22). As a result of socializing to these norms, engineering students lose the 
ability to reflect on the broader context of their work, to define and prioritize social concerns, and 
to assess problems, methods, or outcomes from multiple perspectives. In essence, students learn 
to dissociate public impacts as tangential to their field of study (21).  
My acculturation into the biomedical engineering community was disrupted by an 
emerging partnership with a local cancer support center, which I helped initiate during my second 
year of graduate school. Our collaboration is logistically simple, comprising a monthly 
colloquium for patients, survivors, and students. Seminars are complemented by a variety of 
informal activities that facilitate dialogue between patients and scientists. 
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As my relationship with the cancer community grew stronger, it gradually infringed on my 
identity as an engineer. My priorities and attitudes toward research seemed misaligned with the 
expectations of my colleagues. For example, a faculty member once complained to me that the 
“broader impacts” criteria should be eliminated from the funding mechanisms of the National 
Science Foundation. The professor stated, “I don’t write grants so that [my student] can do 
outreach. I'm training her to be a scientist, not a babysitter.” According to this professor, broader 
impacts, such as public engagement activities, are a waste of time. Because of my involvement in 
the cancer community, I found myself becoming an outsider in my discipline. 
In an analysis of participatory research, Nyden observed that “sometimes [academic] 
culture can be indifferent to community involvement; other times it is actually hostile” (23). For 
graduate students, “being in opposition does not simply mean confronting abstract ideas; 
frequently and most uncomfortably it means confronting one’s professors” (18). Given these 
circumstances, “successful” students are often those who readily assimilate to disciplinary 
paradigms, while students who re-define these paradigms have a more difficult experience (13, 
24). In some cases, this environment might tacitly discourage civic engagement activities, social 
justice concerns, and the retention of graduate students who espouse them.  
Cognitive dissonance is a painful but important element of disciplinary learning. But in my 
case, the cognitive dissonance between the discipline of engineering and community engagement 
evoked feelings of guilt, shame, and self-doubt. Through my academic training, I had internalized 
the belief that public engagement was outside the purview of engineering. My relationships with 
community members challenged my assumptions about the purpose, process, and products of 
biomedical engineering research. At the time, I was unable to articulate this dissonance, but I felt 
an overwhelming anxiety surrounding what I was coming to perceive as my deviant patterns of 
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thought and behavior. My commitment to the community partnership violated my beliefs about 
what it meant to be an engineer. 
Reflection, as a cornerstone of service-learning and with roots often attributed to the 
education theories of John Dewey (25) and David Kolb (26), is the vital link between experience 
and knowledge. In Where’s the Learning in Service-Learning, reflective practices predicted 
learning outcomes associated with personal development, citizenship, problem-solving, and 
perspective transformation (27). In service-learning pedagogy, cognitive and emotional processes 
are inseparable dimensions of reflection (28), both of which are essential for making meaning from 
experience.   
Self-reflection was facilitated through my role in developing curriculum, writing grant 
proposals, and drafting manuscripts. Through this process, I learned how to tell my story, and I 
gained a deeper understanding of my experiences. By pursuing community-engaged activities, I 
felt I was “breaking the rules” of what an engineering student is “supposed to do." But ultimately, 
who decides how an engineer should think or behave? Why did I maintain the inexorable 
conviction that community engagement was verboten?  
As I reflected on this, I arrived at Walt Kelly’s startling conclusion: “We have met the 
enemy and he is us.” I discovered that I was trapped by tunnel-vision: I had internalized a system 
of values and beliefs from my discipline. But I also realized that I had the capacity to change those 
values and beliefs. This realization enabled me to construct a new, integrated concept of my 
professional identity: “I thought I knew what it meant to be an engineer, but that was partly a 
myth. It’s okay to be different.”  
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According to Mezirow, transformative learning “makes it possible for us to […] become 
emancipated from our constraining habits of expectation and move to a perspective that permits 
interpretations which are more inclusive, differentiating, permeable, and integrative of experience” 
(29). Transformative learning empowered me to step beyond my existing patterns of thought and 
behavior and to extend the definition of my profession. 
My involvement in public engagement transformed my perspective of graduate education. 
I am no longer the passive recipient of professional socialization. As a graduate student, I am 
responsible for my own academic development, including attentiveness toward the intellectual and 
social norms that permeate my discipline. I have agency to define the values, goals, and methods 
of my scholarship. I have an obligation to reflect on the usefulness of knowledge, the social 
consequences of my work, and its relation to the world beyond campus (30). In short, I am a co-
creator of the intellectual communities that I inhabit and an advocate for my ongoing formation 
as an engaged scholar. 
In graduate education, students internalize the profession’s concept of ethical behavior and 
social norms. If community dialogue is marginalized, emerging scholars will continue to define 
public engagement as irrelevant to the practice of their discipline. Conversely, graduate students 
are uniquely positioned to disrupt the cycle of assimilation, and to cultivate an academic identity 
that accommodates public engagement. We can foster an intellectual community that “provides 
explicit emphasis on how to value and engage in such work” (1).   
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CHAPTER 8 
CONCLUSION 
 
There are countless elements that contribute to cancer pathogenesis, and it is important to 
determine which factors ultimately lead to better patient outcomes. This may include the physical 
properties of the tissue microenvironment, as well as the communities of people who are grappling 
with cancer in its full human complexity. Both basic science labs and community support 
organizations provide irreplaceable services to improve human health and reduce the burdens of 
cancer. 
In Part I, I document the scientific approaches that are traditionally associated with 
biomedical research. My laboratory research demonstrates how the tumor microenvironment 
influences cancer cell behavior. The results show that the three-dimensional tissue context has 
substantial effects on hypoxia response and angiogenesis. These laboratory-based investigations 
led to sophisticated tools to study how the tumor microenvironment regulates cancer cell behavior 
and microvascular function.  
Looking forward, it is exciting to consider the future implications that might emerge from 
these projects. With regard to the microvascular networks, there is potential application in multiple 
settings. In the clinic, these products may provide an important platform for precision medicine; 
microphysiological models containing patient-derived tissues might be used to test novel drug 
combinations, potentially improving personalized treatments for cancer patients. More elaborate 
body-on-a-chip platforms offer systemic models of metastasis or treatment. Appropriate vascular 
transport is essential for mimicking the physiology of health and disease in vitro.  
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A spectrum of biological questions are made tractable by well-controlled microvascular 
models. This technology might be used to assess the effects of matrix fiber architecture on vascular 
function or the influence of angiocrine signals in the tumor niche. The system is well suited for 
testing vessel response to new therapeutic agents or cell-derived cues like microvesicles. When 
combined with genetically-encoded fluorescent sensors, the device can be used to monitor cell 
status in response to exogenous factors. For example, we used a FRET-based lactate sensor to 
measure real-time, single-cell metabolic changes while manipulating nutrient availability, 
glycolysis, or oxidative phosphorylation. Finally, our platform may provide a suitable surrogate 
for validating computational models of disease. Mathematical models are useful for simulating 
metabolic processes or tumor evolution, and in vitro systems might allow researchers to test 
predictions from such experiments. 
Two features will make the microphysiological platform even more useful. First, the 
platform should closely recapitulate the specific properties of host tissue. For example, in vitro 
models of breast cancer ought to include matrix and cellular components that reflect the adipose 
tissue microenvironment. This is also true in modeling metastatic processes like intra- and 
extravasation, where local tissue properties play a role in tumor colonization. Second, the devices 
must become more robust and reproducible for use in non-engineering labs. So far, sensitive device 
assembly prevents wide-spread application of these tissue engineering models. Improving the 
device fabrication procedure will significantly enhance the impact of these technologies. Appendix 
I presents one example of a facile tool for reconstructing elements of the tumor microenvironment, 
including spatially-resolved molecular characterization and autologous transport gradients.  
In Part II, I report on an unconventional aspect of biomedical research: the patient-
researcher partnership. This project is directly relevant to a convergence toward public engagement 
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in health research, higher education, and science communication. The approach is not focused on 
molecular mechanisms of disease; instead, the best possible outcome is a sustained and equitable 
partnership. Patient involvement reveals a different dimension of cancer: how cancer affects 
people's lives. The personal aspects of cancer are critical determinants of research training. By 
interacting with cancer patients and survivors, we gain concrete knowledge that cannot be 
replicated in a laboratory. Through my involvement in the patient-researcher partnership, I have 
discovered an entirely different way of understanding the purpose, process, and products of 
science. These relationships provide a more complete understanding of this disease. 
The patient-researcher partnership transforms the relationship between scientists and 
community members. Scientists begin to see themselves as members of the patient support 
network, with a personal concern toward improving the wellbeing of individual patients and 
survivors. The parternship welcomes new forms of knowledge and expertise that arises from the 
lived-experiences of cancer patients and their families. The partnership allows new voices to 
influence our choices and perspectives when approaching scientific phenomena, and it offers the 
possiblity of seeing things that we miss in the laboratory. When we expose ourselves to diverse 
perspectives, we are more aware of the limitations and biases of our own worldviews. When 
science is inclusive to public participation, it engages a range of perspectives that would otherwise 
be excluded; the scientists who listen are rewarded with valuable insights and irreplaceable 
relationships. 
The patient-researcher partnership leads to a more complete understanding of cancer and a 
stronger commitment toward reducing the burdens of this disease. Looking ahead, it is exciting to 
think that our simple collaboration might become a normative aspect of biomedical training. We 
hope that the concept of patient-researcher dialogue will be replicated at other research insitutions 
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and community support organizations. If successful, this paradigm could change the way that 
scientists perceive their role in the cancer landscape, just as it has for me. 
There are many ways of producing knowledge. In biomedical sciences, discovery often 
progresses through an incremental process of generating and testing hypotheses. In addition to 
discoveries, scholarship can also involve the integration or application of knowledge in new ways, 
or the transmission of knowledge across new boundaries. Since the 1990's, there has been sustained 
interest in accommodating a wider variety of epistemologies within scholarly discourse, for 
example by elevating the practice of applied research, teaching, and outreach to equal status with 
traditional forms of inquiry. This shift reflects an appreciation for multiple responsibilities and 
forms of expertise that co-exist within universities. 
 Ultimately, my PhD was six years learning how to improve human health and 
reduce the burdens of cancer. I found three ways to do this:  First, by developing laboratory 
models that better reflect the conditions in the body so that our experiments are most likely to lead 
to reliable and useful data. Second, by forming personal relationships with members of the Ithaca 
cancer community and taking actions to support people who are affected by cancer. And third, by 
training new cancer scientists to be diligent researchers who are also attentive and committed to 
listening to patient perspectives and maybe learning something unexpected. For me, all three 
outcomes are integral parts what it means to be a cancer scientist. 
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ENGINEERED TUMOURS: ROLL-ON SCAFFOLDS 
 
Peter DelNero and Claudia Fischbach. (2016) Engineered tumours: roll-on scaffolds. 
Nature Materials 15(2):138-39. 
  
Manuscript 
Aberrant biological and physical properties of the microenvironment - such as vascular 
dysfunction and the ensuing perturbations of diffusive and convective transport - are both cause 
and consequence of malignant transformation (Fig. la). To study the underlying cellular and 
molecular mechanisms, biomaterials and tissue-engineering strategies that mimic specific 
physicochemical properties of tumours in vivo are increasingly applied (1). In contrast to 
conventional two-dimensional monolayers, cells embedded within a three- dimensional artificial 
extracellular matrix (ECM) recreate tissue structures and soluble gradients that resemble those of 
actual tumours (Fig. la) (2). Although biomaterials-based models achieve relative success in 
predicting cell signalling and drug response, they often conceal the exact mechanisms by which 
the microenvironment regulates disease, in part because of the difficulty of decoupling the 
feedback mechanisms by which extracellular conditions and intracellular pathways synergistically 
promote tumour aggressiveness. Reporting in Nature Materials, Alison McGuigan and colleagues 
introduce a ribbon-on-a-spool biocomposite (Fig. lb) that can help untangle these interactions by 
permitting the analysis of distinct, localized regions in quasi-physiological tumours (3). 
In the scaffold-tumour construct, which McGuigan and colleagues termed tumour roll for 
analysis of cellular environment and response (TRACER), cancer cells are embedded on a 
biocomposite film, wrapped around an aluminium mandrel, and cultured in a standard well-plate. 
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Fig. 1. a) Cancer initiation, progression, and therapy are controlled by aberrant features of the surrounding tissue
environment, such as inflammation, angiogenesis and desmoplasia. The resulting heterogeneous distributions of
nutrients and drugs (green), cell-secreted factors (blue), and oxygen and pH (purple), collectively contribute to
tumour malignancy. To study the underlying biological and physical mechanisms, biomaterials-based tumour
models attempt to recapitulate the corresponding tumour–host-cell interactions, soluble-factor gradients, and
extracellular-matrix (ECM) properties. b) A cell-laden biocomposite roll allows for the correlation of phenotypic
changes with specific microenvironmental niches. Within the spool, passive diffusion and cell-mediated
processes generate gradients of soluble factors that mimic the spatial distributions imposed as a function of
progressive distance from the nearest functional blood vessel. By unrolling the spindle and isolating cells from
spatially distinct locations, specific extracellular conditions (such as hypoxia or acidosis) can be correlated with
changes in intracellular signalling.
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Consumption and secretion activities by encapsulated cells create radial molecular gradients (Fig. 
lb; inset). Subsequently, the film is unravelled, cut into sections, and analysed with conventional 
biological assays. Hence, this cell-culture platform offers an exquisite tool for the generation of 
well-defined autonomous gradients and for the characterization of cellular behaviours at precise 
regions along these gradients. Because the design of TRACER does not require sophisticated 
instrumentation or technical expertise, the platform is simple enough to be widely implemented as 
a pathologically relevant model of cancer. 
Cancer-cell metabolism is a poignant example of the reciprocity between cells and their 
local microenvironment. It is commonly accepted that tumour cells dynamically adjust their 
metabolic signalling to meet the increased needs for macromolecule biosynthesis and for redox 
balance associated with excess cell prolife ration (4). These changes have been primarily 
associated with aberrant intracellular signalling pathways. However, asymmetric biochemical 
gradients caused by the combined effects of vascular transport and cellular consumption and 
secretion play a similarly important role, and may terminate in severe local hypoxia, lactic acidosis, 
and nutrient depletion (5). Cancer cells respond to these adverse conditions through a variety of 
adaptive responses, including a switch toward glycolytic metabolism. Therefore, the metabolic 
phenotype of an individual cancer cell is affected by both oncogenic alterations and spatial 
differences in microenvironmental stress. 
McGuigan and co-authors first used TRACER to investigate the effect of spatial variations 
in oxygen concentration on the activity of hypoxia-inducible factor-I (HIF-1; a canonical regulator 
of the hypoxia response (6)) and resultant changes in tumour-cell metabolic reprogramming. Gene-
expression and metabolomic analyses of TRACER layers confirmed that cellular phenotypes 
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varied as a function of their spatially distinct microenvironments. Interestingly, inhibition of HIF-
1 with short-hairpin RNA (shHIF) broadly altered the metabolic profile in TRACER. Although 
some of these changes are expected, a number of surprising connections that may represent new, 
context-dependent metabolic pathways also emerged. Moreover, metabolic changes were 
corroborated by indirect measures of oxygen concentration in the TRACER system. TRACERs 
containing shHIF manifested a fixed oxygen gradient after 12 hours, whereas control experiments 
showed increasing oxygen levels. The authors attribute these observations to the inability of 
shHIF-treated cells to modulate their oxygen consumption under hypoxic conditions, possibly as 
a consequence of the altered metabolic profiles. Altogether, the authors directly correlated HIF-1-
dependent changes in intracellular metabolic processes and extracellular oxygen gradients to 
unique regions in the tumour. Their analysis provides an excellent protocol for using TRACER to 
study the intersection of gene-regulatory pathways and the tumour microenvironment. 
Although McGuigan and co-authors discuss their findings in the context of hypoxia, 
oxygen gradients are only one of the multiplexed environmental factors regulating tumour 
metabolism and thus malignancy. Distributions of lactic acid, paracrine signals, therapeutic drugs, 
and other soluble factors concomitantly affect cellular phenotype and could be studied with 
TRACER. Likewise, insoluble ECM components play a critical role, as their chemical, structural, 
and mechanical properties can affect cellular/metabolic behaviours directly by altering 
mechanotransduction and indirectly by modulating transport phenomena (7). In fact, hypoxia and 
ECM physical changes are dynamically linked, as hypoxia can promote tumorigenic physical 
changes of the ECM that may further perturb oxygen transport (for example, by increasing 
expression of the collagen crosslinking enzyme lysyl oxidase (8)). Moreover, tumours not only 
consist of tumour cells, but interactions with host cells are equally important. For example, 
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integrating endothelial cells or activated fibroblasts would improve the physiological relevance of 
the model system and enable studies focused on metabolic coupling between both cell types, such 
as through the reverse Warburg effect (9). TRACER provides an opportunity to carefully 
reconstruct (and subsequently analyze) the intersecting soluble gradients, matrix properties, and 
cellular components of the tumour microenvironment. 
The cancer microenvironment is a diverse biological ecosystem. Biomaterials and tissue-
engineering strategies provide well-defined and reproducible models that may afford a unique 
window into the evolutionary dynamics of cancer progression. By recreating physiologically 
appropriate conditions and gradients, engineered tumours could help elucidate adverse 
microenvironmental parameters that may select for the resilient or aggressive phenotypes that 
promote malignancy and drug resistance (10). Using TRACER, McGuigan and colleagues have 
developed an easily accessible and adaptable approach to correlate cellular phenotypes with local 
microenvironmental conditions. Ultimately, it is the design of such simple and versatile platforms 
that may lead to meaningful collaborations between biomaterials scientists, tissue engineers, and 
cancer biologists to accelerate the discovery of new therapeutic targets and advance the effective 
treatment of cancer. 
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Abstract 
Prevailing evidence has established the fundamental role of microenvironmental 
conditions in tumorigenesis. However, the ability to identify, interrupt, and translate the underlying 
cellular and molecular mechanisms into meaningful therapies remains limited, due in part to a lack 
of organotypic culture systems that accurately recapitulate tumor physiology. Integration of tissue 
engineering with microfabrication technologies has the potential to address this challenge and 
mimic tumor heterogeneity with pathological fidelity. Specifically, this approach allows 
recapitulating global changes of tissue-level phenomena, while also controlling microscale 
variability of various conditions including spatiotemporal presentation of soluble signals, 
biochemical and physical characteristics of the extracellular matrix, and cellular composition. Such 
platforms have continued to elucidate the role of the microenvironment in cancer pathogenesis and 
significantly improve drug discovery and screening, particularly for therapies that target tumor-
enabling stromal components. This review discusses some of the landmark efforts in the field of 
micro-tumor engineering with a particular emphasis on deregulated tissue organization and mass 
transport phenomena in the tumor microenvironment. 
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Introduction 
Despite sustained progress in our knowledge of biological signaling events regulating 
tumor malignancy, the clinical prognosis for many cancer types has scarcely changed since 1950 
{Howlader 2012}. Increasing experimental evidence suggests that this discrepancy may be due in 
part to an under-appreciation of physical phenomena contributing to disease progression. As a 
result, cancer biologists are increasingly collaborating with physical scientists and engineers to 
study physicochemical characteristics of solid tumors and their role in modulating intracellular 
signaling (1). Particular emphasis is placed on analyzing microenvironmental changes that 
fundamentally influence tumor progression and therapy, including aberrant mechanical properties 
(e.g. cell forces, matrix stiffness), transport phenomena (e.g. mass and energy transfer, fluid 
dynamics), and growth/reaction kinetics (e.g. metabolism, signaling, proliferation). For example, 
quantifying therapy-associated mass transport, reaction rates, and the resulting cellular growth 
kinetics may help to better understand the evolution of drug resistance and inform more efficacious 
dosing regiments (2, 3). To determine such variables, new experimental platforms are needed that 
accurately recapitulate salient characteristics of the tumor microenvironment.  
By integrating strategies from tissue engineering, microfabrication, and cancer biology, 
biologically-inspired culture models (a.k.a. tumor surrogates) enable studies of physicochemical 
disease dynamics across multiple scales (4, 5). Tissue engineering technologies, including 
biomaterials, scaffold fabrication techniques, and bioreactor design, allow facile manipulation of 
tissue-level phenomena such as culture dimensionality, cell-cell and cell-extracellular matrix 
(ECM) interactions, and soluble factor transport and signaling. Complementing these tools, 
microfabrication principles can exert exquisite control over the chemical and physical environment 
on the cellular scale, for example via incorporation of microfluidic channels or precise variation 
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of mechanical and topographical properties, respectively (6, 7). Hence, the combination of tissue 
engineering and microfabrication affords the development of novel in vitro approaches to 
quantitatively assess constitutive microenvironmental features that are frequently neglected by 
conventional tissue culture methods or obscured by the complexity of in vivo models (8-10). 
Moreover, these platforms may interface in real-time with sensitive analytical instrumentation, 
such as confocal microscopy or mass spectrometry, for unprecedented access to cellular and 
biomolecular dynamics (11, 12).  
Here, we briefly introduce prominent characteristics of the tumor microenvironment, 
describe current state-of-the-art in vitro technologies to quantify these phenomena, and provide a 
perspective on future opportunities for micro-engineered tumor platforms in cancer research and 
clinical application with the ultimate goal of illuminating the multiscale regulation of cancer 
pathogenesis and therapy response.  
Biological and physical hallmarks of the tumor microenvironment 
Carcinomas comprise the majority of all solid tumors, and their malignancy is driven not 
only by the genetic transformation of epithelial cells, but also by the remodeling of contiguous 
stromal tissue to foster growth, metastasis, and therapy resistance (13-15). This tumor stroma 
derives from reciprocal tumor-host cell crosstalk, whereby tumor cell-secreted growth factors and 
cytokines stimulate the otherwise quiescent host cells to initiate a variety of processes, including 
desmoplasia and angiogenesis (16-19). The ensuing physiological changes resemble wound 
healing processes; however, tumor-associated stromal cells undermine tissue homeostasis rather 
than normalizing it, eliciting the analogy that tumors function as ‘wounds that do not heal’ (20, 
21). As a result, an asymmetric distribution of physical and chemical cues emerges, comprising 
spatiotemporally altered matrix mechanical properties and mass transport (18, 19, 22).  Below, we 
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describe these pathological consequences of tumor-stroma interactions from both biological and 
physical science perspectives and summarize microscale tissue engineering strategies to explore 
the underlying mechanisms. 
Deranged tissue organization: Dimensionality and ECM characteristics 
Structural ramifications of malignant transformation begin with the transition from 2D to 
3D tissue architecture caused by the hyper-proliferation of epithelial cells. Healthy epithelia are 
generally organized in polarized sheet structures, with a basolateral surface supported by a 
basement membrane, an apical lumen with secretory function, and tight junctions between 
neighboring cells in a confluent pseudo-monolayer (Fig. 1). Disruption of this arrangement by 
aberrant proliferation, loss of E-cadherin-mediated cell-cell contact, or secretion of matrix-
degrading enzymes such as matrix metalloproteinases (MMPs) subverts epithelial homeostasis and 
promotes carcinogenesis (23-26). Independent of other environmental conditions, this dimensional 
shift affects tumor cell growth (27, 28), migration (29, 30), signaling (31), and drug response (32, 
33). Conversely, restoration of appropriate geometrical context, or inhibition of integrin receptors 
that mediate 3D cellular engagement to the ECM, can normalize the malignant phenotype of 
transformed epithelial populations, in part by interrupting bidirectional cross-talk between growth 
factor and cell adhesion receptors {Wang 1998; Kenny 2003; Weigelt 2010}. For these reasons, 
appropriate choice of culture dimensionality is critical for the development of and interpretation 
of results collected with biomimetic tissue constructs in cancer research (9, 34, 35).  
Moreover, ECM properties, such as elasticity, nano- and microstructure, as well as 
composition affect tumorigenesis and need to be considered when designing matrices for in vitro 
culture models (36-38). Namely, desmoplastic matrix remodeling by tumor-associated 
myofibroblasts entails the assembly of a highly dense ECM (Fig. 1), whose physicochemical 
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Fig. 1. Biological and physical changes inherent to the tumor microenvironment. Tumors are characterized
by aberrant tissue organization (A) and mass transport (B). While normal epithelia form sheets that adhere to a
layer of basement membrane, which is anchored to the underlying stroma, malignant transformation perturbs
this architecture and leads to the development of a 3D tumor mass. During this process, basement membrane
integrity is compromised and ECM composition, conformation, and mechanical properties are altered due in part
to transformation of normal fibroblasts into cancer-associated fibroblasts (A). Excessive tumor cell proliferation
results in diffusion-limited oxygen and waste transport and consequential development of hypoxia and acidosis.
This induces secretion of pro-angiogenic factors including VEGF that activate neovascularization via
angiogenesis and recruitment of bone marrow progenitors. These newly formed vessels, in turn, enable tumor
growth and metastasis by providing vascular conduits for nutrients and extravasated circulating tumor cells,
respectively (B).
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attributes enhance malignancy through morphogenic deregulation, tumor cell proliferation, 
vascular recruitment, and myofibroblastic differentiation (19, 39, 40). Mediated by increased 
deposition, unfolding, and crosslinking of fibrillar adhesion proteins (e.g. fibronectin, collagen 
type I), desmoplastic stiffening contributes to epithelial transformation in part through integrin-
mediated increases in cell contractility (41, 42). This change in cell contractility, in turn, can 
directly and indirectly alter gene expression via altering transcription factor activity and the release 
of matrix-bound, pro-tumorigenic growth factors (e.g., transforming growth factor beta; TGFbeta), 
respectively (43, 44). Similarly, changes in the distribution of pore sizes, chemical composition, 
and fiber arrangement due to myofibroblastic remodeling can control aspects of tumor cell 
phenotype such as adhesion, mechanics, and motility (30, 45). Recapitulating these diverse 
physical aspects of biological matrices comprises a critical design criterion for tissue-engineered 
tumor models. 
Engineered models to evaluate the effect of tissue dimensionality and ECM interactions 
Microfabrication techniques in conjunction with natural or artificial ECM molecules afford 
investigations into the role of 3D cell-cell and cell-ECM interactions (38, 46-48). Originally 
pioneered on planar surfaces, micropatterning of natural ECM molecules (e.g. fibronectin) onto 
cell culture substrates by polydimethylsiloxane (PDMS)-based microcontact printing or soft 
lithography has been extensively utilized to interrogate topographical and biochemical effects on 
individual cells and small cell populations (10, 49). For example, such studies were used to 
decouple the effects of cell shape, spreading, and receptor ligation on cell fate (50). However, the 
sagging and swelling of PDMS in solution limits homogeneous patterning of large surface areas 
as necessary for proteomic or transcriptional analysis of protein expression. Parylene patterning 
can address this challenge and has enabled seeding of individual cells or small cell clusters on 
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fibronectin-functionalized surfaces of varying area to examine the role of direct cell-cell contact 
on tumor cell behavior (51). Although both techniques have provided numerous insights regarding 
cell-matrix and cell-cell interactions, by maintaining monolayer cell culture, they neglect authentic 
tissue architecture. In contrast, fully-enclosed 3D tissue culture has proved its utility for mimicking 
the structural environment of tumor-associated stroma and subsequent effects on disease 
progression. For example, organotypic culture arrays comprising lithographically-defined 
epithelial tissue structures sandwiched between layers of collagen were used to study geometrical 
influences on neoplastic progression (52). Likewise, hydrogel-based 3D microwell arrays have 
emerged as a robust platform to examine cell culture space and intercellular interactions, including 
their effects on drug response {Charnley 2009, Håkanson 2012}. One particular advantage of 
microscale 3D matrices is the reduction of diffusion barriers to allow homogeneous, temporally-
controlled stimulation of cell populations (53). Furthermore, such systems can be incorporated 
with lithographically defined microchannels to mimic cellular confinement within 3D tissue, an 
approach which has revealed that lower ECM porosity due to increased stiffness may promote cell 
migration (54). 
In order to explore the role of matrix composition, structure, and mechanical properties in 
cancer pathogenesis, biomaterials from regenerative medicine and drug delivery can be adapted to 
microfabricated culture systems discussed above (55), including complex mixtures of biological 
ECM (e.g., Matrigel®, a basement membrane preparation isolated from Engelbreth-Holm-Swarm 
murine sarcoma) and isolated ECM components from animal tissue (e.g., collagen I, fibronectin) 
(56). These natural biomaterials offer unique advantages due to their inherent provision of cell 
binding sites and the fact that porosity, fiber structure, and stiffness can be readily tailored via 
adjusting gelling conditions such as temperature, concentration, gel thickness, and media 
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composition (38, 47, 57). Nevertheless, natural polymers suffer from batch to batch variations and 
provide limited parameter space for the above-described physical variables. In fact, their 
modulation often simultaneously alters other materials properties that independently affect cell 
behavior (e.g. concentration changes affect stiffness but also density of adhesion ligands and 
porosity) (58, 59). Artificially combining functional protein building blocks via protein 
engineering strategies provides an attractive route to overcome these shortcomings and generate 
biological materials systems with unprecedented control over cell adhesion, proteolytic 
degradation, or stiffness (60). However, the fabrication of such molecules is highly specialized 
and therefore frequently not amenable for routine applications. 
Biologically-inspired partially or fully synthetic hydrogels may help to overcome some of 
the inherent limitations of natural biomaterials. They can be produced in large quantities, a highly 
reproducible manner, and are increasingly used by both the cancer biology and engineering 
community to selectively tune the physicochemical composition and structure of cell culture 
matrices. For example, synthetically modified fibrin or hyaluronic acid have been developed 
previously to guide endothelial cell behavior for regenerative approaches (61, 62), but are also 
relevant in the context of cancer as the deposition of these ECM components is increased during 
tumorigenesis (63, 64). Modifying natural ECM components takes advantage of the inherent cell 
affinity to the polymer backbone, while introducing selective variations of matrix mechanical 
properties and degradation via synthetic side chains {Hanjaya-Putra 2012; Anathanarayanan 
2011}. Polyacrylamide gels covalently coated with ECM components provide another system to 
independently control elastic moduli and ECM ligand presentation and revealed 
mechanoregulatory mechanisms of perturbed epithelial tissue homeostasis (36). These substrates 
are widely utilized by many labs for 2D studies, but as they cannot be remodeled by cells, 
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translation to 3D culture formats or animal studies (i.e., for verification of in vitro data) is limited. 
Furthermore, recent findings indicate that stiffness-related changes in porosity of polyacrylamide 
gels may affect the conformation of covalently attached cell adhesion proteins, which, in turn, 
could also regulate cell behavior (65). Poly(ethylene glycol) (PEG)-based scaffolds provide an 
attractive alternative as not only the stiffness of these materials can be readily adjusted, but also 
the density of conformation-independent cell adhesion sites and/or proteolytically degradable 
crosslinkers ultimately enabling studies of cellular invasion in 3D culture formats (66).  
Modifications of PEG-based materials in which molecular moieties have been introduced to enable 
in situ photo-degradation or crosslinking are particularly exciting because this approach affords an 
opportunity to determine cellular response to dynamic changes of matrix stiffness that may result 
from tumor development or drug treatments (67, 68). 
Cancer, A mass transport problem 
Within the tumor stroma, convective and diffusive forces are intrinsic mediators of the 
biochemical landscape that sustains neoplastic development (35, 69, 70). The predominant 
conduits of mass transport, microvascular networks define the spatial distribution of oxygen, 
nutrients, endocrine signals, and therapeutic drugs. Moreover, as a consequence of diffusion-
limited nutrient and waste transport, the absence of a functional vasculature regulates the 
development of hypoxia and acidosis during tumor initiation and at interior regions of advanced 
cancers (Fig. 1). These microenvironmental conditions promote malignancy by driving the 
selection of cells that mitigate oxidative stress via autonomous energy production, typically 
through glycolysis (71-73). Metabolic rewiring, known as the ‘Warburg effect’, can further 
enhance the proliferative, metastatic, and therapy-resistant behavior of the adapted cell population. 
Furthermore, hypoxia is known to dramatically alter the secretion profile of tumor cells, 
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particularly by inducing pro-angiogenic factors (e.g. vascular endothelial growth factor [VEGF], 
interleukin-8 [IL-8], basic fibroblast growth factor [bFGF]) that promote angiogenesis and 
vasculogenesis via the recruitment of adjacent blood vessels and bone marrow-derived progenitor 
cells, respectively (74). This process of sustained neovascularization constitutes a hallmark 
capability of cancer and, by surmounting nutrient limitations and providing vascular conduits, 
enables tumor growth and metastasis (75). However, compared to healthy vasculature, tumor-
associated blood vessels exhibit increased leakiness, tortuosity, instability via absence of mural 
cells, and subsequent aberrant fluid mechanical forces {Hashizume 2000; Nagy 2008, 2012}. As 
a result, they fail to normalize the hypoxia/acidosis of the tumor core, but instead cause spatial and 
temporal variations of these conditions (76). Notably, by contributing to elevated fluid pressure in 
the tumor, dysfunctional vasculature compromises drug delivery and modulates interstitial flow at 
the tumor margins (77). Pressure gradients and subsequent drainage from the tumor perimeter 
directly and indirectly guide the behavior of tumor and stromal cells by redistributing morphogen 
and chemokine gradients and by mechanically-inducing stromal differentiation (78-80). From a 
physical science perspective, these integrated fluid mechanical forces establish the prevailing 
biochemical profile of the tumor microenvironment and direct disease progression (81). Likewise, 
tools to deconvolute convection-diffusion-reaction kinetics, paracrine signaling, vascular supply, 
and interstitial fluid mechanics are required for the comprehensive study of pathophysiological 
transport processes, including metabolic maintenance, drug delivery, and evolution of therapy 
resistance (82).  
Biomimetic approaches to study tumor-associated transport phenomena 
Whereas conventional in vitro technologies lack spatiotemporal variations of soluble 
chemicals, and animal studies prohibit quantitative control over mass transport, microfabricated 
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tissues can effectively access these critical pathological parameters (83). Therefore, researchers 
have employed microfabrication technologies to mimic physiological transport processes, 
including perfusion for metabolic maintenance, diffusion-controlled soluble factor gradients, 
convective transport through microfluidic conduits, and more recently, tissue-engineered 
biomimetic vasculature (7, 84, 85). For example, microfabrication technologies have surmounted 
diffusion-limited metabolic maintenance in 3D culture by the development of microscale perfusion 
bioreactors and by providing access to scaffold geometries within the Krogh length (i.e., to control 
hypoxia-associated effects in culture studies) (86, 87). From the profusion of tissue-engineered, 
microfabricated assays with well-controlled tissue structure and transport conditions, surprising 
data has emerged. For example, studies comparing 2D-cultured tumor cells with tumor cells 
incorporated within microfabricated hydrogel disks have revealed that changes in tissue 
dimensionality may be similarly if not even more important to the proangiogenic capability of 
tumor cells as oxidative stress (88). Moreover, by the tuning of physical and chemical stimuli as 
well as cellular complexity, microfabricated platforms afford a unique opportunity to examine both 
the isolated and integrated effects of multiplexed parameters.  
Another aspect to consider is that cell responses to gradients of soluble factors, for 
example, may be different in 2D vs. 3D culture systems, and not only depend on the specific 
morphogen applied, but also its combination with other molecules as well as the specific spatial 
and temporal dynamics of exposure. Two-dimensional microfluidic models have proved their 
utility in the generation of stable, linear concentration gradients to independently evaluate 
directional responses to biomolecular assymetries, such as chemotaxis and morphogenesis {Jeon 
2002; Selimović 2011; Saadi 2007; Dertinger 2001; Georgescu 2008; Mak 2011}. Three-
dimensional microfluidic gradient generators with single- or multi-layered factor gradients will 
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additionally be able to distinguish biochemical synergies in a physiologically relevant tissue 
context, which is essential for the study of tumor cell migration and perturbed morphogenesis 
{Choi 2007; Chung 2009, 2010; Shamloo 2008, 2010; Shin 2011}.  
While most of the current approaches are still relatively low-throughput, automated 3D 
microfluidic co-culture arrays may revolutionize this limitation. Such systems will be critical for 
economically more effective low-volume, high-throughput drug screening, and have already 
proved efficacious for interrogating tumor-stromal signaling within 3D culture formats without 
typical drug-diffusion limitations (89-92). By coupling biomaterials with microfabrication, further 
3D platforms have emerged to study cellular responses to spatial distribution of physical and 
chemical stimuli. For example, collagen-based microfluidic channels enable studies of endothelial 
sprouting in response to VEGF gradients (93, 94) and the presence of pericytes (95), and aqueous 
two-phase systems allow patterning of cells as well as delivery of biochemical factors (96). 
Together, these systems can recapitulate the heterogeneity of tumor and stromal cell-secreted 
factors, drug distribution and reaction kinetics, or the gradients of hypoxia and acidosis described 
above.  
In the particular case of tumor angiogenesis, tissue-engineered microvascular constructs 
will undoubtedly advance the development of artificial tumor surrogates and can be fabricated by 
a variety of techniques (Fig. 2). Whereas some models employ surface-cultured endothelial 
monolayers to study tumor-endothelial signaling and angiogenic invasion independent of transport 
effects, other assays generate fully-enclosed endothelial networks in remodelable matrices (53, 95, 
97-102). For the fabrication of the latter, microfluidic conduits may be incorporated into 
biomimetic hydrogels through a variety of approaches including pull-through technique, sacrificial 
fiber molds, modular assembly and soft lithography (87, 103-106). Incorporating such 
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Fig. 2. Microfabrication techniques to recapitulate vascular networks in vitro. Cylindrical 3D networks can
be incorporated into hydrogels using carbohydrate glass as sacrificial templates. Labeled human umbilical vein
endothelial cells (HUVECs) seeded into these channels form perfusable vascular networks that can be induced
to sprout (arrowheads), while incorporation of a second labeled cell type (e.g.10T1/2 cells) into the hydrogel
bulk permits recapitulation of stromal tissue. Scale bars represent 1 mm and 200 µm (Miller 2012) (A).
Similarly, lithographically patterned microfluidic devices may be used to generate functional vascular networks
within remodelable hydrogels. In particular, incorporation of pericytes (indicated by α-SMA staining) into the
bulk leads to the recruitment of these cells to HUVEC-lined vessels (indicated by CD31 staining) and their
corresponding stabilization. Scale bar, 100 µm (Zheng 2012) (B). Microdevices composed of two parallel
endothelial cell-coated channels (GFP-labeled HUVECs in top and dsRed-labeled HUVECs in bottom channel)
separated by an invadable collagen matrix allow studies of vascular anastomosis in response to VEGF gradients
as well as interstitial flow (dashed arrow) and axial shear flow (solid arrow). Scale bar, 100 µm (Song 2012) (C).
Microvascular structures generated in microfluidic type I collagen gels using a pull-through technique can be
stabilized by cyclic AMP (cAMP)-elevating agents as shown via perfusion of endothelial cell-coated vessels
with fluorescently labeled BSA; *indicates focal leaks. Scale bar, 100 µm (Wong 2010) (D). Culture of stromal
cells (10T1/2) and endothelial cells (HMVEC) in adjacent channels separated by a 3D collagen scaffold allows
studying the effect of bi-directional paracrine signaling on invasion and sprouting behavior of these cells,
respectively. 10T1/2 invaded at an enhanced rate in the presence of HMVECs. Additionally, HMVECs formed
sprouts towards the blank collagen scaffold located in the left channel (red arrowheads), whereas vessels were
stabilized in regions directed towards 10T1/2s (Chung 2009) (E). Images are modified and reproduced with
permissions from the publishers.
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microfabricated, endothelial-coated vessels into engineered tumor models will undeniably 
improve in vitro studies of sprouting angiogenesis, endothelial barrier function, and drug delivery 
{Zheng 2012, Chung 2009, Zervantonakis 2011}. In fact, pulsed injections of fluorophores or 
fluorescently-labeled proteins as mimics of small and large therapeutic molecules allows the 
measurement of their diffusivity and permeability from microengineered vasculature and permits 
the analysis of changes in leakiness due to exposure to excess concentrations of proangiogenic 
molecules (95). Likewise, these devices can be utilized in the quantification of diffusion-reaction 
metabolic processes in 3D and determination of cell growth rate constants, which are significantly 
different from suspension and monolayer culture (86).  
In addition to solute delivery, microvascular models can be used to introduce a permissive 
mechanical regulator of the microenvironment, namely convective transport via interstitial flow 
(9, 107). In fact, interstitial flow can affect tumor progression via multiple mechanisms; for 
example, through biasing the distribution of cell-secreted factors, forcing mechanical aberrations 
of the tumor microenvironment by promoting stroma remodeling, and regulating endothelial 
sprouting (78-80, 108, 109). Integrated in tumor-engineered platforms selective perfusion of 
microvascular network recreates inherent pathological properties such as hypoxia/acidosis, 
compromised drug delivery, edema, and in some cases the direct visualization of migration and 
intravasation. By quantifying hitherto unexplored responses to transport processes, this 
unprecedented control of multiple-parameter in vitro models is indispensable for the improved 
understanding of tumor growth and clinical treatment. 
Future opportunities 
Over the past decade or so, reductionist approaches have helped to decipher the biological 
and physicochemical complexity of tumors, but as the discipline of tumor engineering matures and 
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technologies improve, we encounter the question of what can be gained by adding complexity. We 
propose applications for microengineered tumor-mimetic assays in drug development and delivery 
strategies, simulation of whole-body physiologically-based pharmacokinetic models, and 
screening of rationally-designed therapeutic regimens. Furthermore, experimental integration of 
convective-diffusion-reaction processes will provide unprecedented access to quantitative 
parameters that are instrumental to the validation of comprehensive computational models 
describing the intra- and extracellular signaling networks underlying tumorigenesis. 
Engineering of functional, fully-human and/or patient-specific micro-tissues 
The immediate advantage of complex microengineered tumor models derives from the 
opportunity to observe interactions between various constituents of the tumor microenvironment 
in real time with implications for both basic research and drug development. Whereas certain 
physicochemical parameters may be independently important, it is likely that combinatorial effects 
accentuate or attenuate their functional significance. Thus, robust platforms that can controllably 
add or subtract layers of physiological complexity will be indispensable for interrogating variates 
and co-variates in cancer therapy. For example, the emergence of drug resistant subpopulations 
may rely on microenvironmental signatures dictated by the cellular and acellular heterogeneity of 
the tumor mass; identification of the underlying molecular mechanisms has the potential to identify 
novel therapeutic targets that may improve current therapeutic interventions (110-112). Likewise, 
tumor-engineered assays will provide unprecedented ability to disambiguate the indirect effects of 
targeted cancer drugs. As one poignant example, the underwhelming clinical benefit of VEGF-
inhibiting, anti-angiogenic therapies has received considerable attention (113, 114). Low 
therapeutic efficacy is due in part to a poor understanding of the mechanisms underlying vessel 
growth and drug response as well as the forced upregulation of alternative proangiogenic factors 
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(e.g., bFGF and IL-8) that render vessels VEGF-independent (74, 115-118). To explore these 
questions, our lab is developing microengineered tumor models to determine cooperative 
parameters that may control endothelial cell sprouting, including cell density, vessel geometry, 
and endothelial cell autocrine signaling mechanisms (119). As biomimetic vascular assays 
continue improving, the pros and cons of anti-angiogenic therapy and drug delivery (e.g. 
mechanisms of actions, delivery mode, dosing intervals) will become more apparent and therapies 
can be adjusted (118, 120-122).  
Validation of whole-body PBPK-PD models  
Knowledge and treatment of the primary tumor site only locally palliates a more pernicious 
systemic disorder. Through metastasis and colonization, circulating tumor cells can infiltrate 
distant tissues, often with morbid consequences; similarly, organ distribution and side effects are 
critical considerations during drug development. Therefore, pre-clinical tools that contribute to 
holistic understanding of both disease progression and treatment will benefit the development of 
better pharmaceuticals and dosing strategies. To this end, microengineered tumor cultures may 
integrate with current “body-on-a-chip” technologies for comprehensive culture models of disease 
progression across multiple tissues {Esch 2011; Sin 2004; Sung 2010; Vivaraidya 2004}. Such 
systems have already been used to validate whole-body physiologically-based pharmacokinetic 
(PB-PK) models and improve estimation of critical parameter such as Theile modulus or Peclet 
number, dimensionless coefficients that describe relative rates of transport and reaction kinetics, 
and measurement of variability and co-variation with disease or treatment among different organs 
(123). These systems will potentially contribute to the prediction of metastatic homing, dosing 
regimens, and side-effects, or selection of patients for specific clinical trials (124).  For example, 
priming an in vitro tumor with downstream osteogenic or pulmonary compartments to resemble 
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the pre-metastatic niche may help determine mechanisms of organ homing, including 
characteristics or organ-specific tropisms such as stages of lung inflammation due to smoking (Fig. 
3A-B). In addition, microfluidic PB-PK models can inform pharmacodynamic computational 
models and assist in the extrapolation of such models to animal and human predictions (Fig. 3C). 
While such devices have been used in toxicity and dosing studies (125, 126), testing of new cancer 
therapies may also benefit from this technology. Particularly, it could help to better understand the 
current disconnect between promising preclinical data and lack of clinical efficacy of new 
compounds, as well as inform dosing strategies and combination therapies to optimize biological 
response.  
In vitro platforms for integrative mathematical oncology 
A final application for tissue-engineered tumor surrogates lies in the realization of 
comprehensive mathematical cancer models (127). By selective incorporation of individual or 
multiplexed physiological components of the tumor microenvironment, in vitro tumor models can 
be used to determine critical in silico parameters, including correlation or interaction coefficients 
between various elements (82, 128-131). For example, it is known that integrin engagement, 
matrix stiffness, and growth factor receptor signaling are intimately linked, but quantitative 
parameters and modeling of co-variation are yet undetermined. Tissue-engineered models could 
test predictive behaviors and confirm computational hypotheses regarding disease dynamics. One 
example where such systems may prove beneficial is the modeling of tumor evolution, by which 
malignant or resistant populations propagate by somatic selection in resource-constrained tissues 
(132-135). Computational models of this process show that microenvironmental conditions are 
key determinants of population phenotype. This observation is consistent with emerging 
appreciation for the local heterogeneity within primary tumor site and in distant metastases, and it 
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Fig. 3. Integration of microengineered tumor cultures with “body-on-a-chip” models. Cancer progression
and therapy are controlled by systemic interactions. For example, endocrine signaling between tumors and
distant tissues such as brain, bone, lungs, and liver regulate the tropism of certain cancers to particular sites (e.g.
breast cancer to bone). Additionally, the efficacy of anti-cancer therapies is regulated by systemic distribution
and metabolism in various tissues and organs such as adipose tissue, kidney, heart and liver. Therefore,
connecting multiple organ components via vascular conduits in ‘cancer on a chip’ models has the potential to
improve our understanding of metastatic homing mechanisms of tumor cells as well as drug therapy (A–B).
Already, microscale cell culture analogs have been used to improve the predictability of pharmacokinetic-
pharmacodynamic models in vitro (Sung 2010) (C). This platform, comprising bone, liver, and tumor
compartments, was used to assess the toxicity of 5-fluorouracil in a 3D tissue context with multi-organ
interactions. The combination of in vitro experimental data and mathematical PB-PK modeling may improve
screening for drug development, as well as inform our understanding of cancer pathogenesis during therapy.
Images are reproduced with permission from the publisher.
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has spawned new hypotheses for therapeutic dosing regiments based on ecological principles 
{Basanta 2012, 2012; Maruskyk 2012; Navin 2011; Snuderl 2011}. However, such simulations 
are difficult to examine biologically. In vitro systems that include diverse cell populations and 
heterogeneous physicochemical environment would help validate the mathematical models and 
perhaps elucidate novel parameters to improve such systems. 
Conclusions 
Microfabrication techniques have the potential to yield important new insights into the 
pathogenesis of cancer. While great progress has been made in developing model systems for 
deciphering mechanisms of tumorigenesis, improved throughput and applicability by non-
engineers (e.g. cancer biologists and clinicians) will further enhance the significance of these 
platforms. Moreover, exploring currently unrealized opportunities of recapitulating cancer 
complexity will help in elucidating molecular, cellular, tissue, and systems level phenomena that 
could be explored in the future for more efficacious clinical therapies. 
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